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Abstract 
DNA methylation is an epigenetic mark that has profound affects on the genome of 
higher eukaryotes. The majority of DNA methylation in mammalian genomes is 
found on cytosine bases in the context of symmetrical CpG dinucleotides. The main 
biological affect of DNA methylation is regulatory control of surrounding gene 
expression and chromatin structure. DNA methylation is unequivocally linked to 
repressed genes and regions of the genome that are permanently silenced and 
referred to as heterochromatin. The affect of DNA methylation is to a great extent 
realized through interpretation of the methyl-CpG signal by a family of methyl-
binding proteins (MBP's). MBP's include: MeCP2, MBD1, MBD2, MBD3, MBD4, 
and Kaiso. With the exception of MBD4, which is involved in the repair of methyl-
CpG deamination events, MBP's are all transcriptional repressors. The capacity of 
MBP molecules to modify chromatin structure and silence genes is in part dependent 
on associated co-factors that possess enzymatic activities directed towards 
chromatin. 
This thesis deals predominantly with the MBP protein MeCP2. MeCP2 is a 
transcriptional repressor that recruits the Sin3a chromatin remodelling complex to 
methylated loci. Sin3a-associated histone deacetylases contribute to the ability of 
MeCP2 to repress transcription and modulate chromatin structure. The biomedical 
importance of normal MeCP2 function is highlighted by the discovery that 
inactivating mutations in MeCP2 cause the severe neurological disease Rett 
syndrome. By deleting the Mecp2 gene, a mouse model of Rett syndrome has been 
generated and used to study the molecular and physiological outcome of MeCP2 
deficiency. Inefficient regulation of neuronal gene expression may have a role in the 
etiology of Rett syndrome. 
By studying the biochemical properties of MeCP2 this thesis addresses in detail three 
basic questions; (1) what are the native biochemical properties of MeCP2? (2) what 
specific DNA sequences does MeCP2 bind? and (3) what are the affects of post-
translational modification on MeCP2? To address the composition of any 
V1 
mammalian MeCP2 complexes, native MeCP2 was purified to near homogeneity 
from rat brain. Native MeCP2 is an elongated monomer that does not stably 
associate with other cofactors including Sin3a. Analysis of MeCP2 binding sites in 
vivo demonstrates that MeCP2 binds unique loci when compared to other MBP's. 
Using an unbiased in vitro DNA binding site evolution assay, Methyl-SELEX, 
MeCP2 was shown to require methyl-CpG sequences containing a flanking run of 
A/T rich DNA for high affinity binding. Finally, biochemical fractionation of 
nuclear proteins revealed activities that phosphorylate MeCP2, and the potential 
affects of this modification were explored. These biochemical studies shed new light 
on how MeCP2 may function to target genes for methylation-dependent repression 
and recruit co-factors that modulate chromatin structure and gene expression. 
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1. Chapter one-
Introduction 
1.1 DNA methylation 
1.1.1 Methyl-cytosine, the fifth base in eukaryotic DNA 
The complementary double stranded DNA helix consists of four basic 
deoxyribonucleic acid building blocks; deoxyadenosine, deoxyguanosine, 
deoxycytidine, and thymidine. These nucleotide building blocks are linked by 
phophodiester bonds to create the linear polymers that make up each individual 
strand of DNA. Biochemical examination of DNA identified a cytosine base pair 
variant which has a methyl group in the 5' position of the pyrimidine ring (Figure 
1.1)(Hotchkiss, 1948; Johnson and Coghill, 1925). This methyl group is transferred 
to cytosine after DNA replication by DNA methyltransferase enzymes. Since the 
initial discoveries of 5-methyl cytosine it has become clear that this modification has 
profound implications for the biology of simple prokaryotes through to higher multi-
cellular organisms. 
1.1.2 DNA methylation in prokaryotes 
DNA methylation in bacteria can occur on the N6 position of adenine and on the N4 
and CS positions of cytosine (Figure 1.1). DNA methylation in bacteria is part of a 
host restriction-modification system (Wilson and Murray, 1991), which is used to 
protect the organism from virus infection. The restriction modification system is 
composed of an endonuclease that attacks the invading viral genome, while the 
bacterial genome is protected by blockage of endonuclease sites with methylated 
DNA bases. Therefore, the bacteria can specifically target destruction of foreign 
DNA but not harm the coding and replication potential of their own genome. Other 
functions for DNA methylation in prokaryotes, including DNA repair and regulation 
of transcription, have also been proposed (Palmer and Marinus, 1994). 
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Figure 1.1 - Methylated DNA bases 
Methylation of cytosine occurs on the amine group at the 4' position and the carbon 
at the 5' position in the DNA base. Adenine is methylated the amine group at the 6 
position. 
1.2 DNA methylation in eukaryotes 
1.2.1 Cytosine methylation profiles in fungi 
DNA methylation has not been observed in fission or budding yeast (Proffitt et al., 
1984) despite exploratory efforts to identify this modification (Wilkinson et al., 
1995). A DNA methyltransferase homologue, pmtl+ (Pinarbasi et al., 1996; 
Wilkinson et al., 1995), has been identified in fission yeast which has all the 
conserved domains found in functional methyltransferase enzymes, except a point 
mutation in the catalytic domain renders this enzyme non-functional. In contrast, 
DNA methylation has been observed in other species of fungi including Candida 
albicans (Russell et al., 1987) and Neurospora crassa (Bull and Wootton, 1984). 
The DNA methylation system in Neurospora crassa has been thoroughly studied, 
(Selker et al., 2002) and appears to function in concert with a genome defence 
mechanism called repeat induced point mutation (RIP). RIP is induced by duplicated 
DNA sequences in the haploid genome of Neurospora during the sexual phase of its 
13 
life cycle, and results in mutations within the repeated DNA sequence (Selker et al., 
2002). RIP functions in Neurospora to protect against invasion and exploitation of its 
genome by parasitic repeat elements (i.e. transposons). Induction of RIP directly 
causes accumulation of methylation on cytosine bases within the mutated region 
(Selker et al., 2002). One cytosine methyltransferase, Dim-2, is responsible for all 
DNA methylation in Neurospora, and cytosine methylation is not essential as a Dim-
2 null allele is viable (Kouzminova and Selker, 2001). Cytosine methylation in 
Neurospora affects most (>80%) of the cytosines in RIPed sequences and occurs in a 
sequence context independent manner. The complete genome sequence of 
Neurospora crassa allowed a genome wide survey of the DNA methylation profiles 
and most of the methylated sequences were found on relics of transposons that had 
been inactivated by RIP, and covered 2-3% of cytosine bases (Selker et al., 2003). 
DNA methylation has a very specific role in Neurospora for targeting regions RIPed 
by genome defence mechanisms. Presumably methylation acts as secondary 
silencing mechanism to keep RIPed sequences silenced, but evidence to support this 
suggestion has yet to be uncovered. 
1.2.2 Cytosine methylation in plants 
Cytosine methylation in plants is more widespread than in Neurospora, covering 5 - 
25 % of total cytosine bases (Rangwala and Richards, 2004). The majority of DNA 
methylation is found concentrated in heterochromatic regions, including rDNA 
repeats, centromeric DNA, and parasitic I transposable elements. In contrast to the 
context independent profiles of methylation in Neurospora, cytosine methylation in 
plants is found in three contexts; CpG dinucleotides, CpNpG DNA, and CNN DNA 
(where N is A,T, or G) (Tariq and Paszkowski, 2004). 
DNA methylation in Arabidopsis is mediated by at least four different cytosine 
methyltransferases: met 1, drml, drm2, and cmt3 (Tariq and Paszkowski, 2004). The 
meti DNA methyltransferase is the Arabidopsis homologue of eukaryotic DNMT1 
(Section 1.2.5) and is responsible for maintenance of CpG methylation during DNA 
replication (Saze et al., 2003). Drml and drm2 are homologous to the mammalian 
DNMT3 (Section 1.2.5) enzymes and have roles in setting up DNA methylation 
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profiles at CpG and CpNpG sites (Cao and Jacobsen, 2002). Cmt3 is responsible 
some locus specific non-CG methylation, and plays a role in histone methylation 
directed DNA methylation (Section 1.3.5). DNA methylation in Arabidopsis is 
associated with silenced regions of the genome, and may be actively interpreted 
(Berg et al., 2003). 
1.2.3 Cytosine methylation in lower eukaryotes 
A certain amount of variability exists between the DNA methylation profiles in 
fungi, and the same is true for multi-cellular eukaryotes. The nematode 
Caenorhabditis elegans (Simpson et al., 1986; Tweedie et al., 1997) does not contain 
DNA methylation nor a conventional DNA methyltransferase gene. A small amount 
of DNA methylation has been detected in Drosophila melanogaster (Gowher et al., 
2000; Lyko et al., 2000), and the Drosophila genome encodes a DNA 
methyltransferase protein (DNMT2) which appears to be catalytically active (Kunert 
et al., 2003; Tang et al., 2003). The majority of DNA methylation in Drosophila 
occurs in the context of CpA dinucleotides, and interpretation of the this methylation 
appears to have a role in position effect variegation and normal chromosome 
segregation in Drosophila (Marhold et al., 2004b). 
Most higher invertebrates contain moderate levels of methyl-cytosine (Bird, 2002; 
Tweedie et al., 1997) which is found almost exclusively on CpG dinucleotides. DNA 
methylation in invertebrates covers from 10 - 40 % (Tweedie et al., 1997) of the 
genome, consisting mostly of long stretches of densely methylated DNA 
compartments interspersed within completely unmethylated regions. High resolution 
mapping in Ciona intestinalis has shown that the majority of DNA methylation is 
found over the body of genes and not on intergenic or parasitic repeat sequences 
(Simmen et al., 1999). In invertebrates the absence of DNA methylation on parasitic 
repeat elements suggest the DNA methylation system does not function as a means 
of genome defence as has been suggested (Yoder et al., 1997b), but instead may have 
a role in modulating transcription (Simmen et al., 1999). 
The invertebrate-vertebrate boundary delineates quite distinctly the shift in CpG 
methylation profile from, compartments of methylation that cover genes in the 
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invertebrate genome, to the extensive CpG methylation profile observed in 
vertebrates (Tweedie et al., 1997). Vertebrate genomes have CpG methylation 
virtually everywhere except for the CpG islands which are associated with the 5' end 
of most genes (Antequera et al., 1990). Many similarities are observed in the 
genomic methylation profiles of vertebrates, and this will be introduced in Section 
1.2.4. 
1.2.4Genomic methylation profiles in mammals 
DNA methylation is broadly distributed throughout the mammalian genome, but 
methyl-cytosine only accounts for about 1 % of total DNA bases. This number might 
seem surprisingly small but in the context of CpG dinucleotides, which is the main 
target sequence for DNA methylation in mammals, methylation is found on 70 - 80 
% of cytosine bases. 
Interestingly, the occurrence of methyl-CpG in the genome is actually a factor which 
drives loss of CpG dinucleotides, and this combination of bases is under-represented. 
The cause of CpG loss is a direct result of DNA methylation, as methyl-cytosine can 
spontaneously deaminate to thymine resulting in a G:T base pair mismatches. If 
repair of the mismatch does not occur before DNA replication, this can result in a 
C:G to T:A transition mutation in one of the resulting daughter strands. Therefore, 
simply by analyzing the genome sequence it is relatively easy to identify regions of 
the genome that are methylated and unmethylated based on CpG content. For 
example, regions of the genome which have higher than expected CpG content 
usually contain non-methylated CpG's, as is the case with CpG islands (see below). 
The coding regions of genes are usually under-represented with respect to CpG 
content, and the majority of CpG's contain DNA methylation. In addition to DNA 
methylation affecting the DNA composition of the genome it can also have profound 
affects on the coding potential of a gene. This is evident in human genetics as C:G to 
T:A transitions are a major cause of mutation in human disease (Cooper and 
Youssoufian, 1988). In other instances methylated CpG dinucleotides act as 
important mediators of gene regulation and constitute regulatory control elements, 
like those implicated in imprinted gene expression (Section 1.2.6). In these cases, 
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methyl-CpG is under selective pressure and must be maintained in order for normal 
gene regulation to occur. 
Most non-methylated CpG dinucleotides are found in CpG islands at the 5' end of 
genes. In mammals, a CpG island is generally defined by a DNA sequence of over 
200 base pairs, with greater than 50 % GC content, and an observed over expected 
ratio of CpG greater that 0. 6 (Gardiner-Garden and Frommer, 1987). Because CpG 
dinucleotides are generally under represented (as discussed above) an observed over 
expected value of 0.6 has generally been adopted as a cut off value to define a 
mammalian CpG island. Recent predictions from human genome sequencing efforts 
suggest that 29000 genes have CpG islands (Lander et al., 2001). In most tissues that 
have been analyzed, CpG islands remain non-methylated even if associated with 
silenced genes (Antequera et al., 1990). This suggests the genome has a mechanism 
to keep these regions free of DNA methylation, but the nature of this system remains 
undefined (Macleod et al., 1994). A defined biological role for CpG islands remains 
elusive, but one suggestion is that methylation free islands could act as a buffer to 
keep silenced regions of chromatin from impinging on the regulatory regions of 
genes. 
1.2.5 Mammalian DNA methyltransferases 
The process of DNA methylation in aqueous solution was initially considered to be 
chemically improbable (Bestor, 2000). The co-crystal structure of M. HhaI 
methyltransferase bound to an acceptor CpG (Klimasauskas et al., 1994) revealed an 
interesting mechanism for cytosine methylation. These studies showed that the 
cytosine base is pulled out of the DNA helix and inserted deep into the catalytic site 
of the enzyme. Once situated in the catalytic site, the DNA methylation reaction 
proceeds via thiol attack at the C6 position of the pyrimdine ring, resulting in 
formation of a covalent bond between the enzyme and the cytosine base (Figure 1.2). 
Enamine attack of the methyl donor, s-adenosyl-L-methionine (SAM), results in 
transfer of a methyl group to the C5 position of the pyrimidine ring (Figure 1.2). 
Abstraction of a proton from the C5 position allows the carbon-carbon double bond 
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Figure 1.2- Catalytic mechanisms of 5-methyl-cytosine DNA methyltransferases 
(Adapted from (Bestor, 2000)) 
The DNA methylation reaction proceeds via thiol attack at the C6 position of the 
pyrimdine ring, resulting in formation of a covalent bond between the enzyme and 
the cytosine base. 
Enamine attack of the methyl donor, s-adenosyl-L-methionine, results in transfer 
of a methyl group to the C5 position of the pyrimidine ring. 
Abstraction of a proton from the 05 position allows the carbon-carbon double 
bond to reform. 
The base is released from the enzyme by n-elimination. 
(Bestor, 2000; Klimasauskas et al., 1994). The elegant mechanisms of DNA 
methylation, as revealed by structural studies of the bacterial methyltransferase 
M.HhaJ, are likely to be conserved in mammalian DNA methyltransferase enzymes 
as the catalytic domains of these enzymes share striking sequence similarity. 
Enzymatic activities capable of methylating CpG dinucleotides were identified 
biochemically in many different mammalian tissue sources (Bestor et al., 1988). The 
first mammalian enzyme identified at the cDNA level was DNA methyltransferase 1 
(DNMT1), and its coding sequence revealed homology between the catalytic 
domains of the mammalian and bacterial DNA methyltransferase enzymes (Bestor et 
al., 1988). Since the initial identification of DNMT1, three other mammalian DNA 
methyltransferase enzymes have been identified, and include; DNMT2 (Yoder and 
Bestor, 1998), DNMT3a, and DNMT3b (Figure 1.3) (Okano et al., 1998a). Each of 
these enzymes shares homology to ten characteristic motifs found within DNA 
methyltransferases, six of which are highly conserved (Bestor, 2000; Okano et al., 
1998a). Several functionally important motifs include, motif I and X that form the 
SAM binding region, motive IV that contains the thiol group required for enzymatic 
attack of the cytosine base, and motif IX which has roles in maintaining the structure 
of the enzyme that interacts with the major groove containing the cytosine base 
(Figure 1.3) (Bestor, 2000). Subsequent biochemical and genetic studies have been 
instrumental in delineating the role of each of these methyltransferase enzymes. 
DNMT1 is the main enzyme required for maintenance of DNA methylation during 
DNA replication. As the replication fork passes over methylated CpG-dinucleotides, 
semi-conservative replication results in each newly replicated strand containing 
hemi-methylated CpG dinucleotides. DNMT1 can associate with the DNA 
polymerase clamp loader complex protein (PCNA)(Chuang et al., 1997) and can 
track with the replication fork to convert hemi-methylated DNA sites back into 
symmetrically dimethylated CpG's. Evidence in vitro indicates that DNMT1 has 
between 5 and 30 fold preference for hemi-methylated substrates (Yoder et al., 
1997a) and converts hemi-methylated CpG in a processive manner (Vilkaitis et al., 
2005). The efficient maintenance of DNA methylation patterns between cellular 
19 
	
Cys-rich 	 I 	IV VI VIII 	IX X 
DNMTI I 	 Jtvl I III I II 
I IVVIVIII IX  
DNMT2 	 II_I_II_III 
Cys-rich 	I IV VI 	IX X 
DNMT3a 




Figure 1.3-Domain organization of the mammalian DNA methyltransferase enzymes 
(Adapted from (Bestor, 2000) 
The mammalian DNA methyltransferase enzymes (DNMT 1, DNMT2, and 
DNMT3aIb) contain a series of conserved methyltransferase motifs (I-X) in the c-
terminus of each protein. DNMT3L lacks the methyltransferase motifs but has a Cys-
rich region which is shares with DNMT1 and DNMT3a1b. 
replication events exemplifies why DNA methylation is considered a heritable 
epigenetic state (Bird, 2002). The importance of DNA methylation for normal 
development was realized when Dnmtl null alleles were introduced into mice. The 
mutant Dnn] mice had a recessive lethal phenotype and null ES cells had an 
approximate three fold drop in the level of global DNA methylation (Li et al., 1992). 
Conversely, Dnmtl over-expression in mice causes a loss in the fidelity of the DNA 
methylation system resulting in DNA hypermethylation, loss on normal imprinting, 
and embryonic lethality (Biniszkiewicz et al., 2002). Mice carrying one null allele 
and one hypomorphic allele of Dnmtl survive and are viable despite reduction of 
DNA methylation levels to about 10 % of normal levels. These mice were runted at 
birth and died within 4 - 8 months developing T-cell lymphomas and displaying 
genomic instability (Gaudet et al., 2003). The evidence from mouse studies suggest 
even subtle affects in the expression profile of Dnmt] has pleotrophic affects on 
normal cellular function and development. Because of the difficulty in interpreting 
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the results of various mouse studies, controversy exists as to the exact cause of 
phenotypes resulting from Dnmtl manipulation, especially with regards to the 
catalytic activity of the protein and levels of DNA methylation. Interestingly 
DNMT1 interacts with transcriptional co-repressor molecules suggesting that 
functions in addition to the catalytic activity of DNMT 1 are important for its function 
in vivo (Fuks et al., 2000; Rountree et al., 2000). 
DNMT2 has proved the most enigmatic mammalian DNA methyltransferase. A 
surprising amount of effort has yielded very little useful understanding of how, or if, 
the DNMT2 protein functions in vivo. Dnmt2 null ES cells have normal DNA 
methylation levels and are competent in silencing newly integrated viral DNAs 
(Okano et al., 1998b). Recombinant DNMT2 was generated using bacterial and 
baculovirus expression systems but no DNA methyltransferase activity was detected 
(Okano et al., 1998b). The crystal structure of DNMT2 revealed striking structural 
homology to bacterial methyltransferase M. HhaI (Dong et al., 2001), and DNMT2 
was able to form denaturation resistant complexes with DNA suggesting that the 
protein forms covalent adducts with DNA in a similar manner to functional DNA 
methyltransferases (Figure 1.2). Recently, a detailed biochemical study of 
recombinant human DNMT2 has revealed very weak cytosine methyltransferase 
activity (Hermann et al., 2003) towards CpG in the context of ttnCGga(g/a) DNA. 
Additional in vivo analysis is required to determine the functional relevance of 
DNMT2 in human cells. Interestingly, homologues of DNMT2 have been identified 
in flies (Hung et al., 1999; Tweedie et al., 1999) and fission yeast (Section 1.2. 1) 
suggesting that DNMT2 may have an evolutionarily conserved function. 
The DNMT3 methyltransferases, DNMT3a and DT3b, are encoded by separate 
genes but share wide ranging sequence homology at the amino acid level (Figure 1.3) 
(Bestor, 2000). Original biochemical studies identified several methyltransferase 
activities in cellular isolates, and in addition to DNMT1, the DNMT3 enzymes 
appear to account for these activities. In contrast to DNMT1, which is important for 
maintenance of pre-existing DNA methylation marks during DNA replication, the 
DNMT3 enzymes are largely thought to carry out the role of de novo DNA 
methylation in mammals (Bird, 1999; Okano et al., 1999; Xu et al., 1999). Cells 
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lacking the DNA methyltransferase 3a and 3b enzymes (Chen et al., 2003a) slowly 
lose genomic methylation, presumably because of imperfect fidelity in copying of 
DNA methylation profiles by DNMT1 during replication, and subsequent inability to 
add methylation to these missed methyl-CpU sites (Rhee et al., 2002). 
Reintroduction the DNMT3a enzyme into DNMT3a/b null cells restored wild type 
DNA methylation levels, verifying the role of DNMT3 enzymes in de novo 
methylation in vivo (Chen et al., 2003a). DNMT3a null mice are normal at birth but 
die at about 4 weeks later and DNMT3b null mice die at embryonic day 9. 5 due to 
multiple developmental defects (Okano et al., 1999). Therefore, de novo methylation 
is important for normal mouse development and survival. In support of the important 
role of DNMT3 enzymes in normal human development, mutations in DNMT3b 
have been linked to ICF syndrome (for immunodeficiency, centromere instability and 
facial anomalies)(Hansen et al., 1999; Xu et al., 1999). The ICF mutations in DMT3b 
are all in the C-terminal region of the protein which encodes the DNA 
methyltransferase domain, and at least one mutation is defective for de novo 
methyltransferase activity. In fitting with a loss of methyltransferase activity, ICF 
patients display a marked loss of DNA methylation over the human classical 
satellites 2 and 3 on chromosomes 1, 9, and 16 (Xu et al., 1999). The dynamic de 
novo methyltransferase function of the DNMT3a/b enzymes, in combination with the 
maintenance methyltransferase DNMT1 ensures fidelity of the DNA methylation 
system. 
Recently, a third DNMT3 family member was discovered that shares homology to 
the cysteine rich region of the DNMT3 enzymes, but lacks the conserved 
methyltransferase motifs (Figure 1.3) (Bourc'his et al., 2001; Hata et al., 2002). 
Knockout studies in mice demonstrated that the DNMT3L protein was necessary for 
normal male germ cell development and silencing of transposable elements 
(Bourc'his and Bestor, 2004). DNMT3L also has an important role in setting up 
maternal DNA methylation imprints, and a maternal effect lethal phenotype is 
observed in the progeny of homozygous females (Bourc'his et al., 2001). The loss of 
DNA methylation in DNMT3L knockout mice lead to the speculation that DNMT3L 
may associate with the DNMT3 enzymes, a prediction that turned out to be correct 
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(Hata et al., 2002). Further studies have delineated an interesting role for DNMT3L 
in direct interaction with, and stimulation of the DNMT3 a/b enzymes (Chedin et al., 
2002; Suetake et al., 2004). Stimulation of DNMT3a/b enzymes by DNMT3L results 
from a binding induced conformational change in DNMT3 a/b that causes increased 
DNA binding and catalysis (Gowher et al., 2005). An interesting but poorly studied 
aspect of DNMT3L function is interaction with histone deacetylase enzymes. Two 
reports have indicated that DNMT3L interacts with histone deacetylase enzymes to 
repress transcription, potentially linking active DNA methylation and chromatin 
remodelling (Aapola et al., 2002; Deplus et al., 2002). The contribution of DNMT3L 
to silencing of gene expression remains to be elucidated. 
1.2.6 DNA methylation in development, imprinting, and the X-
chromosome 
One of the most interesting aspects of DNA methylation is its dynamic role during 
development in setting up allele specific gene expression profiles in mammals. DNA 
methylation is involved in two general forms of allelic silencing; firstly, DNA 
methylation contributes to imprinting of a group of genes which are expressed 
exclusively from either the maternal or paternal allele, and secondly DNA 
methylation contributes to the dosage compensation system which results in 
silencing one of the two X-chromosomes in female offspring. 
In mice, the patterns of DNA methylation during development are well characterized. 
The DNA methylation marks in primordial germ cells are initially erased and then 
reform as the germ cells mature (Reik and Walter, 2001). The DNMT3 family of 
proteins are responsible for setting up these methylation marks (Bourc'his and 
Bestor, 2004; Bourc'his et al., 2001; Kaneda et al., 2004). After the egg is fertilized, 
the male pronucleus is rapidly demethylated, but the levels of methylation in the 
maternal genome remain high. From fertilization until the eight cell stage, passive 
demethylation of the maternal genome causes a global reduction in methylation 
levels until the maternal genome has roughly equal levels of methylation to the 
paternal genome (Mayer et al., 2000). Interestingly, there are certain imprinted genes 
which escape these demethylation events likely due to the function of a maternal 
store of DNMT1 (Delaval and Feil, 2004; Howell et al., 2001). From the eight cell 
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stage onwards, there is a gradual increase in the levels of DNA methylation until 
birth. DNA methylation marks are then maintained at high levels in most somatic 
cells with only minor alterations in methylation occurring in specific cells and loci. 
During development, a subset of 'imprinted' loci are unaffected by global changes in 
DNA methylation and they retain information encoded in the maternal and paternal 
gamete. The requirement for imprinting was originally hypothesized during the early 
1980's when 	pronuclear transfer studies using gynogenetic (only female 
chromosomes) and androgenetic (only male chromosomes) embryos highlighted the 
developmental requirement of a male and female gamete complement (Surani et al., 
1984). The term 'imprint' was used to describe the differences in the male and 
female gametes that accounted for their ability to complement one another and 
produce a normal embryo. The insulin-like growth factor II gene (Ig/2), a fetal 
mitogen, was the first to fit the definition of an imprinted gene, being exclusively 
expressed from the paternal chromosome (DeChiara et al., 1991). The importance of 
imprinted 1gf2 gene expression is evident from gene targeting experiments where 
Ig!2 was deleted. In 1gJ2 knockout mice, passage of the null allele through the female 
results in a normal mouse, but passage of the null allele thought the male germ-line 
resulted in growth deficiency (DeChiara et al., 1990). Further studies lead to the 
discovery that 1g/2 and H19 genes were genetically linked on chromosome 7 and 
reciprocally imprinted in gene expression profile on the male and female 
chromosome (Zemel et al., 1992). From studying the 1gJ2/H19 locus, the nature of 
the imprint responsible for control of allele specific expression was found to involve 
DNA methylation (Bartolomei et al., 1993; Ferguson-Smith et al., 1993). The general 
model of imprinting at the 1gJ2/H19 locus depends on a region called the 
differentially methylated domain (DMD) which is located between the 1g(2 and H19 
genes (Figure 1.4). This CpG rich DMD is non-methylated on the maternal allele 
allowing the insulator protein CTCF to bind and block access of a downstream 
enhancer to the Igf2 gene (Arney, 2003). Therefore, on the maternal allele the 
enhancer functions exclusively to drive H19 gene expression while 1gJ2 remains 









Figure 1.4- Imprinting at the H19/IGF2 locus 
The CpG rich DMD is non-methylated in the maternal allele where the insulator 
protein CTCF binds and blocks access of a downstream enhancer to the 1gJ2 gene. 
Therefore the enhancer is free to drive H19 gene expression while Ig2  remains 
silent. On the paternal allele the DMD is methylated which inhibits CTCF binding. 
The downstream enhancer is able to act on Igf2 allowing gene expression, while the 
H19 gene remains silenced. 
(Figure 1.4). The downstream enhancer is able to act on 1g/2 allowing gene 
expression, while the H19 gene remains silenced (Arney, 2003). The biological 
rational for reciprocal imprinting of the Igf2/H 19 locus remains uncertain but it may 
be the result of competing maternal and paternal genomes (Reik and Walter, 2001). 
The 1gJ2/H19 locus has been widely studied, but 60 other imprinted loci have been 
identified, and 100 are predicted to exist in the mouse genome (Scarano et al., 2005). 
In most cases, normal function of imprinted genes is associated with differentially 
methylated regions that also contain other epigenetic modifications (Fournier et al., 
2002). 
The importance of normal imprinting is highlighted by the association of several 
human diseases with loss of imprinting defects. For example, the autosomal 
dominant Angelman and Prader-Willi syndromes (Brannan and Bartolomei, 1999) 
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are caused by disruption of a cluster of imprinted genes on human chromosome 15. 
Normally, a sub-set of genes in this imprinted cluster are expressed exclusively from 
the maternal or paternal allele. These diseases usually result from a parent of origin 
deletion mutation which disrupts the normal balance of imprinted gene expression. 
Maternal defects result in Angelmans syndrome and paternal defects in Prader-Willi 
syndrome. Most mutations in Angelmans and Prader-Willi syndromes are the result 
of gene deletions, but direct defects in imprinting that correlate with perturbed DNA 
methylation accounts for about 5 % of cases (Kantor et al., 2004). 
The female mammalian X chromosome undergoes radical changes in DNA 
methylation patterns associated with near complete silencing of genes on a single X 
chromosome. Early in development the female embryonic cells independently 
choose which of the two X chromosomes will be inactivated and this choice is 
propagated in future cell generations, making females mosaic in terms origin of X 
chromosome expression. The X inactivation choice is made independent of gametic 
imprints, and therefore selection of X chromosome expression is not affected by 
parent of origin. Some exceptions to this rule exist, for instance, there is imprinted X 
inactivation in the placenta of some organisms (Huynh and Lee, 2001). The 
molecular process of X inactivation in mice is regulated by competing expression 
between the Xist and Tsix non-coding RNA's in a region called the X inactivation 
center (XIC). On the active X (Xa), an insulator protein, CTCF, binds elements near 
the Tsix promoter resulting in stable Tsix expression and inhibition of Xist 
accumulation. Repression of Xist on the Xa is partly due to methylation of its CpG 
island (Panning and Jaenisch, 1996). Conversely, on the future inactive X (Xi) 
chromosome, Tsix expression is lost allowing accumulation of the Xist RNA, and the 
Xist promoter region remains free of DNA methylation. Curiously, TSIX does not 
appear to have the same role in regulating human X inactivation, suggesting 
alternative regulatory mechanisms might exists in humans (Migeon, 2003; Migeon et 
al., 2002). With time, Xist RNA is able to coat the entire X chromosome and this 
event correlates with the initiation of silencing and eventually loss of gene 
expression from that X chromosome. Coverage of the Xi by Xist RNA is sufficient to 
initiate silencing but not required for its continued maintenance (Wutz and Jaenisch, 
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2000). Other factors including various chromatin modulators follow Xist coverage 
and progress the silencing program. A unique feature of silencing on the Xi is dense 
methylation of the CpG islands in most genes. Usually CpG islands remain free of 
DNA methylation regardless of expression status, but on the Xi CpG islands are 
specifically targeted for DNA methylation, perhaps as a long term and heritable 
mechanism of maintaining dosage compensation. The exact role DNA methylation 
plays in silencing genes on the inactive X is unclear as embryos deficient for de novo 
methyltransferase activity allow reactivation of gene expression under some 
circumstances, but in other cases normal silencing is maintained (Sado et al., 2000; 
Sado et al., 2004). More recent evidence suggests an important role for polycomb 
proteins, histone modification, and chromatin modeling in the initiation stages of X 
chromosome inactivation (de Napoles et al., 2004; Fang et al., 2004; O'Neill et al., 
2003; Plath et al., 2003). Multiple redundant silencing systems lead to normal X 
inactivation, and as a component of this silencing system DNA methylation is a 
distinct feature of the normal inactivated X chromosome. 
1.2.7 DNA methylation and silencing of parasitic DNA elements 
DNA methylation is integrally linked with genome defense in Neurospora. In 
mammals, DNA methylation protects against the deleterious affects of parasitic DNA 
elements in addition to well characterized roles in modulating gene expression. The 
human genome is littered with repetitive DNA (35 %)(Yoder et al., 1997a), a large 
percentage of which corresponds to inactivated copies of parasitic elements. Most 
parasitic elements consist of short inderdispersed DNA elements (SINE's), long 
interdispersed DNA elements (LINE's), and LTR containing elements (Smit and 
Riggs, 1996). Activation of transposable elements and insertion into novel locations 
within the genome could have devastating affects on the normal coding potential of 
the genome. Most of the functional transposable elements in mammalian cells are 
densely methylated and silenced (Yoder et al., 1997b). DNA methylation likely 
contributes to the long term silencing of these elements through recruitment of 
chromatin modifying transcriptional repressors (Hata and Sakaki, 1997; Yu et al., 
2001). In Dnmtl null mouse embryo's, loss of DNA methylation correlates with 
reactivation of a class of LTR elements called TAP's (Gaudet et al., 2004; Walsh et 
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al., 1998). Interestingly the LTR containing TAP elements do not undergo 
demethylation during the cleavage stages of mouse development (Lane et al., 2003), 
presumably to protect against activation of these functional transposons, during this 
sensitive time of development. A maternal store of DNMT1 (DNMT10) or DNMT3 
proteins likely mediate maintenance of TAP methylation at this critical point during 
mouse development (Howell et al., 2001). DNA methylation is also involved in the 
long term silencing of lAP elements and a general decrease in methylation of TAP 
elements in aged mice correlates with increased transcription of these elements 
(Barbot et al., 2002). 
I .28 Targeting DNA methylation by small RNA's in mammals? 
In plants, DNA methylation can be targeted by small double stranded RNA's to 
homologous DNA sequences as a means of silencing repetitive elements and 
modulating gene expression (Jones et al., 2001; Tariq and Paszkowski, 2004). RNAi 
induced DNA methylation occurs at most cytosines in the affected region, not just in 
context of CpG dinucleotides (Aufsatz et al., 2002). Recent studies in plants have 
identified a DNA methyltransferase (DRM)(Cao et al., 2003) and a class of RNA 
polymerase gene that are responsible for the RNAi mediated DNA methylation (Herr 
et al., 2005). 
Short double stranded RNA in mammalian cells can lead to the active destruction of 
homologous single stranded RNA's via a post-transcriptional silencing mechanism 
(Matzke and Birchler, 2005; Sontheimer, 2005). Endogenous or exogenously 
produced double stranded RNA's generated by pairing of sense and antisense 
transcripts can act as a source of dsRNA that is processed by mammalian Dicer, an 
RNAse III related enzyme (Sontheimer, 2005). Dicer also processes microRNA's, 
which are shorter hairpin RNA's normally made in the cell that can target 
endogenous mRNA's for translational inhibition (Gebauer and Hentze, 2004). 
Substrates processed into small dsRNA's by Dicer are transferred to the RISC (RNA 
induced silencing complex) complex which mediates post transcriptional silencing. 
In plants and S. pombe, processing of double stranded RNA can result in 
transcriptional silencing affects in addition to post-transcriptional mRNA 
degradation (Schramke and Alishire, 2003). In S. pombe the nuclear RNA induced 
initiation of transcriptional gene silencing (RITS) complex binds siRNA's and is 
targeted to the actively transcribing genomic locus corresponding to the bound 
siRNA and contributes to the transcriptional silencing program (Motamedi et al., 
2004). This pathway in S. pombe is particularly important for silencing within the 
centromeric repeats (Motamedi et al., 2004; Verdel et al., 2004). Once RITS is 
located at the corresponding genomic loci it induces transcriptional silencing by 
modifying chromatin structure (Verdel et al., 2004). 
Recently, DNA methylation directed by double stranded RNA has been observed in 
mammalian cells, suggesting that RNA mediated transcriptional silencing pathways, 
like that found in plants and fungi, might also exist in mammals. Two studies have 
successfully demonstrated short double stranded RNA (dsRNA) can target DNA 
methylation to corresponding DNA sequences. The first study used a combination of 
dsRNA's corresponding to the promoter of an endogenous gene and observed DNA 
methylation at CpG dinucleotides in the promoter DNA. Knock down of DNMT 
enzymes revealed that DNMT1 and DNMT3 are capable of mediating DNA 
methylation as a result of the dsRNA (Kawasaki and Taira, 2004). The second study 
confirmed that short double stranded RNA could silence an endogenous gene. In this 
study it appeared as it the nuclear envelope was a barrier for dsRNA entry into the 
nucleus, and effective silencing was only observed when the nucleus was made 
permeable to the siRNA (Morris et al., 2004). Other studies have not been able to 
target DNA methylation by dsRNA, suggesting that this process may be context 
dependent, or require unknown factors for efficacy (Park et al., 2004; Svoboda et al., 
2004). In agreement with the existence of intact transcriptional silencing pathway in 
mammals, Dicer knockout ES cells display up-regulation of centromeric satellite 
repeat transcription, and have decreased levels of DNA methylation in the 
centromeric repeats (Kanellopoulou et al., 2005). More work is needed to delineate 
the functional properties of a nuclear RNAi silencing pathway in mammals, but 
evidence suggests that de novo DNA methylation is an active component. 
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1.2.9 DNA methylation and cancer 
The initial link between levels of DNA methylation and cancer revealed that tumor 
samples were hypomethylated when compared to normal tissue of a similar origin 
(Feinberg and Vogelstein, 1983). Hypomethylation likely contributes to malignancy 
by allowing the re-expression of genes which are normally silenced by DNA 
methylation and by loss of genomic stability that comes from reduced methylation 
profiles (Feinberg and Tycko, 2004). DNA hypomethylation occurs in most cancer 
tissues and cells lines, but other regions of the malignant genome acquire distinct 
hypermethylation (Baylin et al., 1986; Toyota and Issa, 1999). Hyperrnethylation in 
promoter regions of genes is associated with silencing, and if a malignant cell can 
silence a gene that inhibits rapid cellular growth this is an obvious advantage for 
sustained proliferation. A common target of promoter methylation in cancer cells are 
tumor suppressor genes including RB, p16, and MLH1 (Esteller, 2000). Inhibition of 
RB and p16, whose sole job is to control cell cycle events, allow the cancer cell to 
bypass checkpoints normally in place to preclude rapid and continual cell division. 
By silencing the mismatch repair protein MLII 1, a cancer cell can increase the rate of 
mutation and accelerate the likelihood of acquiring new mutations that are 
advantageous to growth. Tumors in which the promoter region of MLH1 is 
methylated and gene expression is silenced, display a reduced mismatch repair 
capacity (Herman et al., 1998). Lack of MLH1 mismatch repair activity has a 
profound affect on the repetitive microsatellite sequences in the genome, and this is 
likely an indicator of an overall inability to repair mismatch events that occur as 
DNA polymerase replicates DNA (Herman et al., 1998). The clinical relevance of 
DNA hypermethylation in cancer is exemplified by positive results in clinical trials 
treating cancer patients with low doses of the demethylating agent 5-Azacytidine 
(Esteller, 2005), and the recent approval of 5-azacytidine by the U. S. Food and Drug 
Administration for the treatment of myelodysplastic syndrome (Esteller, 2005; Leone 
et al., 2002). 
A mouse model deficient in DNA methyltransferase activity has provided genetic 
evidence for an active role of DNA methylation in cancer progression. These studies 
have been carried out in the Apc(M17  mouse which was used as a model for 
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spontaneous colorectal cancer formation. Apc(Mh1  mice carry a germ-line mutation 
in one copy of the tumor suppressor gene, Apc, and are susceptible to polyp 
formation in the intestinal mucosa. In the Apc(M 	mouse, the level of CpG island 
hypermethylation was dramatically increased in the developing polyp, when 
compared to adjacent normal mucosa. Crossing mice with a hypomorphic allele of 
Dnmtl onto the Apc(M1'  mouse background resulted in complete genetic 
suppression of polyp formation (Eads et al., 2002). Hypermethylation of CpG islands 
is normally observed in the developing polyp of Apc(Mu1  mice but was absent in the 
Dnmtl hypomorph mice indicating that CpG island hypermethylation is a rate 
limiting step in polyp formation. These studies provide a direct link between CpG 
island hypermethylation and progression of colorectal cancer. 
1.3 Chromatin remodeling and histone modification in gene 
expression 
1.3.1 Chromatin structure, histones, and histone modification 
nomenclature 
The basic protein unit responsible for compacting DNA into the relatively small 
confines of the nucleus is the histone octamer. The histone octamer consists of two 
dimers of histone H2A:H2B and H3 :H4, around which approximately 147 base pairs 
of DNA is wrapped (Peterson and Laniel, 2004). Hierarchal nucleosome fibers form 
the basic octamer unit further increasing the potential for DNA compaction (Dorigo 
et al., 2004). In addition to the biophysical properties of chromatin, post translational 
modification of histones, and histone variants, can have profound affects on the 
activity of the genetic information wrapped around histone octamers. Over the past 5 
- 10 years a large amount of information about histone modification and histone 
modification states has become available. Histone modifications include; 
biotinylation (Camporeale et al., 2004), ubiquitination, sumoylation, ADP-
ribosylation, phosphorylation, acetylation, and methylation (Strahi and Allis, 2000). 
The nomenclature used to describe histone modification varies, so as a matter of 
clarity this section of the introduction uses the standardized BRNO nomenclature to 
describe histone modifications (Turner, 2005). The most thoroughly characterized 
histone modifications involved in regulating gene activity are acetylation and 
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methylation. This section of the introduction will mostly address these modifications 
as removal of histone acetylation and addition of certain repressive histone 
methylation marks is associated with DNA methylation. 
1.3.2 Active histone modification marks 
To activate gene expression in a genomic context there is a requirement to overcome 
the repressive chromatin environment that keeps genes silenced in the absence of 
activating factors. Most gene activation is associated with hyperacetylation of the 
lysine residues on core histone tails in the promoter region and 5' end of genes, both 
immediately prior to and during active transcription. In budding yeast, acetylation is 
associated with the 5' ends of genes, and in higher eukaryotes hyperacetylation is 
linked to promoter regions of genes (Roh et al., 2005; Roh et al., 2004). Recent 
genome wide chromatin mapping projects have demonstrated a tight correlation 
between the level of histone acetylation and the location of promoter and regulatory 
elements in genes (Bernstein et al., 2005; Roh et al., 2005). Moreover, the levels of 
histone acetylation are tightly correlated with the transcriptional state of the gene, 
and active genes are generally hyperacetylated (Schubeler et al., 2004). Acetylated 
lysines are found on multiple residues within the n-terminal tails of histone 
molecules, including; H2AK(5 ,9)ac, H2BK(5, 12,1 5,20)ac, H3K(9, 14,1 8,23)ac, and 
H4K(5,8,12,16). 
Since the first histone acetyltransferase gene was cloned in Tetrahymena (Brownell 
et al., 1996), a series of acetyltransferase proteins containing the conserved histone 
acetyltransferase (HAT) domain have been identified in eukaryotes. In mammals, 
there are a surprisingly large number of histone acetyltransferase enzymes, which 
likely reflects their diverse substrate specificities and varying functions related to 
transcriptional activation (Ogryzko, 2001). In most cases, histone acetyltransferase 
enzymes do not have DNA binding capacity but instead rely on transcriptional 
activators and local chromatin modification for site specific recruitment and activity. 
Two of the most thoroughly studied acetyltransferase complexes are TFIID and 
PCAF/GCN5. In budding yeast, these two complexes have global affects on 
transcription, combining to affect the expression of about 70 % of genes (Lee et al., 
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2000). A certain degree of specificity exists, as independently TFIID affects 30 % of 
genes and GCN5 (SAGA) 12 % of genes (Lee et al., 2000). The precise substrate 
specificity of the mammalian HAT enzymes in vivo (reviewed in (Kuo and Allis, 
1998; Marmorstein, 2001)) is not entirely clear but individual enzymes do display 
amino acid preference within histones. 
Histone acetylation can alter the charge properties of the N-terminal tails that 
protrude outwards from the core histone octamer, resulting in fewer positive charges. 
The loss of positive charge reduces the affinity of the n-terminal tails for negatively 
charged DNA molecules (Hong et al., 1993), which in turn may contribute to 
increased accessibility of DNA elements within chromatin containing 
hyperacetylated histones (Lee et al., 1993). In addition to the charge affects on 
histone tail/DNA interaction, another role of histone acetylation is to create docking 
sites for proteins that specifically recognize acetylated histone tails, which then act as 
a system to interpret the acetyl-lysine signal. An example of a domain that can 
directly recognize acetylated lysine residues in the N-terminal tales of histones is the 
bromodomain (Dhalluin et al., 1999; Jacobson et al., 2000; Zeng and Zhou, 2002). 
Structural analysis indicates that the bromodomain can interact with acetyl lysine but 
also requires interactions with flanking amino acid sequences providing individual 
bromodomains a certain amount of selectivity within proteins that contain multiple 
acetyl lysine residues (Mujtaba et al., 2002). Functional bromodomain proteins 
include histone acetyltransferases and chromatin remodeling enzymes (Hassan et al., 
2002) suggesting that the bromodomain functions to interpret, and perhaps and 
propagate, active acetylated chromatin states (Cosgrove et al., 2004). 
Methylation of specific arginine and lysine residues in histones H3 and H4 has also 
been linked to transcriptionally active genes. These methylation modifications occur 
on; H3K4, H3K36, H3K79, and H4R3. Unlike lysine acetylation, lysine methylation 
can occur in three different states mono, di, and tri methylation ( ie H3K4mel, 
H3K4me2, and H3K4me3), depending on the enzyme which applies the modification 
(Zhang et al., 2003). Genome wide analysis has revealed that H3K4m2 is associated 
with the 5' and body of genes that are actively transcribed, or are in a poised state for 
transcriptional activation (Santos-Rosa et al., 2002; Schneider et al., 2004). H3K4m3 
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is a better indicator of genes actually in the process of transcription and is usually 
only associated with the 5' regions of the gene (Bernstein et al., 2005; Ng et al., 
2003). Histone H3K36 methylation is intimately associated with the active process of 
transcription and is found over the body of actively transcribed genes (Bannister et 
al., 2005; Strahi et al., 2002; Xiao et al., 2003b). H3K79 methylation is directly 
linked to H3K4 methylation in the 'trans-regulatory' histone modification pathway 
(Briggs et al., 2002; Xiao et al., 2003b). This pathway requires ubiquitination of 
H2B 123 which leads to methylation of both H3K79 and H3K4 in association with 
gene activation. Finally, H4R3 is methylated in response to active transcription by 
hormone receptors (Ma et al., 2001). 
SET domain containing proteins are responsible for the majority of histone 
methylation and catalyze the formation of H3K4, H3K36, and H4K20 methylation 
(Xiao et al., 2003a). H4R3 methylation is catalyzed by PRMT1, a nuclear member of 
the protein methyltransferase family, and H3K79 methylation is mediated by an 
interesting protein, Dotl, that lacks a SET domain and seems to be unique in its 
capacity to modify H3K79. There are a growing number of SET domain proteins 
from yeast to humans that have active histone methyltransferase activity, and each 
uses roughly the same enzymatic mechanism (Xiao et al., 2003a). Although 
extensive similarity exists between SET domain containing proteins, each appears to 
have quite distinct specificity for both amino acid residue and methylation state. 
Several structural studies have identified intrinsic differences that contribute to this 
specificity (Xiao et al., 2003a). 
Recently, the chromodomain was shown to interact with methylated lysine residues 
on histone tails, and may have an analogous roles to the acetyl-lysine recognition by 
the bromodomain (Jacobs and Khorasanizadeh, 2002; Nielsen et al., 2002). A large 
number of proteins associated with chromatin function have chromodomains, 
indicating that a diverse network of factors may be involved in interpreting histone 
methylation marks. For example, the yeast chromodomain containing protein Chdl, a 
component of the yeast SAGA histone acetyltransferase complex, specifically 
recognizes H3K4m2. This interaction suggests that histone methylation on H3K4 
may recruit histone acetyltransferase activity via the chromodomain of Chdl, 
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efficiently coupling histone methylation and acetylation (Pray-Grant et al., 2005). 
Methylation of H3K4 also acts as a binding site for the ATPase dependent chromatin 
remodeling factor ISWI (Santos-Rosa et al., 2003; Zegerman et al., 2002), while 
inhibiting binding of the repressive nucleosome remodeling and deacetylation 
complex called NURD (Zegerman et al., 2002). Further investigation will uncover 
how histone methylation marks contribute to gene activation. 
1.3.3 Repressive histone modification marks 
A key step in gene silencing is the removal of histone modifications that are 
associated with the active state. When genes are silenced, the level of histone 
acetylation rapidly decreases in the promoter region of the gene. The rapid nature of 
this modification reversal is the result of a class of enzymes called histone 
deacetylases that actively remove acetyl groups from lysine residues (Katan-
Khaykovich and Struhl, 2002). The identity of the genes responsible for histone 
deacetylation remained elusive until biochemical purification and cloning revealed 
an active deacetylase enzyme, named histone deacetylase 1 (HDAC1). HDAC1 turn 
out be homologous to the yeast transcriptional repressor Rpd3 confirming a role in 
gene silencing (Taunton et al., 1996). Bioinformatic analysis using HDAC1 amino 
acid sequence led to the identification of a family of enzymes that efficiently catalyze 
the removal of acetyl groups from lysine without co-factors (Taunton et al., 1996). 
Nicotinarnide adenine dinucleotide (NAD)-dependent histone deacetylases have 
subsequently been identified which also efficiently remove acetyl groups from lysine 
(Imai et al., 2000). Histone deacetylase enzymes are found in a variety of co-
repressor complexes in the nucleus and are recruited by transcriptional silencers to 
aid in the removal of active histone acetyl marks, during transcriptional repression 
(Jepsen and Rosenfeld, 2002). 
An enzymatic activity that could remove methyl groups form lysine residues in 
histories was characterized in the early seventies (Paik and Kim, 1973), but studies 
analyzing the turnover of methylated histones suggested that methylation was not 
actively removed once transferred to lysine residues (Waterborg, 1993). Lysine 
specific demethylase 1 (LSD 1) was recently identified, laying to rest the controversy 
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regarding the reversibility of histone methylation (Shi et al., 2004). Very little is 
known about the cellular roles of LSD  but it does specifically remove H3K4m1 and 
H3K4m2 groups by an oxidation reaction involving FAD as a cofactor. Before the 
enzymatic activity of LSD 1 was identified, it was found as a protein component of 
various cellular co-repressor complexes (Shi et al., 2004), that also contain histone 
deacetylase enzymes. Therefore, factors involved in reversing the active post-
translational modification on histories appears to be actively coupled to the 
transcriptional repression systems affirming the importance of clearing active 
chromatin marks during gene silencing. 
In addition to removing active histone modifications, silencing of gene expression 
also involves the addition of specific histone methylation modifications. Methylation 
of H3K9, H3K27, and H4K20 are all causatively linked to silenced chromatin. 
Methylation of H3K9 in mammals is found associated with the promoter regions of 
silenced genes (Kondo et al., 2004), repetitive DNA elements (Kondo et al., 2004), 
and regions of centromeric heterochromatin (Martens et al., 2005). H3K9m3 is 
concentrated in regions of centromeric heterochromatin and is part of a silencing 
pathway that results in H4K20m3 (Schotta et al., 2004). The exact function of the 
H3K9rn3/H3K20m3 pathway remains unclear, but it does contribute to the normal 
silencing of aberrant centromeric repeat transcription (Schotta et al., 2004). 
Methylation of H3K27 is also linked to the repressed state (Peters et al., 2003). The 
best characterized functions for H3K27m are in silencing of transcription associated 
with the ultrabithorax genes in Drosophila (Cao et al., 2002), the Hox gene cluster in 
mammals (Cao and Zhang, 2004), and X-chromosome inactivation (Plath et al., 
2003; Silva et al., 2003). 
Like active histone modification marks, repressive histone methylation marks create 
binding sites for chromodomain containing proteins. The chromodomain containing 
heterochromatin protein 1(HP1), can recognize H3K9 methylation (Bannister et al., 
2001; Jacobs et al., 2001; Lachner et al., 2001), and through interactions with H3K9 
methyltransferase Suv39Hl propagates the silenced chromatin state (Yamamoto and 
Sonoda, 2003). The enhancer of zeste methyltransferase complex (Cao et al., 2002) 
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modifies H3K27, and this mark is recognized by the Polycomb protein which also 
has a chromodomain (Min et al., 2003). 
1.3.4 Does a histone code exist? 
Many modification states can occur on histone molecules in chromatin. Some 
modifications occur in combination, while others exclude subsequent modification at 
on the same molecule (Nishioka et al., 2002; Sarg et al., 2004). The interaction of 
histone modification states is exemplified by the H2BK123u/H3K79rn/H3K4m trans 
regulatory pathway in budding yeast (Briggs et al., 2002; Sun and Allis, 2002). In 
this pathway H2BK123u is a prerequisite for H3K79 and H3K4 methylation, 
exemplifying how one modification can be required for the subsequent modification 
of other residues. Proteins that recognize different modification states on histone tails 
may be a mechanism to interpret these modifications and result in differing 
biological outcomes (de la Cruz et al., 2005; Turner, 2002). The diverse range and 
combinatorial affects of different histone modifications suggest these states may be 
an epigenetic system to code for biological readout. Therefore, the existence of a 
binary histone modification code that shares similarity to the genetic information 
stored in DNA code has been proposed (Fischle et al., 2003; Jenuwein and Allis, 
2001; Turner, 2002). For many, the idea of a histone code is misleading as the 
information stored in histone modifications is not as rigid as protein coding 
information that is found in gene encoding DNA (Peterson and Laniel, 2004). Fine 
scale histone modification mapping and identification of proteins that interpret 
different combinations of histone modification will help to iron out the specificity of 
histone modifications and how their interplay results in biological outcome. 
1.3.5 Interplay between histone modification and DNA 
methylation 
In Neurospora all DNA methylation is directly linked to histone H3 K9 tn-
methylation (H3K9me3). A mutation in the SET domain of the H3 trimethylase dim-
5 results in a complete loss of DNA methylation (Tamaru and Selker, 2001). DNA 
methylation is also completely dependent on HP1 recognition of H3K9me3 (Tamaru 
et al., 2003) suggesting HP1 is necessary to recruit the DNA methyltransferase 
activity of dim-2 (Section 1.2. 1) to loci containing histone methylation. 
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In plants, interdependence between DNA methylation and histone 
H3K9me/H3K27me has also been identified. Arabidopsis with mutations in the 
Kryptonite (KYP) gene, which is a H3K9 methyltransferase, lose DNA methylation 
at CpNpGp sites (Jackson et al., 2002; Malagnac et al., 2002). The DNA 
methyltransferase (CMT3), which is responsible for CpNpGp methylation, is 
recruited by its chromodomain, to sites of H3K9me/K3K27me (Lindroth et al., 2004) 
to induce DNA methylation. This suggests that fungi and plants have evolved 
different methyl-histone recognition modules to induce DNA methylation at loci 
containing histone methylation. In Neurospora loss of DNA methylation does not 
affect histone methylation patterns, but in plants DNA methylation has the capacity 
to direct histone methylation marks (Soppe et al., 2002; Tariq et al., 2003). In plants 
CpG methylation mediated by the plant homologue of DNMT1 (MET1) affects the 
level of H3K9 methylation. Therefore plants appear to have evolved mechanisms by 
which DNA and histone methylation can influence each other. 
In mammals the exact mechanisms by which the DNA and histone methylation 
pathways interact is less clear, but analogous to the situation in plants, histone 
methylation has an impact on DNA methylation and visa versa. In mammals, both 
methylation systems are physically linked with DNMT1 immunoprecipitating 
Suv39H1 (Fuks et al., 2003a) and DNMT3a/b associating with H3K9 
methyltransferase activity (Fuks et al., 2003a; Geiman et al., 2004). There is no 
decisive evidence to indicate whether DNA methylation or histone methylation is the 
initiating signal in the silencing that employs both systems. In some instances, 
histone methylation appears to be the initiating signal, for example, the kinetics of 
silencing the pl6ThhJ(4d1  gene in cancer cells indicates that histone methylation 
precedes DNA methylation (Bachman et al., 2003). A similar observation was made 
in the Suv39hl and h2 double null ES cells that have reduced H3K9 methylation at 
pericentric heterochromatin, delocalized DNMT3b staining pattern, and reduced 
DNA methylation at satellite repeats (Lehnertz et al., 2003). In other instances, DNA 
methylation appears to be the initiating signal, as cells with reduced DNA 
methylation also have reduced histone H3K9 methylation levels (Espada et al., 
2004). In summary H3K9 methylation and DNA methylation in mammalian cells are 
associated but which is the recruiting or initiating signal may be context dependent. 
1.3.6ATP dependent chromatin remodeling factors and DNA 
methylation 
The link between DNA methylation and ATP dependent chromatin remodeling 
activity was first identified in plants. A genetic screen for Arabidopsis mutants that 
have decreased DNA methylation levels revealed a causative gene, called ddml, that 
has homology to yeast SWI2/SNF2 protein (Jeddeloh et al., 1999; Vongs et al., 
1993). In vitro evidence suggests that the DDM1 protein can actively utilize ATP to 
remodel assembled chromatin templates (Brzeski and Jerzmanowski, 2003), and 
DDM1 may function in vivo to maintain DNA methylation levels by allowing access 
of DNA methyltransferase enzymes to their substrates in chromatin. 
In mammals, efficient DNA methylation also relies on SWI2/SNF2-like ATPases. 
The mammalian LSH and ATRX (alpha thalassemia/mental retardation syndrome X-
linked) proteins both contain SWI2/SNF2-like ATPase domains, and are required to 
maintain normal DNA methylation levels (Dennis et al., 2001; Gibbons et al., 2000). 
LSH null embryos have global losses of DNA methylation, with some tissues having 
40 % total reduction in methyl cytosine content (Dennis et al., 2001). Loss of DNA 
methylation in ATRX patients is slight and localized in rDNA arrays, a Y-specific 
satellite, and subtelomeric repeats (Gibbons et al., 2000). Whether LSH is a 
functional ATPase remains to be determined, but ATRX has been demonstrated in 
vitro to contain ATPase and helicase activity (Tang et al., 2004; Xue et al., 2003). 
Another mammalian SWI2/SNF2 protein hSNF2H interacts with the de novo 
methyltransferase DNMT3b (Gelman et al., 2004), but its affects on DNA 
methylation in vivo have yet to be investigated. The exact molecular role that 
ATPase containing chromatin remodelling factors play in maintaining DNA 
methylation remains poorly characterized, but chromatin remodelling activities likely 
permit DNA methyltransferase enzymes access to CpG dinucleotides within a 
chromatin context. 
1.4 Interpretation of DNA methylation 
1.4.1 DNA methylation and silencing 
In some instances, transcription factor binding can be disrupted by the presence of 
DNA methylation within its recognition site. If the transcription factor is an 
activator, interference by DNA methylation can act as an indirect and passive 
silencing mechanism (Watt and Molloy, 1988). Passive mechanisms of repression 
only partially contribute to the affect of DNA methylation on silencing. If methylated 
and non-methylated reporter vectors are injected into rodent cells, initially gene 
expression from both constructs is equal, but within 24 - 48 hours the methylated 
construct becomes completely repressed, suggesting an active silencing program 
exists (Buschhausen et al., 1985; Buschhausen et al., 1987). From these experiments 
it was hypothesized that chromatin may be required for DNA methylation dependent 
silencing and the lag period required for efficient silencing was due to the gradual 
addition of nucleosomes to the exogenous reporter DNA. Subsequent studies 
indicated that methylated reporter vectors pre-assembled into chromatin and then 
injection into living cells were more rapidly silenced than the equivalent naked 
DNA, indicating that chromatin was a major contributor to the silencing phenomena 
(Buschhausen et al., 1987). Addition of nucleosomes to an unmethylated reporter 
vector did not silence its expression to the same extent, so it was presumed that other 
nuclear factors may be recognizing the methylated reporter vector and contributing to 
the robust silencing observed in vivo (Buschhausen et al., 1987; Kass et al., 1997). 
Subsequent studies using methylated reporter genes in transient transfections and in 
vitro transcription assays defined an indirect role of DNA methylation in silencing 
transcription (Boyes and Bird, 1991). Silencing of methylated reporter vectors in 
vitro was dependent on the level a methyl-CpG binding activity (MeCP 1 )(Meehan et 
al., 1989)(Section 1.4.2), suggesting that a protein component that recognizes DNA 
methylation was important in mediating silencing. 
1.4.2 Identification of activities that bind methyl-CpG 
The first indication that proteins might exist that bind methyl-CpG in vivo came from 
restriction endonuclease accessibility assays in isolated cellular nuclei (Antequera et 
al., 1989). In these assays, intact nuclei were refractory to endonuclease digestion at 
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methyl-CpG, but the same DNA in protein free isolates was easily digested. Two 
activities in were isolated from nuclear extracts that could specifically recognize 
sequences containing methyl-CpG in vitro, but not the equivalent sequence when it 
was non-methylated (Lewis et al., 1992; Meehan et al., 1989). The protein identity of 
the first activity, MeCP 1, was not identified until several years later (Feng and 
Zhang, 2001), but the second activity, MeCP2, was very abundant in brain extracts 
facilitating conventional biochemical purification. A single polypeptide 
corresponding to the MeCP2 activity was micro-sequenced by Edman degradation 
and a corresponding cDNA isolated (Lewis et al., 1992). 
1.4.3 Isolation of a family of Methyl-CpG Binding proteins 
Mapping studies using southwestern blot analysis allowed localization of a methyl-
CpG binding domain (MBD) within MeCP2 (Nan et al., 1993). The protein sequence 
of the MBD was used to search cDNA databases and a second methyl binding 
protein was identified and named PCM1 (protein containing methyl-CpG binding 
domain 1)(Cross et al., 1997). PCM1 specifically recognized methylated-CpG, and 
was later renamed MBD1 (Figure 1.5)(Hendrich and Bird, 1998). Using a similar 
bioinformatic approach three more mammalian MBD containing proteins were 
isolated and named MBD2, MBD3, and MBD4 (Hendrich and Bird, 1998). 
Mammalian MBD2 and MBD4 both bind methylated DNA specifically, but MBD3 
lacks methyl-CpG dependent DNA binding capacity (Hendrich and Bird, 1998). 
1.4.4 Structure of the MBD 
The basic fold of the MBD consists of a wedge shaped oc/P sandwich as determined 
by NMR structures of both the MeCP2 and MBD1 MBD domains (Ohki et al., 1999; 
Wakefield et al., 1999). The three dimensional structure of the MBD is made up of a 
four strand anti-parallel beta sheet linked to a single short alpha helix (Figure 1.6). 
An NMR structure of the MBD domain of MBD 1 in complex with methylated DNA 
has provided an atomic level resolution the DNA I protein interface (Ohki et al., 
2001). The beta sheet region of the MBD is composed of two short outer strands and 
two long inner strands. A nine amino acid loop between the inner strands of the beta 
sheet becomes structured upon DNA binding, and together with inner beta strands 
41 
	
MeCP2 	 IHI 	 IlI 	
I 
(XXC CXXC (XXF 
MBDI 	






MBD4 	 IIIP 
Kuiso 	
I I I 
Figure 1.5- The methyl-CpG binding protein family 
The DNA binding domains the methyl-CpG binding proteins are indicated by MBD, 
ZF, and CxxC domain. The MBD and ZF (Kaiso) are responsible for recognizing 
methylated DNA and the third CxxC domain of MBD1 binds non-methylated CpG. 
The transcriptional repression domains are in indicated by TRD (or POZ for Kaiso), 
and the DNA repair domain of MBD4 is indicated by its glycosylase domain 
Figure 1.6- Structure of the MBD domain of MBD 1 bound to methylated DNA 
(Adapted from (Ohki et al., 2001)) 
The long beta strands of the MBD bind deep in the major groove specifically 
recognizing one of the methylated bases. The loop joining to two long beta strands 
becomes structured upon DNA binding contributing to DNA recognition. The amino 
acids between the beta sheet and the alpha helix contribute to recognition of the 
second methyl-CpG while the alpha helix mostly contributes to DNA backbone 
contacts. 
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forms the bulk of the DNA biding face that lies in the major groove (Figure 1.6). The 
loop joining the beta sheet to the alpha helix projects into the major groove and 
makes important base contacts. The alpha helix mostly contributes contacts with the 
phosphate backbone (Figure 1.6). The methyl groups are directly recognized by 
hydrophobic amino acids in the beta sheet and also two residues in the loop between 
the beta sheet and the alpha helix. 
1.4.5 The ancestral MBD protein 
Bioinforrnatic analysis has successfully mapped the evolution of MBD containing 
proteins with the aid of newly available genome sequence information (Hendrich and 
Tweedie, 2003). MBD2 and MBD3 are likely the ancestral MBD proteins as they are 
the only vertebrate MBP'S that have homologues in invertebrate genomes (Hendrich 
and Tweedie, 2003). The MBD2/3 protein is encoded by a single gene in invertebrate 
genomes but diverges into two similar proteins in vertebrate genomes (Hendrich and 
Tweedie, 2003). The following sections will mostly deal with the MBP's found in 
vertebrates. 
1.4.6 MeCP2 
MeCP2 will be discussed in detail in the following section (Section 1.5) 
1.4.7 MBDI 
The MBD1 protein contains a N-terminal MBD and a potent transcriptional 
repression domain in the C-terminus (Figure 1.5). Between the MBD and TRD are 
several cysteine rich domains (CxxC) which potentially coordinate zinc ions. The 
MBDJ gene gives rise to five splice variants in human cells (Fujita et al., 1999), and 
four splice variants in mouse cells (Jorgensen et al., 2004). MBD1 splice variants 
usually affect the number of CxxC domains included in the final protein product, or 
the sequence surrounding the TRD. 
The MBD of MBD1 specifically binds methylated-CpG, but the CxxC3 domain is 
also a functional DNA binding domain (Jorgensen et al., 2004). The CxxC DNA 
binding domain was originally isolated in a screen for proteins that bind to non-
methylated CpG dinucleotides (Voo et al., 2000). On its own the CxxC3 domain of 
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MBD 1 has the capacity to bind non-methylated CpG dinucleotides, suggesting that 
certain MBD 1 isoforms may be recruited to both methylated and non-methylated 
DNA sequences (Jorgensen et al., 2004). Interestingly, the CxxC3 domain of MBD1 
shares homology with the CxxC domains of two other factors involved in chromatin 
methylation: HRX (a histone methyltransferase) and DNMT1 (a DNA 
methyltransferase)(Ayton et al., 2004). 
The transcriptional repression domain of MBD1 is a very short (32 amino acid 
sequence) in the C-terminus of the protein that efficiently represses transcription at 
distance of up to 2 kilo-bases from an active promoter in a histone deacetylase 
dependent manner (Ng et al., 2000). The repression domain of MBD1 interacts with 
a co-repressor molecule called MCAF1 (Fujita et al., 2003b), and MBD1 actively 
recruits MCAF 1 to methylated promoters in vivo. The MBD of MBD 1 also interacts 
with CAF1 providing an indirect link between MBD1 and the CAF1 associated 
protein HP1 (Fujita et al., 2003c). The interaction of HP1 with MBD1/CAF1 might 
account for the observed recruitment of the HP  protein partner, Suv39Hl, to some 
MBD1 bound loci (Fujita et al., 2003c). A recent report has suggested that MBD1 
interacts with methylpurine—DNA glycosylase activity to repress transcription, but 
the relevance of this interaction remains to be demonstrated (Watanabe et al., 2003). 
A study published last year has highlighted a novel role for MBD1 in copying 
histone H3K9 methylation marks to regions of DNA methylation during DNA 
replication (Sarraf and Stancheva, 2004). In this study MBD1 associated with histone 
H3K9 methyltransferase activity, and a yeast two-hybrid study mapped a direct 
interaction between a c-terminal region of MBD 1 and the histone methyltransferase 
SETDB1. MBD1 and SETDB1 can form a complex with previously identified co-
factor CAF 1 during S-phase of the cell cycle, and this interaction is essential for 
deposition of H3K9me marks at MBD1 target loci. This interesting role of MBD1 
during DNA replication indicates that eukaryotic MBD proteins may have diverse 
roles in interpreting the methyl-CpG signal in the mammalian cell. 
An Mbdl null mouse has been generated and displays a very mild neurological 
phenotype (Zhao et al., 2003), but is viable, healthy, and fertile. Adult neuronal stem 
cells from Mbdl null mice also display reduced capacity to differentiate and have 
genomic instability. The null mouse brain has reduced neurogenisis and the mice 
exhibited decreased spatial learning. The subtle defects in Mbdl null mice suggest a 
redundant role for MBD proteins in cellular function, or a specialized role for MBD1 
under certain physiological circumstances not yet examined. 
1.4.8 MBD2 (and MBD3) 
The Drosophila MBD2/3 protein interacts with methylated cytosine in the context of 
a CpA dinucleotide (Marhold et al., 2004b). In vertebrates, the MBD2/3 protein is 
duplicated resulting in separate MBD2 and MBD3 proteins that share significant 
sequence similarity (Figure 1.5). In Xenopus laevis both MBD2 and MBD3 bind 
specifically to methyl-CpG dinucleotides (Wade et al., 1999), but mammalian MBD3 
has an amino acid substitution that abolishes methyl-CpG specific binding (Hendrich 
and Bird, 1998). Mammalian MBD2 is a functional methyl-binding protein which 
specifically recognizes methyl-CpG (Hendrich and Bird, 1998). The repression 
domain of MBD2 overlaps with the MBD, and a GR repeat in the N-terminus has 
been reported to interact with RNA (Jeffery and Nakielny, 2004). 
MBD2 is a potent HDAC dependent transcriptional repressor (Ng et al., 1999; Wade 
et al., 1999). Bioinformatic identification and subsequent characterization of MBD2 
lead to the discovery that MBD2 is the methyl-CpG binding component of the 
MeCP1 activity observed in nuclear extracts (Ng et al., 1999; Zhang et al., 1999). 
Purification of MeCP 1 from both Xenopus laevis and mammalian tissue culture cells 
showed that MBD2 and MBD3 stably associate with the NIJRD chromatin 
remodeling complex (Feng and Zhang, 2001; Wade et al., 1999). The core 
mammalian MeCP1 complex consists of; MBD2, MBD3, HDAC 1/2, MTA2, MI-2, 
RbAP46/48, and p66/68. This large molecular weight complex preferentially 
deacetylates histories (via HDAC1/2) and remodels nucleosomes (via the MI-2 
ATPase) on methylated DNA (Feng and Zhang, 2001; Guschin et al., 2000). The 
p66/68 components of MeCP1 are involved in targeting MeCP1 and RbAP46/48 are 
likely a structural components (Brackertz et al., 2002; Feng et al., 2002). The exact 
role of MTA2 in MeCP1 remains unknown (Bowen et al., 2004). Interestingly the 
association of MBD2/3 with components of the NURD complex is conserved in 
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invertebrates, as the Drosophila MBD2/3 proteins co-fractionate with several factors 
in the Drosophila NURD complex (Ballestar et al., 2001; Barlow et al., 2001; 
Marhold et al., 2004a). In the majority of cases MBD2 has been associated with 
transcriptional repression, but one report suggests that MBD2 can potentiate gene 
expression though protein / protein interaction with RNA helicase A (RHA)(Fujita et 
al., 2003a). It will be interesting to determine what role MBD2 has in transcriptional 
activation 
Mbd3 null mice are embryonic lethal, but Mbd2 null mice are fertile, viable, and 
healthy (Hendrich et al., 2001). Deletion of Mbd3 in mice is presumably lethal due to 
disruption of the NURD co-repressor complex which has broad cellular roles in 
transcriptional repression (Bowen et al., 2004). Close examination of the Mbd2 null 
mice has revealed subtle defects in maternal behavior, with Mbd2 null mothers 
failing to care properly for their offspring (Hendrich et al., 2001). The reason for this 
behavior defect in the Mbd2 null mice remains undiscovered. Because DNA 
methylation plays such an important role in polyp formation in the APC(mhhh/) mouse 
model of colorectal cancer (introduced in Section 1.2.9), it was hypothesized that 
MBD2 might contribute to this affect by interpreting the methyl-CpG modification. 
Mbd2 null mice were crossed onto the Apc(M1 	background and a strong genetic 
interaction was observed, with MBD2 absence inhibiting polyp formation in a dose 
dependent manner (Sansom et al., 2003). The role of MBD2 in promoting polyp 
/+) 	 i formation in the Apc (,nin model is presumably related to its role n binding the 
promoter region of hypennethylated tumor suppressor genes, repressing 
transcription, and promoting tumorogenisis (introduced in Section 1.2.9). In 
agreement with its proposed role in malignancy in the intestine of the Apc'" mice, 
MBD2 is found at the methylated promoter of the p16 gene in cancer cells and 
contributes to its silencing (Magdinier and Woiffe, 2001). Mbd2 null mice are also 
deficient in the normal cytokine gene expression with a stochastic relationship 
existing between the levels of MBD2 and expression of the 11-4 gene in TH1 lineage 
T cells. Normally MBD2 inhibits 114 expression by out-competing the activator 
GATA3 for promoter occupancy. MBD2 binds directly to the 114 promoter to 
repress transcription and in its absence, GATA3 occupancy at 11-4 promoter causes 
ectopic gene expression (Hutchins et al., 2002). In addition to the gene expression 
defect in the null mouse, a more general defect in methylation dependent repression 
exists in MBD2 deficient cells as repression of methylated reporter vectors is 
partially alleviated compared to equivalent wild type cells (Hendrich et al., 2001). In 
depth analysis of the MBD2 null mice continues to reveal subtle defects in 
methylation dependent silencing (unpublished data Bird lab) suggesting that MBD2 
has wide range of affects on normal methyl-CpG dependent repression. 
1.4.9 MBD4 
MBD4 is the only MBD protein which is not apparently associated with 
transcriptional repression, and instead MBD4 has a role in DNA repair. The DNA 
repair activity of MBD4 lies at the C-terminus of the protein, in a domain that has 
homology to DNA glycosylase repair proteins (Figure 1.5). In in vitro studies, the 
primary enzymatic activity of MBD4 is towards removal thymine or uracil within a 
mismatched CpG site (Bellacosa et al., 1999; Hendrich et al., 1999). This is an 
important repair process under normal cellular conditions due to the fact that methyl-
cytosine can undergo spontaneous deamination resulting in a mismatched T:G base 
pairing within CpG (introduced in Section 1.2.4). In the case of methyl-cytosine 
deamination, if this mismatch is not repaired before DNA replication, the daughter 
strand can replicate normally giving rise to a cytosine to thymine transition mutation. 
A lack of complete repair of methyl-cytosine deamination likely contributes to the 
hypermutability of methyl-CpG bases in the mammalian genome (Duncan and 
Miller, 1980). In fact, cytosine to thymine transitions are the most frequent human 
disease causing point mutations, highlighting the importance of MBD4 function 
(Cooper and Youssoufian, 1988). The role of the MBD4 MBD in DNA repair is not 
entirely clear, but one possibility is that the MBD targets the protein to regions of 
methylated DNA where deamination events are most frequent. Another possibility is 
that the MBD binds deamination mismatches and hands the mismatched site to the 
glycosylase domain, which can then initiate the repair process. 
MBD4 null mice are viable, healthy, and fertile, but show a three fold increase in the 
rate of CpG to TpG mutations (Millar et al., 2002; Wong et al., 2002). This increase 
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in mutation frequency is biologically relevant as crossing the MBD4 null mice onto 
the Apc(Muh1  mouse background resulted in an increase in tumor burden and 
reduction in life expectancy compared to normal littermates (Millar et al., 2002). 
Furthermore, sequencing of the Apc gene in the tumors of the MBD4 null mice 
revealed that loss of the second functional Apc allele was in large part due to CpG to 
TpG mutations that caused APC protein truncation. The affects of MBD4 seen in the 
mouse model of colorectal cancer may manifest in humans patients as subset of 
sporadic colon cancer patients have MBD4 truncation mutations, but whether this is 
a causative event in human tumorgenisis remains to be detennined (Bader et al., 
1999; Riccio et al., 1999; Yamada et al., 2002). 
1.4.10 	Kaiso 
Kaiso is a methyl-CpG binding protein that utilizes zinc fingers instead of a MBD to 
recognize methyl-CpG (Prokhortchouk et al., 2001). In contrast to other MBP's that 
bind a symmetrical methyl-CpG, Kaiso recognizes methyl-CpG in the context of a 
CGCG. The Kaiso zinc fingers encompass a bi-modal DNA binding domain that also 
recognizes sequences which do not consist of methyl-CpG (Daniel et al., 2002). 
Kaiso is a transcriptional repressor, and the repression domain maps to the n-terminal 
POZ domain (Prokhortchouk et al., 2001). Kaiso was originally identified as a 
protein partner of the signaling molecule p120 catenin, suggesting Kaiso might 
respond to signals originating from outside of the cell (Prokhortchouk et al., 2001). 
Translocation of p120 catenin to the nucleus inhibits repression mediated by Kaiso, 
suggesting this may compose a biologically relevant signaling pathway (Kelly et al., 
2004; Kim et al., 2004). Repression by Kaiso is mediated through its stable 
association with the NCoR complex (Yoon et al., 2003) which contains several 
repressor proteins, including a histone deacetylase enzyme (HDAC3). In HeLa cells 
the Kaiso/NCoR complex was required to repress the methylated MTA2 gene. Kaiso 
also represses methylated genes in Xenopus laevis, and when knocked down during 
development embryos prematurely activate a set of genes prior to the mid blastula 
transition (Ruzov et al., 2004). Interestingly, depletion of Xenopus Kaiso in 
developing embryos phenocopies depletion of DNMT1 (Stancheva and Meehan, 
2000), suggesting a close link between Kaiso and methylation mediated repression in 
the Xenopus early embryo. 
1.5 MeCP2 
1.5.1 Recognition of Methyl-CpG 
Full length MeCP2 specifically binds methylated DNA in southwestern blot assays, 
which provided a means by which to identify and purify the protein in rat brain 
nuclear extract (Lewis et al., 1992). Recombinant MeCP2 produced in bacteria 
retained the methyl-CpG dependent binding activity, allowing localization of the 
domain responsible for methyl-CpG binding (Nan et al., 1993). Analysis of the 
methyl-binding domain (MBD) demonstrated that MeCP2 has high affinity for 
methylated CpG dinucleotides (10- M), covers roughly 12 base pairs by DNAseI 
footprint analysis, and interacts with the major groove of DNA (Nan et al., 1993). 
Binding of MeCP2 to DNA containing more than one methyl-CpG is not co-
operative and therefore MeCP2 does not likely self association on DNA. Recognition 
of methyl-CpG in chromatin is uninhibited by the presence of nucleosomes and 
MeCP2 retains the capacity to interact with the methyl-CpG containing major groove 
DNA exposed on the surface of a nucleosome (Chandler et al., 1999). In mini-
chromosome binding assays MeCP2 specifically binds methylated chromatin while 
ignoring the corresponding unmethylated template (Nan et al., 1997a). 
1.5.2 Transcriptional repression and protein partners 
MeCP2 can efficiently repress transcription from methylated promoters by in vitro 
transcription assays (Jones et al., 1998; Nan et al., 1997a). Transcriptional repression 
in vitro is mediated through MeCP2 association with the basal transcription factor 
TFIIB, and likely functions through interrupting the initiation stages of transcription 
(Kaludov and Wolffe, 2000). The MeCP2 repression domain (TRD) was mapped by 
reporter assays in vivo and consists of a roughly 100 amino long sequence just 
downstream of the MBD (Jones et al., 1998; Nan et al., 1997a). The TRD domain 
also encompasses a nuclear localization domain which is required for normal sub-
cellular targeting of MeCP2 (Nan et al., 1996). Repression by MeCP2 is not only 
limited to promoter proximal regions as effective repression occurs at a distance of 
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up to 2 kilo-bases from the start site of transcription (Nan et al., 1998). In addition to 
direct affects on transcriptional initiation MeCP2 can also actively repress 
transcription in a histone deacetylase dependent fashion. HDAC sensitive repression 
by MeCP2 has been attributed to its association with the mammalian Sin3a co-
repressor complex (Jones et al., 1998; Nan et al., 1998). The Sin3 co-repressor 
complex is a very large multi-protein complex, which is targeted to genomic loci 
through transient interactions with transcriptional repressor proteins (Silverstein and 
Ekwall, 2005). Core components of the mammalian Sin3a co-repressor complex 
include and Sin3a, HDAC 1/2, and RbAP46/48 (Silverstein and Ekwall, 2005). Most 
Sin3a complexes share the five core components listed above, but various other 
proteins stably associate with the Sin3a complex to form a multitude of sub-
complexes (Kuzmichev et al., 2002). Sin3a complexes use their associated histone 
deacetylase activity to remove active acetyl marks from lysine residues and remodel 
chromatin contributing to the silencing of gene expression. MeCP2 also associates 
with H3K9 methyltransferase activity, complementing the removal of acetylation 
marks with the active deposition of repressive histone methylation marks (Fuks et al., 
2003b). In addition to association with the Sin3a chromatin remodeling complex 
MeCP2 interacts with various other factors including; Suv39Hl, c-Ski, DNMT1, Co-
Rest, LANA, PU1, Splicing factors, Brm, and RNA (Buschdorf and Stratling, 2004; 
Harikrishrian et al., 2005; Jeffery and Nakielny, 2004; Kimura and Shiota, 2003; 
Kokura et al., 2001; Krithivas et al., 2002; Lunyak et al., 2002; Suzuki et al., 2003). 
The relative contribution of these other factors to the normal function of MeCP2 
remain to be investigated. 
1.5.3 Expression, evolution, and conservation 
The MeCP2 protein is expressed from one locus, but differential splicing gives rise 
to two isoforms (MeCP2 a and f3) that have unique amino acid composition at the N-
terminus (Kriaucionis and Bird, 2004; Mnatzakanian et al., 2004). MeCP2 (a) is the 
most highly expressed of the two isoforms in most mouse tissues, but both isoforms 
are more equally expressed in humans (Mnatzakanian et al., 2004). The role of 
alternative MeCP2 splice variants in normal MeCP2 function remains unknown. 
MeCP2 is ubiquitously expressed throughout human and mouse tissues but is most 
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abundant in the brain. The human MeCP2 mRNA codes for a highly basic 486 amino 
acid protein, which is evolutionarily conserved having homologues in fish, 
amphibians, birds and mammals (Figure 1.5). In all cases, the protein domain 
arrangement of MeCP2 is similar, with the MBD and TRD clustering towards the N-
terminus of the protein and a long C-terminal region of unknown function (Figure 
1.5 and Figure 1.7)). The MBD and TRD domains function in both mammals and 
amphibians to bind methylated DNA and repress transcription respectively. The 
conservation of MeCP2 function is exemplified by the observation that human 
MeCP2 supports embryonic development in Xen opus laevis when the endogenous 
Xenopus MeCP2 protein is depleted (Stancheva et al., 2003). 
1.5.4 MeCP2 and Rett Syndrome 
Rett syndrome is a relatively frequent form of severe neurological disease that 
occurs approximately one in every 10000-22000 female births (Kriaucionis and Bird, 
2003). Rett syndrome is characterized by a normal period of development during the 
first year life, after which a rapid regression in development occurs with patients 
exhibiting; loss of acquired speech and motor skills, microcephaly, seizures, autism, 
ataxia, intermittent hyperventilation and stereotypic hand movements (reviewed in, 
(Kriaucionis and Bird, 2003) Many patients survive into adulthood, but few 
procreate. 
Genetic linkage analysis revealed a region on Xq28 that was responsible for a rare 
familial case of Rett syndrome (Arnir et al., 2000). Sequencing of the MECP2 gene, 
on the Xq28 region, identified a mutation that segregated with the disease (Amir et 
al., 1999). Rett syndrome is a dominant disease and usually arises from a 
spontaneous mutation in the MeCP2 gene. Large scale screening programs have 
revealed numerous types of Rett syndrome mutations in all regions of the MeCP2 
protein (Figure 1.7). Interestingly, there is not an extensive genotype / phenotype 
correlation between the type of MeCP2 mutation and disease prognosis. Some 
mutations that occur in the MBD and that affect DNA binding are phenotypically 
similar to mutations found outside of mapped functional domains (Kriaucionis and 
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how Rett mutations affect MeCP2 function (Free et al., 2001; Kudo et al., 2001; Kudo 
et al., 2003; Yusufzai and Woiffe, 2000). 
1.5.5 MeCP2 null mouse 
MeCP2 null male ES cells were unable to contribute to germ line transmission, and it 
was originally believed that loss of MeCP2 in mice was lethal (Tate et al., 1996). 
Subsequently, using a conditional knockout allele strategy, MeCP2 null animals were 
achieved by two groups independently (Chen et al., 2001; Guy et al., 2001), and the 
original conclusion regarding embryonic lethality was revised. No phenotype was 
observed in MeCP2 null animals until about 3 to 8 weeks of age, at which point they 
developed stiff uncoordinated gait, and a loss of spontaneous movement. Most 
animals eventually developed hind limb clasping, irregular breathing, and on average 
died at 54 days after birth (Chen et al., 2001; Guy et al., 2001). Female mice 
heterozygous for loss of MeCP2 displayed a similar phenotype except that the onset 
of symptoms occurred between 3 to 9 months and these mice were able to raise 
normal litters (Chen et al., 2001; Guy et al., 2001). The similarity in time of disease 
onset and symptoms between human Rett patients and the MeCP2 heterozygous mice, 
makes this a reasonable genetic model to study Rett syndrome. Another male Mecp2 
allele resulting in truncation of the MeCP2 protein at amino acid 308 displays a 
similar phenotype to the null animals, except that the onset of symptoms occurs later 
(Shahbazian et al., 2002). 
1.5.6 MeCP2 depleted Xenopus embryo 
Xenopus laevis is tractable experimental system to study early development. 
Depletion of xMeCP2 in the in the developing Xenopus embryo resulted in a cessation 
of development at the neurula stage (Stancheva et al., 2003). Development could be 
rescued by re-expressing human MeCP2, suggesting a significant amount of 
functional overlap between MeCP2 orthologues. Interestingly, re-introduction of a 
mutant form of MeCP2 (R168X) found in human Rett syndrome patients resulted in a 
partial rescue of development in the MeCP2 depleted embryo. The mutant embryos 
exhibited a bent morphology and hyperactive spastic behavior (Stancheva et al., 
2003). In contrast to the normal early developmental pattern in the MeCP2 null mice, 
differences appear to exist in function of the amphibian protein as MeCP2 deficiency 
results in a clear early developmental defect. 
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1.5.7 MeCP2 target genes 
A series of studies have analyzed the function of MeCP2 in regulating specific genes 
in cancer cell lines, but few MeCP2-regulated genes have been identified in normal 
cells. Micro-array analysis comparing the gene expression pattern in normal wild type 
and MeCP2 null mouse cells has revealed very few changes in gene expression 
(Tudor et al., 2002). Similar gene expression analysis by micro-array using cell lines 
or tissue from human MeCP2 patients have given variable results (Ballestar et al., 
2005; Colantuoni et al., 2001; Traynor et al., 2002). The surprising observation from 
all the large scale gene expression studies using MeCP2 null tissue is the apparent 
lack of mis-regulated genes. Given the wide genomic distribution of methyl-CpG, it 
was predicted that MeCP2 would have pleotrophic and global affects on gene 
expression, but this is not the case. 
Recently, the mouse Bdnf gene was identified as a direct target for MeCP2-mediated 
repression in mouse neurons (Chen et al., 2003b; Martinowich et al., 2003). MeCP2 
binds the promoter proximal region of the gene and maintains silencing of Bdnf in 
isolated mouse brain neurons. Activation of the Bdnf gene through calcium signaling 
pathways results in MeCP2 phosphorylation and subsequent loss of binding to the 
Bdnf promoter. Because MeCP2 may function to keep Bdnf silent in the absence of 
activators, the level of Bdnf re-expression observed in the MeCP2 null cells was 
small. This type of gene expression change would not have been identified in genome 
wide micro-array from tissues with a complex cellular make-up. I will be important to 
look at gene expression patterns in isolated cell types from the brain to identify genes, 
like Bdnf, that are specifically regulated by MeCP2. 
Xen opus laevis embryos depleted of xMeCP2 fail to develop past the neurula stage. 
Developmental defects in the depleted embryos appear to stem from inappropriate 
silencing of the transcriptional regulator Hairy2a (Stancheva et al., 2003). In MeCP2 
depleted embryos enhanced expression of the Hairy2a gene results in a decrease in 
the number of neuronal precursor cells, which likely contributes to the phenotypic 
cessation of growth during neurulation. MeCP2 works in a similar way at the Hairy2a 
gene as it does at the Bdnf gene. MeCP2 binds the promoter proximal region of the 
repressed Hairy2a gene and maintains the silenced state. Upon developmental 
activation of Hairy2a, MeCP2 leaves the promoter and gene activation can proceed 
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unimpeded. It appears from studies in both mice and frogs that MeCP2 may have a 
role in silencing inducible genes. It will be interesting to establish whether other 
inducible neurological genes are regulated in this manner by MeCP2. 
Initial studies in cells from Rett patients revealed no changes in the expression of 
imprinted genes (Balmer et al., 2002). Recently mis-regulation of the imprinted 
DLX5/6 (Horike et al., 2005) and UBE3A (Makedoriski et al., 2005; Samaco et al., 
2005) genes in MeCP2 patients and mice was observed. In these studies, other 
imprinted genes were not mis-regulated, suggesting DLX5/6 (Horike et al., 2005) and 
UBE3A may be unique target genes for MeCP2. A more thorough analysis of the 
growing list of imprinted genes will be required to understand the contribution of 
MeCP2 to normal imprinted gene expression. 
1.6 Aims of this thesis 
The flurry of interest in MBD proteins over the last decade has revealed many new 
and exciting discoveries regarding the diverse properties of methyl-CpG binding 
proteins. To try and understand in more detail the function of MeCP2 the work 
described in this thesis uses a biochemical approach to address three basic questions 
regarding MeCP2 function; (1) what are the native biochemical properties of MeCP2? 
what specific DNA sequences does MeCP2 bind? and (3) what are the affects of 
post-translational modification on MeCP2? 
Chapters 3 and 4 address question (1) though biochemical purification of native 
MeCP2 from rat brain and recombinant sources. This investigation clarifies the nature 
of the biochemical association between MeCP2 and Sin3a and also uncovers some 
interesting biophysical properties of MeCP2. Chapter 5 addresses question (2) and 
uncovers an unexpected DNA binding specificity of MeCP2. These data suggest that 
MeCP2 is targeted to specific methyl-CpG sites in vivo. Chapter 6 addresses question 
and uncovers a biochemical activity that is capable of phosphorylating MeCP2. 
Together these biochemical studies reveal new attributes of the MeCP2 molecule 
which may be relevant to normal function in vivo and Rett syndrome. 
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2. Chapter two- 
Materials and Methods 
2.1 Common solutions 
Phosphate buffered saline (PBS) - 140 mM NaCl, 3 mM KC1, 2 mM KH2PO4, 10 mM 
Na2HPO4. 
Tris-glycine SDS (TGS) (1 X) -25 mM Tris, 250 mM Glycine, 0.1 % SDS. 
Tris-buffered saline (TBS) (1 X) - 50 mM Tris-HC1 pH 8.0, 150 mM NaCl 
Tris-acetate EDTA (TAE ) (1 X ) - 40 mM Tris, 20 mM glacial acetic acid, 1 mM 
EDTA and pH adjusted to 8.0. 
Tris-borate EDTA (TBE)(IX)- 89 mM Tris, 89 mM Boric Acid, 2 mM EDTA and pH 
adjusted to 8.0. 
2.2 Bacterial methods 
2.2.1 Media 
Luria-Bertani (L.B.) Media - 10 g / I Bacto tryptone, 5 g /1 Yeast extract, 10 g / 1 
NaCl, and adjusted to pH 7.0. L.B. was then autoclaved and stored at room 
temperature until required. 
L.B. Agar - Formulated as per L.B. except that 15 g / I of bacto-agar was included. 
L.B. agar was autoclaved and stored at room temperature until required. 
2.2.2 Antibiotics 
Ampicillin - Ampicillin was diluted in distilled water to a stock concentration of 50 
mg / ml, sterilized through a 0.2 jim filter, and stored at - 20 °C . Ampicillin was 
thawed and added to LB or LB agar at a working concentration of 50 jig / ml. 
Kanamycin - Kanamycin was diluted in distilled water to a stock concentration of 50 
mg / ml, sterilized through a 0.2 jim filter, and stored at - 20 °C. Kanamycin was 
thawed and added to LB or LB agar at a working concentration of 50 jig / ml. 
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Gentamicin - Gentamicin was diluted in distilled water to a stock concentration of 10 
mg / ml, sterilized through a 0.2 im filter, and stored at - 20 °C. Gentamicin was 
thawed and added to LB or LB agar at a working concentration of 7 tg / ml. 
Chloramphenicol - Chloramphenicol was diluted in ethanol to a stock concentration 
of 34 mg / ml and stored at -20 °C. Chloramphenicol was added to LB or LB agar at 
a working concentration of 34 jig / ml. 
Tetracycline - Tetracycline was diluted in ethanol to a stock concentration of 10 mg I 
ml and stored at -20 °C. Tetracycline was added to LB or LB agar at a working 
concentration of 10 jig / ml. 
2.2.3 Culture on plates 
L.B. agar was taken either immediately out of the autoclave or re-dissolved in a 
microwave and allowed to cool to 50 °C before antibiotic was added. The L.B. agar 
mix was poured into round 10 cm dishes and allowed to cool at room temperature 
until solidified. The plates were then stored inverted at 4 °C. Prior to use plates were 
warmed to 37 °C. Bacteria were grown by streaking a single colony on the plate, or 
by diluting liquid culture and spreading evenly over the surface of the plate using a 
sterile bent glass rod. Plates were inverted and incubated overnight at 37 °C. 
2.2.4 Liquid culture 
Antibiotic was added to L.B. media and mixed thoroughly. For small cultures, a 
single bacterial colony was scraped from the plate using a Gilson pipette tip and 
dropped into a 20 ml falcon tube. The culture was grown shaking at 250 rpm 
overnight at 37 °C. For larger cultures small overnight cultures were grown as above 
and the following afternoon diluted 1:500 - 1:1000 in fresh L.B. containing 
antibiotics and grown at 250 rpm overnight at 37 °C. 
2.2.5 Preparing chemically competent strains 
Bacterial cells were streaked from a glycerol stock onto LB agar plates and incubated 
overnight at 37 °C. A single colony was inoculated in 5 ml of LB overnight shaking 
at 37 °C. The 5 ml culture was then inoculated into a 500 ml flask of LB and 
incubated shaking at 37 °C until cell density reached an absorbance ob 0.5 at 650 nm. 
The cells were collected by centrifugation at 2400 rpm 15 min 4 °C and placed on ice 
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for 10 min. Using sterile technique the cells were resuspend in 165 ml of sterile 
filtered buffer A (100 mM RbC1, 50 mM MnC12, 30 mM K-Acetate, 10 mM CaCl2, 
15 % glycerol) pH 5.8. Cells were incubated on ice 45 mm, and then recovered by 
centrifugation at 2400 rpm for 15 min 4 °C. The cells were resuspended in 40 ml of 
sterile filtered buffer B (10 mM MOPS, 10 mM RbC12, 75 mM CaCl2, 15 % glycerol) 
pH 6.8 and incubated on ice for 15 min. Aliquots of competent cells (200 [tL) were 
snap frozen in liquid nitrogen and stored at - 80 °C. Competency was evaluated by 
transforming 0 ng, 10 ng, or 100 ng of super-coiled plasmid DNA into aliquots of the 
newly made competent cell stock, and tranformants per jig derived by counting viable 
plasmid selected colonies arising the next day on LB agar plates. Competent cells 
were typically 106  to 108  colonies per jig of plasmid DNA. 
2.2.6 Transformation 
Competent cells were defrosted on ice and DNA was swirled into the competent cell 
mix with at pipette tip. The transformation reaction was then allowed to rest on ice 
for 20 mm. The cells were heat shocked for 1 min and 30 s at 42 °C in a water bath, 
immediately followed by at 2 minute resting period on ice. 800 jil L.B. was then 
added to the transformation mixture and it was incubated at 37 °C shaking for 1 hr. If 
the DNA was a ligation reaction the cells were collected at 6000 g for 1 min and then 
re-suspended in 150 jil of LB before plating on selective LB agar. If the 
transformation DNA was supercoiled plasmid 35 p1 of the transformation reaction 
was directly plated on selective LB agar. 
2.3 Isolation of exogenous DNA from bacteria 
2.3.1 Small scale plasmid DNA preparation 
Analytical digest quality DNA was isolated by growing a single colony overnight in 5 
ml L.B. containing antibiotic selection. 1 ml was transferred a 1.5 ml Eppendorf tube 
and the remainder saved at 4 °C for subsequent sequencing grade DNA preparation. 
The 1 ml sample was centrifuged at room temperature for 40 s, and the supernatant 
removed and discarded. The cell pellet was resuspended in 100 p1 of STET (8 % 
Sucrose, 5 % Triton x-100, 50 mM Tris-HC1 pH 8.0, 50 mM EDTA) supplemented 
with 25 p1 of 10 mg I ml lysozyme. Stock Lysozyme was prepared in 10 mM Tris-
HC1 pH 8.0 with 1mM EDTA and stored at - 20 °C. The sample was boiled for 45 s, 
and then centrifuged for 15 min at 13000 rpm. The cell debris was removed with a 
sterile tooth pick and discarded. 125 il of isopropanol was added to the supernatant to 
precipitate the DNA, and the DNA was collected by centrifugation at room 
temperature for 10 mm. The supernatant was removed and discarded, followed by 
resuspension of the DNA pellet in a 25 tl volume of Tris-HC1 pH 8.0 supplemented 
with 80-100 g / ml of DNAse free pancreatic RNAse. 
2.3.2 Sequencing grade plasmid DNA preparation 
The remaining bacterial culture from the analytical DNA preparation (Section 2.3.1) 
was used to purify plasmid DNA for sequencing. Sequencing grade DNA was made 
using the Qiagen mini preparation DNA kit according to the manufactures 
recommendations. 
2.3.3 Large scale plasmid DNA preparation 
Large scale preparation of plasmid DNA was done according to the Qiagen Maxi Prep 
Kit instruction manual. The precipitated DNA was resuspended in 10 mM Tris pH 
8.0 and stored at -20 °C. 
2.3.4 Large scale preparation of Bacmid DNA 
Large scale preparation of Bacmid DNA was done according to the Qiagen Midi Prep 
Kit with the exception that Bacmid DNA was eluted from the resin by first heating the 
elution buffer to 65 °C. The Bacmid DNA pellet was resuspended in 10 mM Tris pH 
8.0 and stored at - 20 °C. 
2.4 Manipulation of DNA and cloning 
2.4.1 Restriction endonuclease digestion of DNA 
Restriction digest were generally done in 20 t1 or 50 jt1 volumes in the appropriate 
buffers supplied with restriction enzyme (NEB). The reactions were supplemented 
with 100 ng / t1 bovine serum albumin (BSA) if the product literature recommending 
its addition. Most digests were carried out at 37 °C overnight, or at the temperature 
given in the product literature. Efficiency and completeness of digestion was verified 
by agarose gel electrophoresis in 1 X TAE or TBE and visualization by ethidium 
bromide staining. 
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2.4.2 Dephosphorylation of DNA fragments 
The 5' phosphate of DNA molecules was removed with calf intestinal alkaline 
phosphatase (CIP) (NEB). DNA was diluted to 50 ng / j.il in NEB buffer 3 and 0.5 
units of CIP per jig of total DNA was added to the reaction. The reaction was allowed 
to proceed for 1 hr at 37 °C and the DNA re-purified on a gel extraction column 
(Qiagen). 
2.4.3 Methylation of DNA fragments 
Methylation reactions using M.HpaII, M.HhaI, or M.SssI methyltransferases (NEB) 
were carried out according to manufactures instructions, with the exception that 
methylation reactions were carried out overnight at 37 °C follow by the addition of 
fresh enzyme and SAM in the morning followed by an additional 1 - 2 hour 
incubation time. 
2.4.4 Oligonucleotides 
All oligonucleotides were supplied by Sigma-Genosys and purified by desalting or 
poly-acrylamide gel electrophoresis. Stock oligonucleotides were diluted in H20 to 1 
ug / jil and stored at -20 C. 
2.4.5 Polymerase chain reaction 
Polymerase chain reactions were carried out in 20 jil or 50 jil reaction volumes 
generally with 50 ng of each primer per reaction. If template DNA was plas mid 5 ng 
of DNA was used and if genomic DNA 50 - 100 ng was used. Cycling parameters 
varied depending on DNA source and primer properties. If the PCR products were 
subsequently to be cloned for protein expression PFU polymerase (Stratagene) was 
used to amplify the DNA. If the PCR was for analytical purposed Red Hot Taq 
polymerase (Abgene) was used. In each case the reaction buffer and salt solution 
provided with these commercial polymerases were used. 
2.4.6 Purification of PCR fragments 




Sequencing reactions were assembled using the Big Dye terminator V3 kit (Roche). 
Reactions were assembled in 10 p1 volumes containing 2 p.1 of Big Dye sequencing 
mix, 20 ng of sequencing primer, and 200 - 400 ng of template DNA. The sequencing 
reactions were done using the following program on an MJ thermo-cycler 96 °C for 
1 minute followed by 25 cycles at 96 °C for 10 seconds, 50 °C for 5 seconds, and 60 
°C for 4 mm. Sequences were analyzed on an ABI 3730 sequencer by the ICAPB 
sequencing facility at the University of Edinburgh. 
2.4.8 Agarose gel extraction of DNA fragments 
DNA was extracted from agarose gels using the Qiagen gel extraction kit according to 
the manufacturer's instructions and the DNA eluted in 30 p.!. 
2.4.9 Ligation 
Ligation reactions were carried out in a 10 p.l reaction volume using 6 Weiss units of 
T4 DNA ligase (NEB) according to the manufactures recommendations. 
2.4.10 Site directed mutagenesis 
Site directed mutagenesis was carried out with the QuikchangeXL mutagenesis kit 
(Stratagene) according to the manufactures recommendations. All mutagenesis 
primers were PAGE purified by Sigma-Genosys. 
2.4.11 Radioactively labeling DNA fragments 
50 - 100 ng of template DNA was end labeled in a 30 p.1 reaction volume with 20 
units of T4 polynucleotide kinase (NEB) and 1 p.1 of 10 mCi / ml of gamma-32P dATP 
for 1 hour at 37 °C. Unincorporated isotope was removed by purification of the 
labeled DNA on a Qiagen gel purification column, and the purified DNA was eluted 
in 75 - 150 p.! of Tris.HC1 pH 8.0. 
2.5 Mammalian cell culture methods 
2.5.1 Mammalian cell culture 
Mammalian cells were grown in defined growth media (DMEM or Alpha MEM 
(Invitrogen)) with 10 % donor calf serum, and 100 p.g / ml of a penicillin / 
streptomycin antibiotic mix (Invitrogen). The cells were maintained at 37 °C in 5 % 
CO2. Adherent cells were dislodged at 90 % confluence by washing with a dilute 
solution of trypsin I EDTA and replating at a 1: 5 ratio. Suspension cell culture was 
maintained in a similar manner except cells were diluted and replated omitting the 
trypsinization. 
2.5.2 Cryogenic storage of mammalian cells 
Cells were collected by centrifugation at 1500 g for 5 min and supplemented with 1 
ml of media containing 10% DMSO per 5 X 106  cells. Cells were stored on ice for 1 
hour followed by storage at - 80 °C overnight. The following day the cells were 
transferred to liquid nitrogen for permanent storage. 
2.5.3 Transfection 
Cells were transfected with lipofectamine (Invitrogen) according to the manufacture 
recommendations. The next day the cells were washed with fresh media and allowed 
to recover for 48-72 hours before cells were harvested for further manipulation. 
2.5.4 Isolation of nuclei from tissue culture cells 
Adherent tissue culture cells were scraped into 1 X PBS with the aid of a rubber 
police man. The cells we collected by centrifugation at 1500 g for 5 min at room 
temperature. The cells were washed once with PBS and resuspended in 10 volumes 
of buffer A (10 mM Hepes pH 7.9, 1.5 mM MgC12, 10 mM KCI, 0.5 mM DTT, 0.5 
mM PMSF, and complete protease inhibitors (Roche)). The cells were incubated on 
ice for 10 min and recovered by centrifugation at 1500 g for 5 mm. The cells were 
then resuspended in 3 volumes of buffer A and nuclei released by 20 - 40 plunges of 
a tight fitting dounce. Nuclei were recovered by centrifugation at 1500 rpm for 5 mm. 
2.5.5 Isolation of nuclei from brain tissue 
Rat brains (obtained from Pel-Freez Biologicals) were ground to a fine powder in 
liquid nitrogen with a mortar and pestle. The brain powder was diluted 5 volumes to 1 
in ice-cold buffer A (10 mM Hepes (pH 7.5), 25 mM KC1, 0.15 mM spermine, 0.5 
mM spennidine, 1 mM EDTA, 2 M sucrose, 10 % glycerol, and complete protease 
inhibitors (Roche)) followed by homogenization in a 60 ml Dounce (Braun) on a 
Potter S (Braun) motorized homogenizer (five strokes at 1100 rpm). The homogenate 
was layered onto a 10 ml cushion of buffer A and centrifuged in pre-chilled SW28 
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rotor at 24,000 rpm in a Beckman XL 100 ultracentrifuge for 40 min at 3 °C to recover 
the nuclei. 
2.5.6 Nuclear protein extracts from mammalian cells 
Recovered nuclei were resuspended in 1 volume of buffer C containing 5 mM Hepes 
(pH 7.9), 26 % glycerol, 1.5 mM MgC12, 0.2 mrvi EDTA, and complete protease 
inhibitors (Roche Applied Science) supplemented with 400 mM NaCl. The extraction 
was allowed to proceed for 1 h on ice with occasional agitation, and then the nuclei 
were pelleted at 13,000 rpm for 20 min at 4 °C. The supernatant was taken as the 
nuclear extract. Nuclear extract was either used immediately or snap frozen in liquid 
nitrogen and stored at - 80 °C 
2.6 Insect cell and baculovirus culture methods 
2.6.1 Insect cell culture 
All baculovirus stock generation and expression was done using SF9 cells 
(Invitrogen) which are derived from the papal ovarian tissue of the fall army worm 
Spodopterafrugiperda. Cells were grown in serum free SF900 II medium containing 
L-glutamine (Gibco) supplemented with penicillin and streptomycin (100 tg / ml), 
and incubated at 27 °C. Cells were grown as a monolayer in tissue culture flasks and 
split when confluent by dislodging the cells physically. Cells were diluted 1:10 to 
1:20 in fresh SF900 II medium and either re-plated in new tissue culture flasks or 
inoculated as 50 ml cultures in a 200 ml spinner culture flask at 80 - 90 rpm. S179 
cells grown as suspension cultures in spinner flasks were maintained at densities of 
less than 2.5 X 10 6  cells per ml. Cells were passaged by centrifuging the cells at 
1500 rpm for 5 min to isolate the cells, and the old media was removed and replaced 
with fresh SF900 II media at 0.5 X 106  cells per ml. 
2.6.2 Cryogenic storage of insect cells (SF9) 
SF9 cells were cryogenically stored by centrifuging the cells at 1500 rpm for 5 mm 
and then resuspended the collected cells at 1 X 10 7  cells per ml in SF900 II media 
supplemented with 10 % DMSO. Cells were stored on ice for one hour and then 
placed at -70 °C overnight. In the morning the cells were transferred for permanent 
storage in liquid nitrogen. To recover stocks from liquid nitrogen the cells were 
rapidly defrosted at 37 °C and immediately diluted in fresh SF900 II media and 
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placed in tissue culture flasks. Flasks were incubated at 27 °C and dead cells 
removed and replaced with fresh media the following day. 
2.6.3 Generation of recombinant baculovirus genome 
The Fastbac system (Invitrogen) was used to generate recombinant baculovirus 
genome. The virus was generated according to instructions of the manufacturer and 
described briefly here. 10 ng of Fastbac plasmid DNA was added to 100 tl of 
competent DH1OBac cells which had been defrosted on ice. Cells were incubated on 
ice for 30 mm. Cells were then heat shocked for 45 seconds at 42 °C, and 
immediately chilled on ice for 2 mm. 900 j.tl of L.B. broth was added and the tubes 
were shaken for 4 hours at 37 °C. The cells were then plated as 15 l of the 
transformation mix or 100 tl each of a 10 , 10 -2 , and 10 dilution. Cells were 
grown on plates containing kanamycin, gentamicin, tetracycline, X-gal, and IPTG for 
48 hours at 37 °C. White colonies should contain transposed baculovirus genome 
but as a second screening 10 white colonies were re-streaked onto the same selective 
media and incubated overnight at 37 °C. Then a single white colony from the 
streaked plate was selected and grown in liquid culture overnight under the same 
selective pressure. In the morning cells were pelleted and the baculovirus genome 
recovered by Midi prep (Qiagen). To elute the DNA from the Midi prep column the 
elution buffer was heated to 65 °C before applying to column. To verify the 
transposition of the protein coding sequence into the baculovirus genome, diagnostic 
PCR was carried out using M13 forward and reverse primers that flank the insertion 
site, and additional internal gene specific primers. To facilitate amplification of the 
large diagnostic PCR fragments a PCR reaction with an initial denaturation of 94 °C 
for 3 min followed by 34 cycles of 94 °C for 30 second, 55 °C for 45 seconds, and 72 
°C for 5 min was carried out. A final extension of 72 °C for 7 min was used to extend 
PCR products. Diagnostic PCR reactions consisted of 100 ng of bacmid DNA and 50 
ng of diagnostic primer in a 50 jil reaction volume. 
2.6.4 Transfection of SF9 cells and isolation of p1 baculovirus 
To generate infectious baculovirus particles SF9 cells were seeded at a density of 9 X 
10 5 in six well plates. In one tube 1 g of baculovirus genome was diluted in 100 1 
with un-supplemented Graces Medium (Invitrogen) and in a second tube 6 tl of 
Ceilfectin (Invitrogen) was diluted in 100 i.tl Graces Medium. The two tubes were 
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mixed and allowed to incubate for 45 min at room temperature. While the DNA I 
Ceilfectin reagents were incubating the cells were washed once with 2 ml of Graces 
medium and replaced with 800 p1 of Graces medium. After 45 min the DNA / 
Ceilfectin mixture was added to the plates and allowed to incubate at 27 °C for 5 
hours. After 5 hours the transfection mix was removed and 2 ml of SF900 II medium 
was added. Cells were incubated at 27 °C for 72 hours and the supernatant collected 
as the viral p1 stock. The p1 stock was stored at - 70 °C for long term storage. The 
cells from the transfection were collected and lysed in 100 p1 of 2 X SDS loading 
buffer. The lysate was analyzed by western blotting for the expressed protein as a 
verification of baculovirus genome transfection. 
2.6.5 Amplification of viral stock 
To amplify the P1 viral stock a 20 ml culture of SF9 cells was grown to 2 X 10 6  cells 
per ml and 1 ml of p1 viral stock was added to the SF9 culture which was incubated 
spinning for 48 hours. The cells were centrifuged for 5 min at 1500 rpm and the 
supernatant collected as p2 stock and stored at 4 °C protected from light. Several 
aliquots of the p2 stock were frozen at - 70 °C for long term storage. The cell pellet 
was used to make whole cell extract from which small scale purifications were done 
to test solubility and functionality of the expressed protein. 
2.6.6 Infection of SF9 cells for protein production 
To generate preparative amounts of protein using Baculovirus, 500 ml spinner 
cultures were set up and grown to a density of 2 X 10 6  cells per ml at 27 °C. 25 - 30 
ml of baculovirus amplified from the p2 stock was used to infect the cells for 48 
hours. Cells were collected by centrifugation at 1500 rpm for 5 min and the 
supernatant removed and discarded. The cell pellets were stored at - 70 °C until 
protein preparation. 
2.7 Xenopus Iaevis methods 
2.7.1 Isolating Xenopus I. oocytes 
Female Xenopus laevis were sacrificed by Dr. Donald MacLeod and the oocytes 
dissected immediately before oocyte extract was prepared. 
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2.7.2 Making Xenopus I. oocyte extract 
Xenopus laevis oocytes were isolated and washed several times in OR-2 (5 mM 
Hepes pH 7.9, 1 mM Na2(PO4), 82.5 mM NaCl, 2.5 mM KC1, and 1 mM MgCl2) and 
collagenase Type II (Sigma Chemical) was added to 0.75 mg/ml. The oocytes were 
incubated on a shaking platform for 60 - 90 min until the oocytes were dispersed. 
Immature oocytes and follicle cells were removed by constant washing with OR-2. 
Oocytes were then washed several times in extractions buffer (20 mM Hepes pH 7.5, 
5 mM KC1, 1.5 mM MgCl2, 1 mM EGTA, 10 % glycerol, 10 mM - 
glycerophosphate, 0.5 mM DTT, 1 mM PMSF, and complete protease inhibitor 
(Roche)) and placed in 6 ml volumes into 5W40 ultracentrifuge tubes and the 
remainder of the volume made up with extraction buffer. The oocyctes were 
centrifuged in a SW40 rotor at 38 000 rpm for 1 hr at 4 °C. The clarified extract was 
used immediately for biochemical fractionation. 
2.7.3 Xenopus I. MeCP2 and Sin3a antibodies 
Xenopus laevis MeCP2 and Sin3a antibodies were a generous gift of Peter L Jones. 
The specificity of the MeCP2 antibodies was verified by western blot using 
recombinant Xenopus laevis protein as bait. Sin3a antibodies gave an immunoreactive 
band at the predicted size in oocyte extract. 
2.8 Protein methods 
2.8.1 Measuring protein concentration 
Protein concentration was measured using the BioRad bradford reagent kit. Briefly, 
the stock reagent was diluted 1 in 4 with water and mixed thoroughly. Increasing 
volumes of protein were then added to 1 ml of bradford reagent. The reagent was 
allowed to incubate with the protein for five min and the absorbance at 595 nm 
recorded. Known concentrations of BSA were added to bradford reagent in parallel to 
generate a standard curve by which the concentration of the test protein sample could 
be determined. 
2.8.2 Dialysis 
Protein was added to sealed dialysis tubing or cassettes (Pierce) with an appropriate 
molecular weight cut off range (as recommended by manufacturer). Dialysis was 
allowed to proceed overnight in the appropriate buffer at approximately 300 - 500 
fold excess of dialysis buffer. The following morning the dialysis buffer was replaced 
with an equivalent volume of fresh dialysis buffer and allowed to proceed for an 
additional 3 - 4 hours before the protein sample was collected and either stored at - 70 
°C or used immediately. 
2.8.3 SDS-PAGE 
Proteins were diluted in loading buffer (8 % SDS, 100 mM Tris (pH 6.8), 100 mM 
DTT, 10% glycerol, and 0.1% brophenol blue) and boiled for 5 min at 100 °C. 0.75 
mm thick gels were assembled in either a Bio-Rad mini protean II apparatus or a large 
Bio-Rad XL casting apparatus according to the manufacturer's recommendation. 
Gels consisted of a stacking gel buffered at pH 6.8 and a separating gel pH 8.8. All 
gels used an acrylamide to bis-acrylamide ratio of 29:1 with 0.001% SDS and the 
acrylarnide was polymerized by the addition of ammonium persulfate and TEMED as 
a catalyst. Gels were run in TGS at 25 mA per gel small gel or 45 mA per large gel at 
4 °C until the loading dye migrated off the bottom of the gel. 
2.8.4 Coomassie blue stain 
Coomassie blue stain consisted of 50 % methanol with 10 % glacial acetic acid and 
0.1 % Brilliant blue R250 dye. SDS PAGE gels were incubated with fresh Coomassie 
blue stain rocking for one hour. Excess stain was removed with H20 and the gel was 
immersed in de-stain solution consisting of 30 % methanol and 10% acetic acid. The 
dc-stain was allowed to proceed for several hours until the background staining was 
no longer visible. Gels were then soaked overnight in H20 and imaged the following 
morning. 
2.8.5 Semi-Dry transfer to nitrocellulose membrane 
Semi-Dry transfer was carried out on a Bio-Rad electro-blot system according to the 
manufacture recommendations. Briefly, three layers of 0.3 mm whatman paper was 
soaked in semi-dry transfer buffer (39 mM glycine, 48mM Tris, 0.037% SDS, and 20 
% methanol). A single layer of nitrocellulose filter paper was wetted in transfer 
buffer and placed on top of the three layers of whatman paper. The SDS PAGE gel 
was carefully placed on top of the nitrocellulose membrane and an additional three 
layers of moist 0.3 mm Whatman paper was placed on top. Bubbles were removed by 
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rolling a 25 ml pipette several times over the assembled gel sandwich. The top 
electrode was place over of the gel sandwich and the transferred with 0.2 amps for 
between 1 and 1.25 hours. After transfer the gel sandwich was disassembled and the 
SIDS PAGE gel Coomassie stained to ensure efficient transfer and the nitrocellulose 
membrane blocked for at least one hour in 5 % milk 1 X TBS solution. 
2.8.6 Western blot 
For most antibodies the following western blot procedure was used. After a 1 hour 
block in a 5 % milk 1 X TBS solution, fresh blocking solution containing a 1:500 to 
1:1000 dilution of the primary antibody was applied. The primary antibody was 
incubated for one hour at room temperature or overnight at 4 °C followed by three 
consecutive ten minute washes in a 5 % milk / 1 X TBS solution. The secondary 
antibody was applied at a dilution of 1:5000 in a 5 % milk / 1 X TBS solution for one 
hour at room temperature. Two consecutive ten minute washes in a 5 % milk I 1 X 
TBS solution were followed by one ten minute wash in 1 X TBS. The nitrocellulose 
membrane was then placed in a freshly prepared equal volume mixture of ECL 
solution 1 (2.5 mM luminal, 0.396 mM p-coumeric acid, and 100 mM Tris-HC1 pH 
8.5) and solution 2 (5.6 mM H202, 100 mM Tris-HC1 pH 8.5) for one minute. The 
nitrocellulose blot was wrapped in a single layer of ceran wrap and exposed to ECL 
hyper-film (Amersham Biosciences). 
2.8.7 Immunoprecipitation 
Antibodies were incubated with 500 .ig of rat brain nuclear extract diluted in binding 
buffer (20 mM Hepes (pH 7.9), 0.15 M NaCl, 10% glycerol, 0.2 mM EDTA, 0.01% 
Triton X-100) at 4 °C for 4 h. 20 pJ of protein A conjugated Sepharose beads 
(Amersham Biosciences) were added to the immunoprecipitation and incubated for 1 
h at 4 °C rocking. Beads were washed four times with binding buffer and eluted with 
1 X SIDS PAGE loading buffer. 
2.8.8 Sucrose gradient sedimentation 
Sucrose gradients were formed at 4 °C in 13 ml SW40 tubes using a manual two 
chamber gradient former. Chamber one was loaded with buffer A (300 mM KC1, 20 
mM Hepes pH 7.9, 2 mM EDTA, 10 % Glycerol, 10 mM beta-mecaptoethanol) 
containing 5 % sucrose and chamber 2 with buffer A containing 20% sucrose. The 
sample containing 25 - 50 ug of standard proteins BSA, Appoferritin, B-amylase, and 
ADH were loaded onto the 5 - 20 % sucrose gradient and centrifuged at 40 000 rpm 
in a SW40 rotor for 19 hours at 4 °C. 500 tl fractions were collected manually from 
the top of the gradient using a peristaltic pump fitted with a capillary tube. Each 
fraction was TCA precipitated and roughly an equal portion of the precipitated protein 
was used for an SDS PAGE gel followed by Coomassie stain to identify marker 
proteins or a western blot to identify MeCP2. 
2.8.9 Kinase Assay 
Kinase assays were carried out by adding 1 - 3 ul of crude protein extract, or protein 
fraction, to a 20 jt1 reaction in buffer HB5 (60 mM f3-glycerophosphate, 15 mM p-
nitrophenylphosphate, 25 mM MOPS (pH7.2), 5 mM EGTA, 15 mM M902, 1mM 
DTT, 0.1 mM Na3VO4 , 1% Triton X- 100) supplemented with 15 uM ATP, 60 ng / ul 
recombinant MeCP2 (or control protein), and 5 nl of 10 mCi / ml of gamma-32P 
dATP. The reaction was allowed to proceed for 45 min at 30 °C and stopped by the 
addition of 1 X SDS PAGE loading buffer. Samples were separated by SDS PAGE 
and Coomassie stained prior to drying the gel onto Whatman paper for 1 hour at 80 
°C. The dried gels were visualized by exposure to a phosphor-imager screen 
(Amersham) for 1 hour or a Bio-Max MS auto-radiography film (Kodak) for 2 hours. 
2.8.10 	Mass Spectrometry 
To identify purified proteins, excised bands were in-gel trypsinized, and peptides were 
eluted from the gel slice. Mass spectrometry analysis was carried out on an Applied 
Biosystems Voyager DE-STR matrix-assisted laser desorption ionization time-of-
flight instrument using c-cyano-4-hydroxycinnamic acid matrix. Spectra were 
analyzed in MS-Fit and then submitted to Protein Prospector (prospector.ucsf.edu/)  
for peptide matching by the Edinburgh Protein Interaction Center. 
2.9 Expression of proteins in bacteria 
2.9.1 Cell preparation and induction of expression 
A 25 ml starter culture was initiated with a fresh colony from an LB agar plate. The 
starter culture was grown overnight shaking at 37 °C under the appropriate antibiotic 
selection. The next morning the 25 ml culture was diluted in 1 - 2 1 of LB containing 
antibiotic selection and grown shaking at 37 °C until an optical density of 0.6 was at 
600 nm was obtained. At this point the culture was transferred to 30 °C and 1 mM 
IPTG was added to induce protein production. The culture was induced at 30 °C 
shaking for 3 hours and the bacteria were collected by centrifugation at 6000 g for 10 
min at 4 °C. At this point the bacterial were either used to make extract or stored at - 
80 °C for future use. 
2.9.2 Making non-denaturing extracts. 
The cell pellet from a 2 1 culture of bacteria was resuspended in 30 ml of lysis buffer 
(20mM Tris.HC1 pH 8.0, 500mM MCI, 0.1% NP 40) containing complete protease 
inhibitors (Roche) in a 50 ml falcon tube. The resuspended lysate was sonicated on 
ice at output 4 - 5 at duty cycle 30 % (on a Branson Sonifier 250) for 3 mm, followed 
by a 3 min rest period on ice, and then a second 3 min sonication. The insoluble 
material after sonication was pelleted at 12000 g for 20 min at 4 °C. The supernatant 
was collected as whole cell extract. 
	
2.10 	Expression of proteins in insect cells 
2.10.1 	Insect whole cell extracts 
The cell pellet was resuspended 1: 20 in lysis buffer (50 mM NaH2 PO4 pH 7.9, 500 
mM NaCl, 10 mM Beta-glycerphosphate, 15 % Glycerol, 0.01 % NP-40, and 
complete protease inhibitors). The cells were then added to a 40 ml dounce and 
incubated on ice for 30 min over which time frame 40 plunges of the dounce were 
applied. The lysate was then centrifuged at 14500 rpm for 20 min at 4 °C and the 
supernatant taken as soluble whole cell extract. 
2.11 	Protein purification 
2.11.1 	Chromatography media 
All chromatography media was purchased from Amersham biosciences except for 
BioRex 70 cation exchange resin which was purchased from Bio-Rad, and fractogel 
TMAE which was purchased from EMD biosciences. 
Resin 	 Application 
Chelating Sepharose 	affinity chromatography (bound with Ni) 
Bio-Rex70 	 cation exchange resin (50-100 mesh) 
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Sp-Sepharose 	 cation exchange resin 
Mono S 	 cation exchange resin (mono dispersed beads) 
Mono Q 	 anion exchange resin (mono dispersed beads) 
Fractogel TMAE 	anion exchange resin (1 ml analytical and 180 ml 
preparative) 
Superose 12 	 Size exclusion chromatography (24 ml analytical) 
Superose 6 	 Size exclusion chromatography (24 ml analytical) 
Sephacryl S-300 	 Size exclusions chromatography (360 ml preparative) 
Phenyl-Sepharose 	Hydrophobic interaction chromatography (2 ml 
analytical) 
2.11.2 	Chromatography solutions 
Anion exchange buffer contains 20 mM TrisHCl (pH7.9), 0.2 mM EDTA, 1 mM 
DTT, 10 % Glycerol, supplemented with 100 mM NaCl (AE 100) or 1000 mM NaC1 
(AE 1000). 
Cation exchange buffer contains 20 mM Hepes (pH 7.6), 0.2 mM EDTA, 1 mM DTT, 
10% Glycerol, supplemented with 100 mM NaC1 (CE100), or 150 mM NaCI 
(CE150), or 200 mM NaCl (CE200), or 1000 mM NaC1 (CE1000). 
Buffers for his-tag purification contain 50 mM NaH2PO4, 300 mM NaCl, 10 % 
Glycerol (pH 8.0), supplemented with 20 mM imidazole (N20), 100 mM imidazole 
(N100), or 250 mM imidazole (N250). 
Size exclusion chromatography buffers were made in 20 mM HepesKOH (pH 7.9), 3 
mM MgCl2, 10 % glycerol, supplemented with 150 mM KCI (GF150) or 500 mM 
KC1 (GF500). 
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Buffers for hydrophobic interaction contain 0.2 mM EDTA, 50 mM Tris pH 7.9, 1 
mM DTT, and 10 % glycerol supplemented with 0.7 M (NH4)2SO4 (PE700) or no 
(NH4)2SO4 (PE0). 
	
2.11.3 	Preparing disposable columns 
Disposable 10 ml or 20 ml poly-prep columns were purchased from Bio-Rad. 
Columns containing ion exchange resins were prepared by washing the resin in low 
salt buffer and then applying the resin to the column. The resin was allowed to settle 
and then washed with 5 column volumes of high salt buffer to fully charge the resin 
and then was re-equilibrated with low salt wash buffer. 
2.11.4 	Preparing FPLC based HR columns 
Empty FPLC columns were purchased from Arnersham biosciences. The columns 
were filled with resin according to the manufacturer's recommendations. The resins 
were stored in 20 % ethanol, and regenerated for use by washing with water followed 
by high salt buffer and low salt buffer to charge the resin. 
2.11.5 Ion exchange chromatography 
Protein samples were dialyzed into the appropriate CE or AE buffer and applied to the 
prepared resin either in a disposable column of a FPLC based column. The sample 
was then washed with 20 - 40 column volumes of the dialysis buffer followed by 
consecutive step elutions or a linear gradient elution of increasing ionic concentration. 
Factions were collected during all steps and stored at - 80 °C or used immediately. 
2.11.6 Affinity chromatography 
Heparin-Sepharose was used in same manner as described in Section 2.11.5. 
2.11.7 Size exclusion chromatography 
Proteins were applied directly to a gel filtration column equilibrated according to the 
manufactures recommendations. Molecular weight size standards (Sigma) were run 
over the column and their elution volumes monitored by absorbance at 280 nm. 
Protein samples were applied to the column with volumes not exceeding that 
recommended by the manufacturer and eluted with a constant buffer flow rate of 0.2 
ml I minute collecting fractions within the inclusion limit. Samples were stored at - 
80 °C or used immediately 
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2.11.8 	Purification of his tagged bacterial proteins 
Whole cell lysate was transferred to a 50 ml falcon tube conataining 1 ml of Ni-Nta 
beads pre-washed in lysis buffer. The lysate was incubated for 1 hour at 4 °C on a 
spinning fly to allow proteins containing a histidine run to bind the matrix. The lysate 
bead mixture was poured directly onto a disposable 10 ml poly-prep column (Bio-
Rad) allowing the unbound material to flow through. The bound material was then 
washed with 20 - 40 column volumes of wash buffer (50 mM NaH2PO4, 300 mM 
NaCl, 20 mM imidazole, pH adjusted to 8.0). The protein was eluted 5 times with 1 
ml of elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 
adjusted to 8.0). A 3 tl aliquot of each elution was run on SDS PAGE and analysed 
by Coomassie staining. The protein was dialysed overnight into dialysis buffer (20 
mM Hepes pH 7.9, 200 mM NaCl, 0.5 mM E[)TA, 0.1 mM DTT, and 10 % glycerol). 
The concentration of the purified protein was determined by Bradford assay and 
visualized by SDS PAGE and Coomassie staining for purity. Purified proteins were 
stored short term at - 20 °C and long term at - 80 °C. If further purification was 
required other chromatographic methods indicated in Section 2.11 were used where 
indicated. 
2.11.9 	Purification of his tagged baculovirus expressed 
proteins 
Whole cell lysate was transferred to a 50 ml falcon tube conataining 1 ml of Ni-Nta 
beads prewashed in lysis buffer. The lysate was incubated for 1 hour at 4 °C on a 
spinning fly to allow proteins conataining histide runs to bind the matrix. The lysate 
bead mixture was poured directly onto a disposable 10 ml poly-prep column (Bio-
Rad) allowing the unbound material to flow through. The bound material was then 
washed with 20 - 40 ml of column volumes of wash buffer (50 mM NaH2PO4, 300 
mM NaCl, 20 mM imidazole, pH adjusted to 8.0). The protein was eluted 5 times 
with 1 ml of elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 
adjusted to 8.0). A 3 tl aliquot of each elution was run by SDS PAGE and analysed 
by Coomassie staining. The protein was dialysed overnight into dialysis buffer (20 
mM Hepes pH 7.9, 200 mM NaCl. 0.5 mM EDTA, 0.1 mM DTT, and 10 % glycerol). 
The concentration of the purified protein was determined by Bradford assay and 
visualized by SDS PAGE and Coomassie staining for purity. Purified proteins were 
stored short term at - 20 °C and long term at - 80 °C. If further purification was 
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required other chromatographic methods indicated in Section 2.11 were used where 
indicated. 
	
2.12 	Manipulation of protein 
2.12.1 Dephosphorylation of baculovirus expressed MeCP2 
Purified baculovirus protein (Section 2.11.9) was incubated with lambda phosphatase 
buffer 	(50 mM Tris-HC1, 	5 mM dithiothreitol, 	0.1 mM Na2EDTA, 
0.01 % Brij 35, pH 7.5) and 400 units of lambda phosphatase (NEB) for 1 hour at 30 
°C. To verify specificity of the dephosphorylation reaction mock dephosphorylation 
and dephosphorylation reactions carried out with 50 mM EDTA as an inhibitor were 
done in parallel. Changes in relative mobility were determined by SIDS PAGE and 
Coomassie staining. 	To obtain pure dephophorylated MeCP2 large 
dephosphorylation reactions were carried out and the protein re-purified by ion 
exchange chromatography (Section 2.11.5) 
2.12.2 	Nuclease treatment of purified rat MeCP2 
Purified rat brain MeCP2 (15 tl) was added to 240 LI of 50 mM Tris.HC1 pH 8.0 and 
2 mM MgCl2 containing 90 units of Benzonase (Merck). The reaction was incubated 
at 4 °C for 3 hours according to the manufacturer's recommendations, followed by 
size exclusion chromatography on a Superose 12 column in OF 500. 
2.12.3 	Denaturation of rat brain nuclear extract 
Concentrated urea was added to 200 ig of rat brain extract to a final concentration of 
4 M. The sample was heated for 10 min at 65 °C and then applied to a Superose 12 
column in GF 150. 
2.13 	DNA binding experiments 
2.13.1 	Generation of probes using single stranded 
oligonucleotides 
Equal molar amounts of a long single stranded oligonucleotide (30 - 75 bases) and a 
complementary shorter reverse primer were incubated in 10 mM tris pH 8.0 with 50 
mM NaC1 for 10 min in a 100 °C hot block. The hot block was removed from the 
heat source and allowed to cool to room temperature. The annealing reaction was 
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used as a template to generate double stranded DNA by incubating for 1 hour at 37 °C 
with 6 units of klenow polymerase and 5 il of 2 mM dNTP's. 
	
2.13.2 	Electrophoretic Mobility Shift Assay (EMSA) 
Probes used for EMSA were generated either by PCR amplification from plasmid 
DNA followed by purification on a Qiagen PCR purification column, or by extension 
of single stranded of oligonucleotides using complementary oligonucleotides and 
Kienow polymerase extension (Section 2.13. 1) followed by purification on Qiagen gel 
extraction column. EMSA reactions were assembled at room temperature by 
combining 500 ng of competitor DNA (poly(dG-dC).poly(dG-dC)) and protein 
sample in binding buffer (32 % ficoll, 80 mM hepes pH 7.9, 150 mM KC1, 4mM 
EDTA, and 2 mM DTT). This reaction was allowed to incubate 10 min at room 
temperature and then the labelled probe containing brornophenol blue was added and 
the reaction continued for a further 25 min at room temperature. The binding reaction 
was loaded on to a 6 % non denaturing polyacrylamide that had been pre run for 1 
hour at 240 V. The samples were electrophoresed at 240 V until the bromophenol 
blue dye front had migrated 9.5 cm into the gel. The gel was transferred to 2 layers of 
0.2 mm Whatman paper and dried at 80 °C for 1 hour. Dried gels were exposed to a 
phosphor-imager screen overnight and developed the next day. 
2.13.3 	Methyl-SELEX: Systematic Evolution of Ligand by 
Exponential Enrichment (SELEX) 
A 74 base oligonucleotide was generated that has M13 forward and M13 reverse 
primer binding sites at the 5' and 3' ends respectively. The central core of the 
oligonucleotide consisted of an HpaII methyltransferase / restriction endonuclease site 
flanked by 18 base pairs of random sequence on either side (gttttcccagtcactac-(Nl8)-
CCGG-(N18)-gtcatagctgtttcctg) and the primer was purified by Sigma-Genosys 
through polyacrylamide gel electrophoresis. The single stranded oligonucleotide was 
used to generate a double stranded DNA template by mixing 5 tg of the long single 
stranded oligonucleotides library with an equamolar amount of the M13R primer. The 
primers were incubated in 10 mM tris pH 8.0 with 50 mM NaC1 for 10 min in a 100 
°C hot block. The hot block was removed from the heat source and allowed to cool to 
room temperature. The annealing reaction was used as a template to generate double 
stranded DNA by incubating for 1 hour at 37 °C with 6 units of klenow polymerase 
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and 5 tl of 2 mM dNTP's. The resulting double stranded DNA was purified using a 
Qiagen gel extraction column and eluted in 50 p.1 of elution buffer. The purified DNA 
was methylated with 20 units of M.HpaII methyltransferase overnight and purified on 
a Qiagen gel extraction column, and eluted in 50 p.1. The efficiency of methylation 
was tested by digesting 50 ng of the methylated probe with HpaII restriction enzyme 
and resolved on a 10 % polyacrylamide gel. Efficiently methylated probe was 
completely refractory to HpaJI digest as observed by ethidium bromide staining of the 
polyacrylamide gel. The concentration of the purified methylated methyl-SELEX 
DNA was quantified by comparing varying amounts of low mass DNA ladder from 
invitrogen on a 10 % polyacrylamide gel by ethidium bromide staining. A 50 ng 
aliquot of the purified methylated methyl-SELEX template was end labelled using 30 
units of T4 polynucleotide kinase (NEB) and 1 p.1 of - 0.5 MBq / ml gamma-32P 
dATP. The labelled methyl-SELEX DNA was purified on a Qiagen gel extraction 
column, and eluted in 75 p.1 of DNA. Then, 1.6 ng of labelled methylated methyl-
SELEX DNA template was used in a 20 p.! EMSA reaction ( as described in section 
2.13.2) and the binding buffer consisted of 10 mM Tris pH 8.0, 150 mM NaCl, 5 mM 
MgCl2, 0.1 mM EDTA, 8 % Ficol, 1mM DTT, and 0.1 % NP40. 44 ng, 89 ng, or 
133 ng of recombinant MeCP2 1-205 was used as the shifting protein. The EMSA 
was run on a 6 % polyacrylamide gel for approximately 2 hours at 240 V until the 
loading dye had migrated - 10 cm into the gel. After drying the EMSA gel to 0.2 mM 
Whatman paper at 80 °C for one hour under vacuum the blot was exposed to KODAK 
BioMax MS film with a MS intensifier screen at - 80 °C for 1 hr and developed. The 
resulting film was used as a guide to cut out specific bands that were shifted by the 
lowest amount of MeCP2 protein. The gel slices were incubated in 100 p.1 H20 at 100 
°C for 10 mm. 5 p.1 of the DNA eluted from the gel slice was subject to PCR 
amplification in a reaction containing 1.5 mM MgCl2, 50 ng of the M13 forward / 
reverse primer, and 0.5 units of Taq polymerase (Abgene). The PCR reaction 
consisted of 95 °C for 4 mm, followed by 24 cycles of 95 °C for 40 seconds, 60 °C 
for 40 seconds and 72 °C for 10 seconds. An 8 minute extension at 72 °C was 
followed by addition of 100 ng of M13 forward / reverse primer, 2 p.1 of 2 mM 
dNTP's, and 0.5 units taq polyrnerase. A final cycle for 94 °C for 4 mm, 64 °C for 2 
mm, and 72 °C for 10 min was used to fully extend all PCR products (this final cycle 
was essential to obtain all double stranded product). The PCR product was purified 
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with a Qiagen gel extraction kit and the resulting purified PCR product were 
methylated with M.HpaII methyltransferase as described above. This fragment was 
then used for a subsequent round of selection by repeating the EMSA and re-isolating 
shifted DNA by PCR as described above. The selected fragments were enriched over 
8 rounds of EMSA and the final PCR product was cloned into the pGEMTeasy TA 
cloning system (Promega). 	Sequences were analyzed by chain termination 
sequencing using the SP6 primer located in the pGEMTeasy vector (Promega). 
	
2.13.4 	End labeling DNA for foot-printing 
A single stranded DNA fragment corresponding to the foot-printing probe was first 
labelled. Labelling was done in a 30 tl reaction containing 500 ng of single stranded 
template DNA, 1.5 il of p32 dATP, and 3 pA of T4 polynucleotide kinase. Un-
incorporated nucleotide was removed by purification of the single stranded DNA on a 
Qiagen nucleotide removal column and eluted in 60 pA of tris pH 8.0. An equal molar 
amount of an oligonucleotide corresponding to the reverse complement of the 3' end 
of the labelled single stranded DNA was added and incubated in a 100 °C heat block 
for 10 min in Tris.HCI pH 8.0 with 50 mM NaCl. The block was removed from the 
heat source and allowed to cool to room temperature. The annealing reaction was 
directly used in a klenow extension reaction containing 6 units of klenow polymerase 
and 5 pA of 2 mM dNTP's. The extension reactions was purified on a Qiagen gel 
extraction column and eluted in a 60 pA volume of Tris.HC1 pH 8.0. Half of the 
reaction was methylated overnight with M.SssI and the other half mock methylated. 
The final product was purified on a Qiagen gel extraction column and the relative 
incorporation of gamma-32P dATP determined in a scintillation counter adjusting the 
final volume to make a stock of 10 000 cpm in 10 mM Tris pH 8.0. 
2.13.5 	Foot-printing ladder: Maxam-Gilbert G+A sequencing 
reaction 
Probe (approximately 8 jtl) corresponding to 80 000 cpm was added to a reaction 
containing 1 ug of E. coli genomic DNA in a total volume of 10 p.1. 1 p.1 of a 4 % 
solution of formic acid was added and the mixture and incubated at 37 °C for 25 mm. 
During this incubation a fresh stock of 10 % piperidine (1 M) was freshly made. 150 
p.1 of the 10 % piperidine solution was added directly to the formic acid reaction and 
the tube incubated at 90 °C for 30 mm. This reaction was then placed on ice for 5 mm 
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followed by addition of 1 ml of n-butanol. After vortexing, the sample was 
centrifuged for 2 min at maximum speed in a micro-centrifuge to pellet the DNA. The 
DNA pellet was resuspended in 150 l of 1% SDS and an additional 1 ml of n-butanol 
was added followed by vigorous vortexing and centrifugation at maximum speed for 
2 min in a micro-centrifuge. The supernatant was removed and extracted twice more 
in 0.5 ml of n-butanol with centrifugation between each step. To remove the 
remaining traces of n-butanol the pellet was dried under vacuum for 10 mm. The 
resulting pellet was resuspended in 40 tl of loading buffer (98% formamide, 10 mM 
EDTA, 0.05% Bromophenol Blue, 0.05% Xylen Cyanol) and stored at -20 until 
required. 10 il of this sequencing reaction was sufficient per lane on a typical 
sequencing gel. 
2.13.6 	DNasel foot-printing 
DNA binding reactions were set up in the same manner as an EMSA reaction (Section 
2.13.2). Briefly reactions were assembled in binding buffer containing 0-100 ng of 
poly(dG-dC).poly(dG-dC), 500 ng of BSA, and 140 ng of MeCP2 1-205 protein in a 
18 jtl reaction volume. Reactions were incubated at room temperature for 10 min,and 
then 2 il of probe at 10000 cpm labelled at one end was added to each reaction and it 
was allowed to go for another 25 min at room temperature. 0.025 tg of DNase 1 
from bovine pancrease (Boringher Manheim) diluted in DNase dilution buffer (50 
mM NaCl, 20 mM Tris pH 7.6, 5 mM M902, and 3 mM CaC12) was added to the 
reaction in a 4 tl volume. The DNase 1 digestion was allowed to continue for 2 - 4 
min at room temperature. Then, 50 tl of 8 mM EDTA was added to stop the 
digestion. To recover the DNA fragments 1 ug of E. coli genomic DNA was added to 
the reaction followed by phenol chloroform extraction and ethanol precipitation. Air 
dried DNA pellets were resuspended in 10 j.il of loading buffer (98 % formamide, 10 
mM EDTA, 0.05 % Bromophenol Blue, 0.05 % Xylen Cyanol) and incubated at 100 
°C for 2 min prior to loading on a 6 % sequencing gel that had been pre-run at 1400 V 
until the temperature reached approximately 50 °C. The DNA fragments were 
electrophoresed at 1400 V until the Xylene Cyanol had migrated into the gel 17 cm. 
The gels were dried on 2 layers of 0.2 mm Whatman paper and exposed to a 
phosphor-imager screen overnight before developing. 
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3. Chapter three- 
Purification of Native MeCP2 
3.1 Initial identification of MeCP2 and biochemical properties 
The identification of two biochemical activities in mammalian cells that specifically 
recognize methyl-CpG indicated that DNA methylation could be actively recognised 
and perhaps even interpreted (Lewis et al., 1992; Meehan et al., 1989). The identity 
of the first activity, named MeCPI, was elusive and it was not until recently that 
MBD2 was determined to be the methyl-CpG binding component of MeCP1 (Feng 
and Zhang, 2001; Ng et al., 1999). The second biochemical activity, MeCP2, was the 
first to be purified and have its coding sequence identified. 
MeCP2 was originally purified from rat brain by nuclear protein extraction followed 
by conventional biochemical fractionation. Using south-western analysis to follow 
methyl-CpG binding activity, a relatively pure fraction consisting of only one main 
polypeptide was achieved (Lewis et al., 1992). A partial polypeptide sequence of 
MeCP2 was obtained by Edman degradation, and degenerate oligonucleotides probes 
were used to isolate a full length MeCP2 cDNA. For many years MeCP2 was the 
only methyl binding activity for which the polypeptide sequence was known (Lewis et 
al., 1992) demonstrating how this brute force biochemical approach was instrumental 
in advancing the understanding of factors that interpret methyl CpG. 
Two important functional domains have been mapped in MeCP2: the methyl-CpG 
binding domain (MBD) and the transcriptional repression domain (TRD)(Nan et al., 
1997a; Nan et al., 1993). The MBD was used in bioinformatic studies to identify other 
methyl CpG binding proteins (MBP's) (Cross et al., 1997; Hendrich and Bird, 1998; 
Nan et al., 1993). The TRD of MeCP2 represses transcription when bound to 
methylated CpU's near promoter sequences and also from promoter proximal regions 
(Nan et al., 1998; Yu et al., 2000). The versatile repressive capabilities of MeCP2 
rely on its tight association with chromatin, and interaction with proteins that 
modulate chromatin structure (Meehan et al., 1992; Nan et al., 1997a). One 
chromatin remodelling machine that MeCP2 interacts with is the Sin3a co-repressor 
complex. The chromatin remodelling and histone modifying capabilities of this large 
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multi-protein complex contribute to HDAC-dependent transcriptional repression by 
MeCP2 (Jones et al., 1998; Nan et al., 1998). In addition to Sin3a, various other 
factors have been shown to bind MeCP2 (Section 1.5.2) but the relative contribution 
of these proteins to MeCP2 function remains a matter of uncertainty (Fuks et al., 
2003b; Kimura and Shiota, 2003; Kokura et al., 2001; Krithivas et al., 2002; Lunyak 
et al., 2002; Suzuki et al., 2003). 
Recent advances in protein biochemistry have simplified the purification of proteins 
and protein complexes from crude cellular extracts (Forler et al., 2003). With the aid 
of mass spectrometry and extensive genome information very small amounts of 
purified protein can be identified. This is achieved through peptide mass fingerprint 
analyses combined with bioinfomatic comparison to theoretical peptide fingerprints in 
publicly curated databases (Steen and Mann, 2004). 
To try and understand the relative biochemical contribution of the MeCP2 protein to 
the Sin3a complex and to identify other factors that stably associated with MeCP2, 
MeCP2 was purified by conventional biochemistry. In contrast to previous 
mammalian MeCP2 isolations (Lewis et al., 1992; Nan et al., 1997a) this analysis was 
done under milder conditions with the aim of maintaining and evaluating stable 
protein I protein interactions. 
3.2 Biochemical evaluation the MeCP2ISin3a interaction 
3.2.1 MeCP2 co-immunoprecipitates with Sin3a 
Mammalian Sin3a co-immunoprecipicates with MeCP2 in experiments using MeCP2 
and Sin3a specific antibodies (Nan et al., 1998). In vitro analysis using recombinant 
proteins showed that MeCP2 binds directly to Sin3a. To verify this interaction in vivo 
a co-immunoprecipitation from rat brain nuclear extract with MeCP2 specific 
antibodies was done and the immunoprecipitated material probed with Sin3a 
antibodies (Figure 3.1A). Sin3a was immunoprecipitated with MeCP2 antibodies but 
not an irrelevant antibody (Gal4), in agreement with previously published 
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Figure 3.1- Mammalian MeCP2 does not stably associate with the Sin3a chromatin 
remodelling complex. 
An MeCP2 specific antibody or an irrelevant antibody (anti-gal4) were used to 
immunoprecipitate proteins from rat brain nuclear extract. The immunoprecipitates 
were probed by western blot with an anti-Sin3a antibody. The MeCP2 antibody 
specifically co-immunoprecipitates Sin3a signal from rat brain nuclear extracts, but an 
irrelevant antibody does not. 
Rat brain and NG1O8 nuclear extracts were separated by Superose 6 size 
exclusion chromatography and fractions probed by western blot with antibodies 
against Sin3a, MeCP2, and HDAC1/2. Native molecular weight markers are 
indicated as arrows above the western blot. MeCP2 elutes between 400-500 kDa 
devoid of the majority of Sin3a and HDAC 1/2 signal. 
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observations (Nan et al., 1998). A relatively weak signal for Sin3a is observed in 
MeCP2 immunoprecipitates suggesting that MeCP2 associates with a small amount of 
cellular Sin3a. 
32.2 Absence of a stable MeCP2/Sin3a association in rat brain 
and cell line nuclear extracts 
To address, in a more qualitative manner, the biochemical association between 
MeCP2 and Sin3a, brain extracts were analyzed by Superose 6 size exclusion 
chromatography. MeCP2 and components of the Sin3a co-repressor complex (Sin3a 
and HDAC 1/2) were identified in the size exclusion fractions by SDS PAGE and 
western blot analysis (Figure 3.IB). As previously reported (Kuzmichev et al., 2002), 
Sin3a complexes eluted between the void volume and the 443 kDa marker in fractions 
also containing HDAC 1/2 western blot signal. Interestingly very little Sin3a signal 
was observed in fractions containing MeCP2 western signal (Figure 3.113). This 
observation is in agreement with the small amount of Sin3a associated with MeCP2 
by co-immunoprecipitation (Figure 3.1A). A similar elution profile for Sin3a and 
MeCP2 was also observed in nuclear extracts from the neural-glial fusion cell line 
NG108 (Figure 3.113) and several other transformed human cells (data not shown). 
3.2.3 Xenopus Iaevis MeCP2 does not stably associate with 
Xenopus !aevis Sin3a 
Studies of MeCP2 in the African clawed frog (Xenopus laevis), also identified an 
interaction between xMeCP2 and xSin3a in oocyte extract (Jones et al., 1998). In 
these experiments, association between xMeCP2 and xSin3a was evaluated by co-
immunoprecipitation and western blot analysis using antibodies raised against the 
Xenopus proteins. In agreement with the observations in mammalian extracts these 
co-immunoprecipitations suggested that only small amounts of xSin3a/xMeCP2 are 
stably associated. In the same study, a rudimentary biochemical fractionation of 
oocyte extract was combined with size exclusion chromatography analysis to evaluate 
the relative amount of xMeCP2 and xSin3a that associate. In these experiments the 
authors observed that the majority of xMeCP2 was associated with xS1n3a, in contrast 
to the small amount of xSin3a immunoprecipitated with MeCP2 antibodies. The 
different results with these two assays could be explained by disruption of the 
xSin3a/xMeCP2 association during antibody binding in the immunoprecipitation 
experiments, but two more aspects of this study necessitate re-evaluation. Firstly, 
xMeCP2 and xSin3a do not precisely co-elute from the size exclusion 
chromatography column bringing into question the homogeneity of the proposed 
stable xMeCP2/xSin3 complex. Secondly, and most importantly, the xSin3a western 
blot signal in the biochemical fractionation migrated just above the xMeCP2 protein. 
This is much smaller than would be expected for xSin3a which is a 1275 amino acid 
protein. In other organisms Sin3a migrates by SDS PAGE at roughly 175 kDa. It is 
difficult to reconcile the abnormal migration of the proposed xSin3a molecule in this 
study. 
To address these inconsistencies newly generated xMeCP2 and xSin3a antibodies 
were obtained from Peter L Jones. The specificity of the xMeCP2 antibodies were 
verified by western blot analysis of recombinant xMeCP2 (data not shown). In 
Xenopus laevis oocyte extracts the xMeCP2 antibodies recognized a band just under 
80 kDa by SDS PAGE, suggesting endogenous xMeCP2 was recognized by this 
reagent. The xSin3a antibodies reacted with three bands at approximately 175 kDa, 
and looked similar to the signal observed in mammalian Sin3a western analysis. 
Multiple xSin3a bands may arise in oocyte extract due to Sin3a splice isoforms or 
proteolyic degradation the full length protein. To partially purify MeCP2, oocyte 
extract was applied to Bio-Rex 70 cation exchange resin and washed with low salt 
buffer (Figure 3.2A). xMeCP2 and xSin3a eluted from the Bio-Rex70 column with 
500 mM NaCl and the presence of each protein was verified by western blot analysis 
(Figure 3.213). The eluted proteins from the Bio-Rex 70 column were then applied to 
a Superose 6 size exclusion column. The size excluded fractions were TCA 
precipitated and run on an SDS PAGE gel followed by western blot analysis (Figure 
3.2C). 	xMeCP2 eluted between 400-500 kDa and xSin3a eluted over several 
fractions in the high molecular weight range, indicating the xSin3a complex is intact 
(A) 	Oocyte extract 	 (B) 
+ 	 kDa 
175 BioRex7O 	 xSin3a 	
- 
BE100 	BE500 	 81 
+ xMeCP2 	- 
Superose 6 
GF!50 	GF15O 	 —62 
(C) 
kDa 	Vo 	669 	443 200 	66 
	
Input V V v v V 	 kDa 
xSin3a * 	 - 175 
xMeCP2 	 * -• 
	 —83 
Figure 3.2- Xenopus laevis MeCP2 does not stably associate with the Sin3a chromatin 
remodelling complex. 
Xenopus laevis oocyte extract was separated by Bio-Rex 70 ion exchange 
chromatography followed by Superose 6 size exclusion chromatography. 
The 500 mM NaC! elution from the Bio-Rex 70 cation exchange column contains 
xMeCP2 and xSin3a as analysed by western blot analysis. 
An aliquot of the 500 mM NaC1 elution from the Bio-Rex 70 cation exchange 
column was separated by Superose 6 size exclusion chromatography and the fractions 
analysed by western blot analysis using xMeCP2 and xSin3a antibodies. Native 
molecular weight markers are indicated as arrows above the western blot. xMeCP2 
was found in fractions ranging from 400-500 kDa devoid of the majority of xSin3a. 
in these experiments (Figure 3.2C). These results suggest that very little xMeCP2 is 
stably associated with xSin3a. This observation is analogous to the results in Figure 
3.2C using mammalian sources and is consistent with poor co-immunoprecipitation of 
Sin3a with MeCP2 antibodies. In light of these observations, the original finding that 
Xenopus laevis xMeCP2/xSin3a exist as a stable complex is in doubt. 
3.3 Purification of Native MeCP2 
3.3.1 MeCP2 elutes from size exclusion chromatography 
columns with a molecular weight of 400-500 kDa 
Although MeCP2 does not form a stable complex with Sin3a, MeCP2 eluted from 
Superose 6 size exclusion column with a relative molecular weigh between 400-500 
kDa (Figure 3.2C). This MeCP2 elution profile is nearly ten times larger than its 
predicted size by amino acid composition (52.4 kDa). To determine if native MeCP2 
has a large size exclusion profile due to unidentified stably associated proteins, 
MeCP2 was purified from rat brain. 
3.3.2 The large molecular weight MeCP2 is stable over multiple 
biochemical purification steps 
To biochemically purify MeCP2 and any stably associated factors, it was necessary to 
verify the stability of MeCP2 over a series of conventional chromatography steps. To 
obtain nuclear extract, rat brain nuclei were isolated by ultracentrifugation of brain 
homogenate over a sucrose cushion, followed by extraction of nuclear proteins with 
400 mM NaCl. A three step purification scheme was devised (Figure 3.3A) 
including; Sp-Sepharose cation exchange, followed by a Mono-Q anion exchange, 
and finally a Ni-Nta affinity step. At each step of the purification fractions containing 
MeCP2 were identified by western blot analysis (data not shown). The nuclear 
extract was diluted to 100 mM NaCl and applied to a 1 ml Sp-Sepharose column and 
eluted with a linear gradient of NaCl from 100 mM to 1 M. The peak MeCP2 signal, 
as determined by western blot, was between 450-500 mM NaCl. The MeCP2 
containing fractions were combined and dialysed into buffer containing 100 mM 
NaCl. The active fractions were then applied to a 1 ml Mono-Q column and MeCP2 
was found in the flow through. The flow through 
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Figure 3.3- The 400-500 kDa MeCP2 is stable over multiple chromatographic steps. 
A four step pilot purification was devised to ensure the large molecular weight 
MeCP2 was not lost during multiple chromatographic steps. This purification 
involved Sp-Sepharose, Mono Q, Ni-Nta, and Superose 12 chromatographic steps. 
MeCP2 was followed by western blot analysis using MeCP2 specific antibodies. 
After the first three chromatographic steps MeCP2 containing fractions were 
separated by size exclusion chromatography and the fractions tested by western blot 
using MeCP2 specific antibodies. Native molecular weight markers are indicated as 
arrows above the western blot. MeCP2 remained as a 400-500 kDa species over 
multiple purification steps. 
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was applied to a 0.5 ml Ni-Nta affinity resin. Ni-Nta resin was chosen at this step as 
MeCP2 has a run of seven histidines in the C-terminus which bind with high affinity 
to Ni-Nta resin. The Ni-Nta resin was washed extensively and eluted with 250 mM 
imidazole. MeCP2 eluted in the 250 mM fraction as determined by western blot. To 
evaluate whether MeCP2 still had a high molecular weight after the purification this 
fraction was applied to a Superose 12 size exclusion column and fractions collected 
within the inclusion limit (Figure 3.313). MeCP2 eluted from the Superose 12 column 
with a relative molecular weight between 400-500 kDa, consistent with the native 
molecular weight of MeCP2 observed in unfractionated rat brain nuclear extract. This 
initial pilot purification demonstrates that the large native molecular weight MeCP2 
species is maintained over several conventional biochemical purification steps and is 
amenable to large scale preparative biochemical purification. 
3.3.3 Large scale purification of native MeCP2 from rat brain 
nuclear extract 
To facilitate preparative purification of MeCP2 from rat brain nuclear extract large 
amounts of rat brain nuclei were isolated. Using approximately 400 rat brains 
(obtained from Pel-freez biological) as starting material, batches of 25 brains were 
pulverized into a fine powder under liquid nitrogen in a large mortar and pestle. The 
brain powder was mechanically homogenized and the nuclei purified by 
ultracentrifugation through a sucrose cushion. The resulting nuclei proved to be of 
high quality and were suitable for salt extraction of nuclear proteins. Using the pilot 
purification as a template, a modified purification scheme was devised including a 
Heparin affinity step to facilitate enhanced purification (Figure 3.4). Rat brain extract 
(140 mg) was dialysed into cation exchange buffer with 100 mM NaCl (CE 100) and 
applied to an 8 ml Sp-Sepharose column. The protein was eluted with a linear 
gradient from 100 mM NaCl (CE 100) to 1 M NaCl (CE 1000) and every second 
fraction was analyzed by western blot with MeCP2 antibodies. At the same time 
antibodies recognizing Sin3a and HDAC 1/2 were used to verify the initial 
observations that MeCP2 was not stably associated with the Sin3a chromatin 
remodeling complex (Figure 3.5A). Figure 3.513 shows the relative purification by 
total protein as measured by absorbance at 280 nm. In the first step, MeCP2 
















Figure 3.4- Preparative MeCP2 purification scheme. 
A five step preparative purification scheme was devised to purify MeCP2 from 140 
mg of rat brain nuclear extract. The purification included Sp-Sepharose, Mono-Q, 
Heparin-Sepharose, Ni-Nta, and Superose 12 chromatography steps. 
eluted in a tight peak between 450-500 mM NaCl. Sin3a eluted over two peaks, one 
in the flow through/wash phase and a second major peak between 100mM NaCl and 
450 mM NaCl. HDAC 1/2 eluted over a wide range of fractions and was found both 
in the flow through/wash phase and the NaC1 elutions from 100mM to 500mM. The 
existence of several Sin3a and HDAC1/2 containing complexes fits with the wide 
elution profiles of these three proteins (Kuzmichev et al., 2002). Importantly, the 
majority of MeCP2 eluted in one major peak which was distinct from the peak 
Sin3a/HDAC 1/2 containing fractions (Figure 3.5A). 
The MeCP2 containing fractions from the Sp-Sepharose column were combined and 
the protein dialyzed into anion exchange buffer containing 100mM NaCl (AE100). 
The dialyzed protein, 8.8 mg as determined by Bradford assay, was applied to a lml 
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Figure 3.5- Sp-Sepharose chromatography of MeCP2. 
Rat brain nuclear extracts were separated on a Sp-Sepharose cation exchange 
column and the fractions probed by western blot with antibodies against Sin3a, 
MeCP2, and HDAC 1/2. The stage of the chromatography run (input, wash/flow-
through, elution) is indicated above the western blot and the fraction number is 
marked below. MeCP2 bound tightly to the cation exchange resin (fractions 29-37) 
and these fractions are mostly devoid of Sin3a. 
The absorbance at 280 nm over the Sp-Sepharose purification was plotted to 
indicate the relative amount of total protein in each fraction. 
Mono-Q column and eluted with a linear gradient of anion exchange buffer from 100 
mM NaCl (AE 100) to 1 M NaCl (AE 1000) (Figure 3.6A). Most of the MeCP2 was 
identified by western blot in the flow through/wash phase with a small amount of 
signal eluting at around 350-400 mM NaCl. This step of the purification revealed a 
complete separation of MeCP2 containing fractions from the residual 
Sin3a!HDAC1/2 that was brought through from the Sp-Sepharose cation exchange 
step. The remaining Sin3a and HDAC1/2 eluted from the Mono-Q column between 
400-450 mM NaCl, completely devoid of detectable MeCP2 (Figure 3.6A). 
Therefore, the first two purification steps completely separate MeCP2 from the 
Sin3a/HDAC complexes, verifying the observation that in crude extracts most cellular 
MeCP2 does not exist in a stable complex with the Sin3a chromatin remodeling 
complex. Although MeCP2 does not bind to the Mono-Q resin, this proved to be a 
very useful purification step as is shown in Figure 3.613. The flow through/wash 
phase is distinct from the major peak of protein as determined by absorbance at 280 
nm (Figure 3.613). 
The MeCP2 containing fractions from the flow through/wash phase of the Mono-Q 
purification were combined and dialyzed into buffer containing 100 mM NaCl 
(CE100). The dialyzed protein, 4 mg as determined by Bradford assay, was applied 
to a 1 ml Heparin affinity column and eluted with a linear gradient from 100 mM NaCl 
(CE 100) to 1 M NaCl (CE 1000) (Figure 3.7A). The Heparin affinity step was added 
to the large scale preparative purification to enhance the overall purification of 
MeCP2. A Heparin affinity resin has two advantages which make it ideal as a 
'polishing step' during the purification of MeCP2. First, Heparin mimics DNA in 
structure and has been shown to associate with DNA binding factors (Gadgil and 
Jarrett, 1999), and secondly the resin also contains a cation exchange moiety which 
was shown in the pilot purification to bind MeCP2 efficiently. Increased binding of 
MeCP2 to the Heparin Sepharose column is demonstrated by the requirement of 
higher ionic strength conditions (500-500 mM NaCl) to elute MeCP2 (Figure 3.7A) 
when compared to a cation exchange resin alone (450-500mM NaC1) (Figure 3.5A). 
Because Sin3a and HDAC 1/2 were completely separated from the MeCP2 containing 
fractions during the Mono-Q step, they were not assayed in subsequent 
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Figure 3.6- Mono-Q chromatography of MeCP2. 
The MeCP2 containing fractions from the Sp-Sepharose purification were 
dialysed and separated on a Mono-Q anion exchange column probing each fraction by 
western blot with antibodies against Sin3a, MeCP2, and HDAC 1/2. The stage of the 
chromatography run (input, wash/flow-through, and elution) is indicated above the 
western blot and the fraction number is marked below. MeCP2 did not bind the 
Mono-Q anion exchange resin (fractions 3-27), and completely separated MeCP2 
away from the remaining Sin3a and HDAC 1/2. 
The absorbance at 280 nm over the Mono-Q purification was plotted to indicate 
the relative amount of total protein in each fraction. 
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Figure 3.7- Heparin-Sepharose chromatography of MeCP2. 
The MeCP2 containing fractions from the Mono-Q purification were dialysed and 
separated on a Heparin-Sepharose affinity column and the fractions probed by 
western blot with antibodies against MeCP2. The stage of the chromatography run 
(input, wash/flow-through, and elution) is indicated above the western blot and the 
fraction number is marked below. MeCP2 bound tightly to the Heparin affinity resin 
(fractions 49-53). 
The absorbance at 280 nm over the Heparin purification was plotted to indicate 
the relative amount of total protein in each fraction. 
An aliquot of fractions 47-53 was separated by SIDS PAGE and Sypro-ruby 
stained with MeCP2 indicated by an asterisk, and the molecular weight markers in 
kDa displayed left. 
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western blot analysis. The increased affinity of MeCP2 for the Heparin column 
proved an efficient purification step as indicated by the absorbance trace at 280 nm 
(Figure 3.7B). On the Heparin column the majority of the contaminating proteins 
from the Mono-Q step elute outside of the MeCP2 containing fractions, as is evident 
from the total protein absorbance trace at 280 nm (Figure 3.7B). To evaluate the 
progress of the purification, fractions 47 - 55 containing MeCP2 were separated by 
SDS PAGE and stained for total protein using Sypro-Ruby stain (Figure 3.7C). 
Sypro-Ruby has advantages over traditional silver stain as it is more sensitive and less 
biased towards preferential interactions with specific amino acids in the protein 
(White et al., 2004). Fractions 47-55 are highly enriched for MeCP2 (as indicated by 
an asterisk) and contain various other proteins of different intensities and unknown 
identity. 
The MeCP2 containing fractions were combined and dialyzed into cation exchange 
buffer containing 100 mM NaCl (CE 100) omitting EDTA and DTT. The dialyzed 
protein, 0.408 mg as determined by Bradford assay, was applied to a 0.5 ml Ni-Nta 
affinity column and washed extensively with Ni-Nta wash buffer containg 20 mM 
imidazole (N20). The column was then eluted in batch with Ni-Nta elution buffer 
containing 100 mM imidazole (N 100) followed by Ni-Nta elution buffer containing 
250 mM imidazole (Figure 3.8A). The MeCP2 containing fractions were again 
monitored by western blot with MeCP2 antibodies. MeCP2 protein was lost at this 
step in the flow through and washes but the vast majority of MeCP2 eluted during the 
100 mM imidazole elution step (Figure 3.8A). The Ni-Nta purification step proved to 
be very efficient in isolating MeCP2 as indicted by analysis of the peak MeCP2 
fractions on a Sypro-Ruby stained gel (Figure 3.8B). The peak MeCP2 containing 
fractions from the Ni-Nta elution consist of only three major polypeptides, with the 
asterisk indicating MeCP2. The purity of the MeCP2-containing sample has 
improved in comparison to the more crude MeCP2-containing fractions from Heparin 
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Figure 3.8- Ni-Nta chromatography of MeCP2. 
The MeCP2 containing fractions from the Heparin-Sepharose column separated 
on a Ni-Nta affinity column and the fractions probed by western blot with antibodies 
against MeCP2. The stage of the chromatography run (input, wash/flow-through, and 
elution) is indicated above the western blot. MeCP2 bound tightly to the Ni-Nta 
affinity resin and eluted with 100 mM imidazole. 
The 100 mM imidazole elutions were combined and an aliquot was separated by 
SDS PAGE and Sypro-ruby stained. The Ni-Nta purification resulted in three 
polypeptides with MeCP2 indicated by an asterisk. The molecular weight in kDa is 
displayed by two different molecular weight markers left and right 
Ell 
point, aliquots of each purification step were separated by SDS PAGE and Sypro-
Ruby stained. To the left of the protein gel is a table indicating the total amount of 
protein at each purification step (Figure 3.9A). MeCP2 is enriched throughout the 
purification. 
To determine whether MeCP2 remained in a high molecular weight fraction over the 
purification and whether this large molecular weight fraction resulted from stably 
associated proteins, the Ni-Nta fractions (0.148 mg of protein) containing MeCP2 
were applied to a Superose 12 size exclusion column and eluted in gel filtration buffer 
containing 500 mM NaCl (GF500) (Figure 3.913). It was found to be essential at this 
step to elute the small amount of total protein from the Superose 12 size exclusion 
column using high salt to inhibit non specific retention on the column matrix. 
Importantly the purified MeCP2 activity was the same native molecular weight (400-
500 kDa) as was observed in the input nuclear extract (Figure 3.913). This suggests 
that native MeCP2 has remained intact over the purification. A portion of each size 
exclusion fraction was separated by SDS PAGE and stained with Sypro-Ruby stain. 
Surprisingly, all three proteins eluted in different peak fractions on the size exclusion 
column suggesting that they are not part of a multi-protein complex (Figure 3.913). 
The smallest polypeptide eluted in fractions devoid of MeCP2, and this protein has 
not successfully been identified by mass spectrometry. The middle band and the 
upper band were excised from the gel and peptides isolated by in-gel tryptic digestion 
and time of flight mass spectrometry. Peptide fingerprinting revealed the upper band 
as topoisomerase I and the middle band is MeCP2. The absorbance at 280 nm plotted 
below the Sypro-ruby stained gel indicates that MeCP2 and topoisomerase I account 
for the majority of protein in these fractions (Figure 3.9C). To verify that MeCP2 does 
not physically interact with topoisomerase I, MeCP2 was immunoprecipitated from 
nuclear extracts and topoisomerase I protein identified with anti-topoisomerase I 
antibodies. Figure 3.91) demonstrates that topoisomerase I does not associate with 
MeCP2 in rat brain nuclear extracts. Although MeCP2 does not stably associate with 
other proteins it still has a large native molecular weight as determined by 
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Figure 3.9- Superose 12 size exclusion chromatography and identification of MeCP2. 
Aliquots of each purification stage were separated by SDS PAGE and Sypro-
ruby stained. Above the Sypro-ruby stained gel is the purification step, to the left is 
molecular weight markers in kDa, and to the right MeCP2 is indicated by an arrow. 
The table to the left indicates the total protein concentration at each step in milligrams 
as determined by Bradford assay. MeCP2 is consistently enriched and purified 
through the first four purification steps. 
An aliquot of the Ni-Nta fraction was separated by Superose 12 size exclusion 
chromatography and the fractions analysed by western blot analysis using MeCP2 
specific antibodies (bottom). MeCP2 eluted in fractions 8-12. The same Superose 12 
fractions were separated by SDS-PAGE and analysed by Sypro-ruby staining (top). 
The two largest proteins were identified by mass spectrometry to be topoisomereasel 
and MeCP2 as indicated (right) with arrows. 
The absorbance at 280 nm over the Superose 12 size exclusion step was plotted to 
indicate the relative amount of total protein in each fraction. 
MeCP2 was immunoprecipitated from rat brain nuclear extract with MeCP2 
specific antibodies and probed by western blot with anti-topoisomerase antibodies. 
MeCP2 failed to immunoprecipitate topoisomerasel specific signal suggesting it is a 
contaminant in the purification. 
size exclusion chromatography. The biochemical and biophysical explanation for this 
observation is determined and discussed in Chapter four. 
3.4 Discussion 
3.4.1 Mechanisms of MeCP2 mediated repression 
DNA binding transcription factors mediate their effects independently or through 
association with other protein co-factors, and in some cases, through a combination of 
both mechanisms (Ogbourne and Antalis, 1998; Thiel et al., 2004). In in vitro 
transcription assays, MeCP2 represses transcription (Nan et al., 1997a). This function 
is likely mediated through interaction with TFIIB, a component of the basal 
transcriptional machinery (Kaludov and Wolffe, 2000). In addition to interfering with 
basal transcription, many transcriptional repressors utilize large protein complexes 
that contain enzymatic activities capable of modulating chromatin structure to repress 
transcription (Bird and Wolffe, 1999; Lusser and Kadonaga, 2003; Peterson and 
Laniel, 2004). Using a candidate approach, MeCP2 was found to interact with the 
mammalian Sin3a protein by co-immunoprecipitation (Nan et al., 1998). The 
mammalian Sin3a protein was identified by its homology with the yeast repressor sin3 
(Ayer et al., 1995; Schreiber-Agus et al., 1995) and several groups biochemically 
purified Sin3a associated with a host of protein co-factors. Histone deacetylases, 
HDAC 1 and HDAC2, were identified as stable components of the Sin3a chromatin 
remodeling complex (Alland et al., 1997; Laherty et al., 1997; Zhang et al., 1997) and 
contribute to the ability of Sin3a to modulate gene expression in a chromatin context. 
Importantly, MeCP2 was shown to associate with an intact Sin3a co-repressor 
complex as both HDAC 1 and HDAC2 bound MeCP2 in an enzymatically active state. 
The contention that MeCP2 existed as a stable component of the Sin3a co-repressor 
complex was the result of work studying the Xenopus laevis xMeCP2 protein. A 
combination of the observations from studies in mammalian and Xenopus sources has 
led to the belief that MeCP2 is intimately associated with Sin3a and that this complex 
is the sole mediator of active transcriptional repression by MeCP2. 
3.4.2 MeCP2 does not stably associate with the Sin3a chromatin 
remodeling complex in nuclear extracts 
Using an unbiased approach, the work described in this chapter evaluates the 
MeCP2/Sin3a association in mammalian nuclear extracts. 	By repeating co- 
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immunoprecipitation experiments in rat brain nuclear extracts it was shown that very 
little cellular Sin3a is associated with MeCP2. Size exclusion chromatography was 
also used to analyze the MeCP2/Sin3a interaction in nuclear extracts and it became 
obvious from these experiments that MeCP2 was not found in fractions containing the 
Sin3a co-repressor complex. This observation fits with the fact that no group has 
identified MeCP2 as a component of a Sin3a chromatin remodeling complex despite 
several independent purifications from different cellular sources (Ahringer, 2000). To 
try and resolve the contradiction regarding the nature of the MeCP2/Sin3a interaction 
in mammals and amphibians newly generated xMeCP2 and xSin3a antibody reagents 
were obtained. By analyzing xMeCP2 and xSin3a in oocyte extracts, it was 
determined that these two molecules do not stably associate. Our observations are in 
agreement with those from Ryan et al who separated oocyte extract by glycerol 
gradient fractionation and found peak xMeCP2 and xS1n3a fractions were distinct 
(Ryan et al., 1999). In light of recent evidence in both mammalian and amphibian 
systems it is apparent that MeCP2 is not a stable component of the Sin3a complex, but 
does weakly associate with Sin3a in a manner that can be observed by co-
immunoprecipitation. 
Purification of MeCP2 from rat brain failed to identify other stably associated co-
factors but left questions as to the cause of its larger than expected apparent molecular 
weight by size exclusion chromatography. MeCP2 is a 52.4 kDa protein but elutes 
from size exclusion column with a relative molecular weight of nearly ten times its 
predicted size. Biochemical and biophysical analysis of MeCP2 in Chapter four 
addresses this discrepancy. 
3.4.3 The contribution of other MeCP2 co-factors in 
transcriptional repression 
Although MeCP2 does not form stable interactions with Sin3a in DNA free extracts, 
there is evidence that they interact on DNA. Chromatin immunoprecipitation assays 
show certain methylated genes recruit Sin3a and/HDAC1 associated proteins in an 
MeCP2 dependent fashion (Chen et al., 2003b; Horike et al., 2005; Martinowich et 
al., 2003). Interestingly, a series of other protein factors have also been shown to 
interact with MeCP2 including; Suv39Hl, c-Ski, DNMT1, Co-Rest, LANA, PU1, 
Brm, Splicing factors, and RNA (Buschdorf and Stratling, 2004; Harikrishnan et al., 
2005; Jeffery and Nakielny, 2004; Kimura and Shiota, 2003; Kokura et al., 2001; 
Krithivas et al., 2002; Lunyak et al., 2002; Suzuki et al., 2003). The relative 
contribution of these factors to MeCP2-mediated repression and cellular function is 
poorly understood and in most cases remains to be thoroughly investigated. The 
realization that MeCP2 is not a stable biochemical component of the Sin3a chromatin 
remodeling complex leaves open the possibility that other factors contribute to the 
normal function of MeCP2. This is exemplified by the recent observation that MeCP2 
associates with histone methyltransferase activity, and that cell lines over expressing 
MeCP2 contain increased histone methylation at loci containing DNA methylation 
(Fuks et al., 2003b). Further investigation of alternative MeCP2 co-factors may help 
to elucidate the repressive capabilities and cellular functions of MeCP2. 
3.4.4 Distinct mechanisms of methylation mediated repression? 
As depicted in Figure 3.1OA, MeCP2 is the only MBD protein that has been isolated 
principally devoid of stably associated co-factors. Other MBP's are all stably 
associated with co-factors; MBD1 stably associates with SetDB1 (Sarraf and 
Stancheva, 2004), Kaiso is a component of NCoR, and MBD2 is part of the MeCP 1 
complex (Feng and Zhang, 2001; Yoon et al., 2003). The fact that MeCP2 is isolated 
independent of associated co-factors suggests a possible mechanistic difference in the 
way MeCP2 functions to read DNA methylation, and perhaps increased flexibility 
once bound to DNA to repress transcription. Because MeCP2 is not part of a stable 
complex, it can bind methylated sites and then repress transcription either 
independently, (Option A, Figure 3.1 OB), or by subsequent recruitment of co-factors 
like the Sin3a chromatin remodeling complex, (Option B, (Figure 3.10B). 
Recruitment of MeCP2 to regulatory regions free of pre-determined co-factors lends 
flexibility as MeCP2 can repress transcription in a context-specific, or even, gene 
specific-manner, perhaps recruiting different co-factors under unique situations; 
(Option C (Figure 3.10B). This starkly contrasts with the rigid nature of repression 
directed by other complex-bound MBD proteins. MBD1, Kaiso, and MBD2 
containing complexes arrive at methylated CpG's ready to modify chromatin and 
repress transcription immediately, using a generalized and predefined set of repressive 
tools. The protein composition of complex bound MBP's may relate to the context in 
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Figure 3.10- Flexibility and diversity of MeCP2 function in vivo? 
MeCP2 is the only MBD containing protein so far that has been purified in the 
absence of stably associated co-factors. 
A schematic demonstrating three of the potential ways MeCP2 may function to 
repress transcription in vivo. Option A, MeCP2 binds methylated DNA and uses 
intrinsic repressive capabilities. Option B, MeCP2 binds methylated DNA and recruits 
the Sin3a chromatin remodelling complex to repress transcription and remodel 
surrounding chromatin. Option C, MeCP2 binds methylated DNA and recruits other 
factors to mediate repression in a gene specific or context dependent manner. 
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which each represses transcription, and the fact that MeCP1 related complexes are 
found in lower organisms suggest that they may have evolved this way (Marhold et 
al., 2004a; Wade et al., 1999). MBD1 is recruited by CAF  to active DNA replication 
forks coupling histone H3 lysine 9 methylation via SETDB 1 to target genes with 
DNA methylation (Sarraf and Stancheva, 2004). Similarily, Kaiso/NCoR and MeCP 1 
(MBD2) may recruit stably associated co-factors to genes which the complex is 
specifically tailored to repress (Hendrich et al., 2001; Hutchins et al., 2002; Ruzov et 
al., 2004). Although MeCP2 has more flexibility in co-repressor recruitment, co-
factor bound MBD proteins have at least one specific advantage in that they do not 
rely on a two step mechanism, binding then recruitment, to impart silencing. 
Interestingly, MeCP2 has different biochemical attributes than other MBP's. Mild 
extraction conditions (300-350 mM NaCl) recover MBD1 and Kaiso (Helle 
Jorgensen, personal communication), and also MBD2 (Meehan et al., 1992) from 
nuclei. The ease by which complexed MBD proteins can be isolated from nuclei 
suggests they are not tightly associated with chromatin. This fluidity may reflect a 
requirement for complex-bound MBP's to constantly associate and dissociate with a 
variety of sites that they target for repression to maintain and re-enforce the repressed 
state. In contrast, MeCP2 is tightly bound to chromatin and requires more harsh 
conditions for efficient release from isolated nuclei (>400 mM NaC1)(Meehan et al., 
1992). MeCP2 might use a different strategy than complexed MBP's, by binding 
tightly to specific loci and re-inforcing silencing by recruiting and then releasing co-
factors. Tight binding, coupled to potentially promiscuous recruitment of co-factors 
might suit the functional requirement of MeCP2 to exploit different co-factors to 
repress different classes of genes (Figure 3.10). If the diverse set of co-factors that 
MeCP2 can utilize to repress transcription in turn permits MeCP2 to affect a range of 
target genes this could partially account for the phenotypic severity of MeCP2 null 
mice in comparison to other MBP null mice. Certain functions and cofactors that 
MeCP2 utilizes may be required to silence a defined sub-set of MeCP2 target genes 
which cannot be modulated by complexed MBP's. In agreement with this contention, 
transcriptional profiling in MeCP2 null mice have revealed little evidence to support 
the notion that MeCP2 is a global methylation dependent repressor of transcription 
(Tudor et al., 2002), as one might expect of a methyl-CpG binding protein. However, 
MeCP2 has been shown to have gene-specific roles in transcriptional repression of the 
101 
Bdnf, Ube3a, and Dlx-5/6 genes (Chen et al., 2003b; Horike et al., 2005; Martinowich 
et al., 2003). Functional analysis of MeCP2 target genes and evaluation of 
redundancy between MBD proteins will begin to address the individual functions of 
MBP proteins. 
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4. Chapter four- 
Biophysical analysis of MeCP2 
4.1 MeCP2 has a large elution profile by size exclusion 
chromatography 
When methyl-CpG binding activities were originally identified, MeCP1 was analysed 
by size exclusion chromatography and eluted in a high molecular weight fraction 
(Meehan et al., 1989). Purification and identification of the proteins in MeCP1 
revealed a multi-protein complex containing MBD2 as the active methyl-CpG binding 
protein (Feng and Zhang, 2001; Ng et al., 1999). In Chapter 3 a purification of native 
rat brain MeCP2 showed that MeCP2 does not stably associate with other proteins, 
yet has a large apparent molecular weight by size exclusion chromatography. 
Because MeCP2 is predicted to encode a 52.4 kDa protein, it was hard to reconcile 
this large elution profile (between 400-500 kDa) based on the predicted molecular 
weight of MeCP2 alone. In this chapter three possibilities were adressed to explain 
this discrepancy; 1- MeCP2 has a DNA or RNA component which was not detected in 
the biochemical purification, 2- MeCP2 self associates and forms a large molecular 
weight complex, or 3-MeCP2 is an abnormally shaped molecule. 
4.2 Biophysical analysis of MeCP2 
4.2.1 Elution profile of native MeCP2 is unaffected by nuclease 
treatment. 
To test whether RNA or DNA components contribute to the large relative molecular 
weight of MeCP2, an aliquot of purified rat brain MeCP2 protein was treated with 
Benzonase (Moreno et al., 1991). Benzonase is a non-specific nuclease that will 
efficiently degrade RNA and DNA even in complex mixtures. After treatment with 
Benzonase the protein sample was separated by size exclusion chromatography on a 
Superose 6 column and the fractions analyzed by western blot with MeCP2 specific 
antibodies (Figure 4.1). Treatment with nuclease had no affect on the mobility of the 
purified material and the elution profile mirrored that of the untreated sample (Figure 
3.1C). This observation suggests that an RNA or DNA does not contribute to the 
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Figure 4.1- Nucleic acid does not contribute to the large molecular weight of native 
MeCP2. 
MeCP2 purified from rat brain was treated with Benzonase and separated by size 
exclusion chromatography on a Superose 12 column. MeCP2 was identified by 
western blot analysis using MeCP2 specific antibodies. Native molecular weight 
markers are displayed above the blot in kDa. 
abnormal size exclusion profile of native MeCP2. In light of a recent report that 
MeCP2 associates with various forms of RNA, it is informative that RNA does not 
contribute greatly to the native size exclusion profile of MeCP2 (Jeffery and 
Nakielny, 2004). 
4.2.2 Producing preparative amounts of native MeCP2 for 
biophysical analysis 
Although native MeCP2 from rat brain was efficiently purified in micro-gram 
quantities, much larger amounts of native MeCP2 protein were required to carry out 
biophysical analysis and determine the cause of the aberrant size exclusion profile of 
MeCP2. To produce preparative amounts of MeCP2 material, both a baculovirus 
expression system and a prokaryotic expression system were utilized. In both systems 
MeCP2 was expressed untagged and purified by a combination of affinity 
chromatography and conventional biochemistry. 
Baculovirus expression of mammalian proteins has proved very convenient for 
obtaining full length proteins that are difficult to express in bacterial systems. 
Historically, full length MeCP2 produced in bacteria as a GST-fusion suffered from 
proteolytic degradation (Xinsheng Nan, personal communication), so baculovirus 
expression was chosen to overcome this problem. Untagged human MeCP2 was 
cloned into the fastbacl baculovirus shuttle vector from Invitrogen (Figure 4.2). The 
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Invitrogen system takes advantage of site specific recombination to produce a 
recombinant baculovirus genome in bacteria (Luckow et al., 1993). This system 
relies on cloning the gene of interest, in this case MeCP2, into a shuttle vector 
followed by transformation into bacterial cells containing a recombination proficient 
viral genome (Figure 4.2). Once recombination is induced in bacteria, only the 
recombined viral genome is maintained through selection for a co-integrated marker 
gene (gentR, Figure 4.2). The viral DNA is then purified and transfected into S179 
insect cells which produce recombinant protein while also assembling and budding 
infectious recombinant viral particles. Recombinant viral particles can be isolated 
from the transfected SF9 cells and subsequently used as a vehicle for further SF9 cell 
infection and recombinant protein expression. 
Recombinant baculovirus DNA was transfected into S179 cells and viral particles were 
collected (P1 viral stock). To ensure the recombinant virus was producing MeCP2, 
the transfected cells were harvested and protein expression assayed by western blot 
using MeCP2 specific antibodies. Strong MeCP2 western blot signal was observed in 
the transfected cell extracts and no signal was observed in the untransfected SF9 line 
(Figure 4.3A). The P1 viral stock was amplified and used for large scale infection of 
S179 cells in spinner culture. S179 insect cells (- 109 cells) were infected with 
amplified MeCP2 virus and whole cell extract obtained (Figure 4.3B). The clarified 
extract was applied to Ni-Nta resin and eluted in 250 mM imidazole. A strong band 
at approximately 80 kDa, corresponding to MeCP2, was observed in the first two 
elutions from the Ni-Nta column (Figure 4.3B). MeCP2 containing fractions were 
pooled, applied to a Sp-Sepharose cation exchange column, and eluted with a linear 
gradient of increasing NaCl concentration from 0.2 M to 1 M. The majority of MeCP2 
eluted over four fractions (Figure 4.3B) which were dialyzed into storage buffer and 
the concentration determined by a combination of Bradford assay and visual 
quantification by Coomassie staining of SDS-PAGE gels. The production of MeCP2 
in baculovirus proved efficient, as purified MeCP2 protein 
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Figure 4.2- Generation of untagged MeCP2 expressing baculovirus. 
MeCP2 expressing baculovirus was generated by cloning MeCP2 into a baculovirus 
shuttle vector. The shuttle vector has recombination sites (Tn7RIL) flanking MeCP2 
and a selectable marker (gentR). The shuttle vector was transformed into bacteria that 
contain a baculovirus genome with a miniattTn7 recombination site. Bacteria 
containing the recombined MeCP2 baculovirus genome were selected for by the 
incorporated antibiotic resistance cassette (gentR). The baculovirus genome was 
purified from bacteria and transfected into SF9 cells to produce P1 viral stock and 















62 	 MeCP2 
48 
kDa 0,2M 	 IM 
175 





Infect 1 billion SF9 cells 
4, 














purified protein 	62 - - 
48 
lug 	3ug 	lug 	31 ig 
MeCP2 RSA 
Figure 4.3- Production of baculovirus MeCP2. 
Western blot analysis for MeCP2 in whole cell extracts from transfected SF9 
cells. Recombinant MeCP2 baculovirus genome isolates (7 and 8) were transfected 
into SF9 cells in duplicate (a and b). 
Amplified viral stock was used to infect one billion SF9 cells and 20 mL of 
clarified whole cell extract was applied to a Ni-Nta column. Unbound proteins were 
washed away and MeCP2 was eluted with 250 mM imidazole. Elutions (El-5) were 
analysed by Coomassie stained SDS PAGE. MeCP2 containing fractions El and E2 
were applied to a Sp-Sepharose cation exchange column and eluted with a linear 
gradient of NaCl from 0.2 M to 1M. MeCP2 eluted between 450-550 mM NaCl as 
determined by Coomassie stained SDS PAGE. MeCP2 containing fractions were 
dialysed into storage buffer and the protein concentration determined by Bradford and 
Coomassie stained SDS PAGE. 
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(1.3mg) was virtually all full length. Therefore, expression of MeCP2 in baculovirus 
overcomes some of the problems associated with production of full length MeCP2 in 
bacteria (Figure 4.3B). 
When applied to a Superose 12 size exclusion column, the baculovirus-produced 
MeCP2 protein showed the same elution profile as the native rat brain material, 
suggesting that this may be a useful source of protein for biophysical studies (Figure 
4.4A). During the purification of MeCP2 from SF9 cells, the presence of a MeCP2 
doublet was evident on SDS PAGE gels (Figure 4.4A). Because insect cells contain a 
repertoire of eukaryotic kinases, it was predicted that this mobility difference might 
exist due to phosphorylation of the MeCP2 protein. To test this possibility, 
baculovirus produced protein was treated with lambda phosphatase and separated by 
SDS PAGE (Figure 4.413). The phosphatase treated protein had increased mobility 
when compared to untreated material indicating loss of phosphorylation (Figure 
4.413). As a control, the de-phosphorylation reaction was carried out in the presence of 
phosphatase inhibitors which did not affect the mobility of treated MeCP2 (Figure 
4.413). Because native MeCP2 purified from rat brain did not migrate as doublet, this 
modification could arise through different kinase substrate preference in insect cells. 
Inappropriate phosphorylation of MeCP2 in insect cells could interfere with normal 
protein function, therefore the baculovirus produced material was held in reserve so 
that MeCP2 produced in bacteria could be investigated further. 
Intact, full-length GST-MeCP2 protein is difficult to purify from bacteria. For this 
reason it would be advantageous to have a bacterial expression system in which 
MeCP2 could be isolated as a full length protein devoid of tags. To this end, the 
His/S-tag was removed from the commercial prokaryotic expression vector pet30b, 
and MeCP2 was cloned in-frame with the translational start site of the vector. To 
overcome any expression problems that might arise because of differential eukaryotic 
and prokaryotic codon usage, the MeCP2 expressing plasmid was transformed into E. 
coli BL21 cells that express rare human tRNA codons. Protein was produced by 
induction of MeCP2 expression at 30 °C for 3 hours, and whole cell bacterial lysate 
was made by sonication followed by removal of insoluble material by 
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Figure 4.4- Baculovirus MeCP2 is a phosphoprotein 
Baculovirus produced MeCP2 was separated by Superose 12 size exclusion 
chromatography and analysed by Coomassie stained SIDS PAGE. Baculovirus 
produced MeCP2 has the same apparent molecular weight as native rat brain MeCP2. 
Baculovirus produced MeCP2 is a phosphoprotein. MeCP2 was purified as a 
doublet from SF9 cells and this doublet is lost by treating the protein with lambda 
phosphatase as observed by Coomassie stained SDS PAGE. Phosphatase inhibitors 







centrifugation. Clarified lysate was applied to a Ni-Nta column followed by extensive 
washing of the bound MeCP2 protein. MeCP2 was eluted from the Ni-Nta column 
with 250 mM irnidazole (Figure 4.5A). The MeCP2 containing fraction from the Ni-
Nta column was applied to a Sp-Sepharose cation exchange column and MeCP2 was 
eluted with a linear NaCl gradient from 0.2 M to 1 M. MeCP2 eluted between 400-
450 mM NaCl and these fractions were then directly applied to a Sephacryl S-300 HR 
26/60 column. MeCP2 eluted from the Sephacryl S-300 HR 26/60 column between 
400-500 kDa. The MeCP2 containing fractions from the Sephacryl S-300 column 
were dialyzed into buffer containing 200 mM NaCl and applied to a Mono S cation 
exchange column. A linear gradient from 0.2 M to 1 M NaCl was then applied to the 
Mono S column and MeCP2 eluted between 400 and 450 mM NaCl. The MeCP2 
containing fractions were pooled and dialyzed into storage buffer. MeCP2 purity was 
>95% when analysed by Coomassie stained SDS-PAGE (Figure 4.5A). After 
extensive purification the MeCP2 yield approached milligram-per-liter quantities, 
indicating the efficiency of this expression regime. To determine whether the 
bacterially produced, untagged, full length MeCP2 behaved like the endogenous rat 
brain protein, purified bacterial MeCP2 was separated on a Superose-12 size 
exclusion column (Figure 4.513). As was previously observed for endogenous rat 
brain MeCP2, the bacterially produced MeCP2 protein eluted between 400-500 kDa. 
As the bacterial protein had the same size exclusion profile as the endogenous protein, 
it was necessary to verify that the protein was functional. Since MeCP2 is a methyl-
CpG binding protein, its ability to bind methylated DNA by EMSA was tested (Figure 
4.5C). MeCP2 was incubated with a probe containing multiple-CpG dinucleotides 
that were fully methylated using the prokaryotic methyltransferase M.SssI. 
Bacterially produced MeCP2 specifically shifted the methylated probe and not its 
unmethylated counterpart (Figure 4.5C). The methyl-specific EMSA could be 
competed with excess unlabelled methylated DNA but not unmethylated DNA, 
verifying the specificity of the observed shift (Figure 4.5C). Although the MeCP2 
EMSA showed specificity for methylated DNA, the MeCP2 DNA complex migrated 
only a short distance into the gel matrix and appeared to consist of one major complex 
(Figure 4.5C). This result is unexpected given that the probe contains multiple 
methyl-CpG's. Theoretically, MeCP2 should associate with 
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Figure 4.5- Production of untagged MeCP2 in bacteria. 
A four step purification scheme was devised to purify untagged MeCP2 from 
bacteria. Purified MeCP2 was determined to be >95% pure by Coomassie stained 
SDS PAGE. 
Recombinant MeCP2 was separated by Superose 12 size exclusion 
chromatography and analysed by Coomassie stained SDS PAGE. MeCP2 produced 
in bacteria has the same apparent molecular weight as native rat brain protein. 
Recombinant MeCP2 specifically shifts fully a methylated CG  1 probe (Meehan 
et al., 1989) by EMSA on a 1.5 % agarose gel. Methylated probe was shifted by 
increasing concentrations of MeCP2 (left panel), and could only be competed by 
unlabelled methylated DNA. MeCP2 did not shift unmethylated DNA (right panel). 
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the probe in an incremental and concentration dependent manner as it occupies 
individual methyl-CpG sites, which would result in multiple DNA proteins complexes 
of differing apparent molecular weight. The results in Figure 4.5C do not behave 
according to this rational, and the reason for this is currently unknown. Despite the 
peculiarities in the EMSA appearance, MeCP2 produced in bacteria appears to be an 
excellent source of material with which to study the biophysical properties of native 
MeCP2. 
4.2.3 Native MeCP2 does not self associate 
Bacterially produced recombinant MeCP2 was used to test the hypothesis that MeCP2 
may self-associate. If two molecules in solution are physically associated, it is 
possible to covalently link the two proteins using cross-linking reagents, but 
molecules that are not associated do not cross-link. When cross-linked, physically 
associated molecules exhibit a reduced mobility when analyzed by SDS-PAGE and 
can be differentiated from unassociated molecules by this feature. MeCP2 was 
treated with increasing concentrations of the chemical cross-linking reagent EGS 
(Figure 4.6A). As a control the same experiment was carried out using BSA, a 
monomeric protein, and ADH a tetrameric complex. BSA was unaffected by 
increasing EGS concentration but ADH cross-linked into higher molecular weight 
dimeric, trimeric and tetrameric species (Figure 4.6A). MeCP2 displayed no cross-
linked species suggesting that it does not self associate. However, an increase in 
mobility of MeCP2 was observed with increasing EGS concentration probably due to 
intramolecular cross-links (Figure 4.6A). Therefore, chemical cross-linking data 
indicates that full length recombinant MeCP2 does not self associate. In agreement 
with the chemical cross-linking experiments, two differently sized molecules of 
MeCP2 also do not associate in solution. A fragment of containing 1-318 amino acids 
of MeCP2 was purified from bacteria and mixed with full length MeCP2 (Figure 
4.113). Size exclusion chromatography of the mixed full length and 1-318 proteins 
resulted in two independent elution profiles, which corresponded to the each protein 
run on the same column individually (Figure 4.6C). Although one cannot rule out the 
possibility that deleting amino acids 319-486 interferes with potential MeCP2 self 
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Figure 4.6- Native MeCP2 does not self associate. 
Full length MeCP2 does not self associate as determined by chemical 
crosslinking. MeCP2, BSA, and ADH were untreated (-) or treated with increasing 
concentrations of EGS and analysed by Coomassie stained SDS-PAGE. 
Diagram showing untagged MeCP2 and MeCP2 1-318, which were produced in 
bacteria and purified. 
Full length MeCP2 and MeCP2 1-318 were mixed and applied to a Superose 12 
size exclusion column with the molecular weight markers indicated above each 
Coomassie stained SDS PAGE gel. Each protein eluted independently (upper panel) 
and with the same apparent molecular weigh as each protein separated individually 
(lower panels). 
Native MeCP2 does not self associate in vivo. Rat brain nuclear extract was left 
untreated (top panel) or treated (bottom panel) with 6M urea and separated by 
Superose 12 size exclusion chromatography. MeCP2 and HDAC 1/2 were identified 
by western blot analysis 
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that full length MeCP2 does not self associate. Therefore, MeCP2 does not self 
associate in vitro. 
To verify that the endogenous rat brain MeCP2 does not self associate, nuclear extract 
was treated with 6M urea at 65 °C for 10 minutes and then applied to a size exclusion 
column. Denaturing conditions did not significantly affect the native mobility of 
MeCP2 but did eliminate most of the high molecular weight HDAC 1/2 complexes 
(Figure 4.6D). This suggests that, like the recombinant MeCP2, native MeCP2 from 
rat brain does not self associate. 
4.2.4 Biophysical analysis of MeCP2 using the Seigel and Monty 
equation 
In the mid-sixties, a very elegant series of experiments by Siegel and Monty 
determined that a combination of the stokes radius (radius of protein) and the 
sedimentation coefficient could be used to accurately determine the native molecular 
weight of both globular and non-globular proteins and protein complexes (Siegel and 
Monty, 1966). 	Their analysis utilized a combination of size exclusion 
chromatography (which determines stokes radius) and density gradient sedimentation 
(which evaluates sedimentation coefficient) to analyze the native properties of 
proteins, and protein complexes. The power of the Siegel and Monty method is 
realized when studying the native molecular weight of non-globular molecules as it is 
essential to account for the radius (size exclusion) and sedimentation co-efficient 
(sedimentation) to accurately calculate mass. Without this biophysical information 
non-globular molecules will appear to have a very large molecular weight by size 
exclusion chromatography (radius) and a disproportionately small sedimentation co-
efficient when compared to protein size markers which are globular proteins. The 
slow sedimentation of non-globular molecules is attributed to drag as the molecule 
sediments though the density gradient. By applying the equation of Seigel and 
Monty, size exclusion and sedimentation anomalies are cancelled and the native 
molecular weight of a non-globular molecule can be precisely determined. 
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Figure 4.7- MeCP2 is an elongated monomer. 
Native recombinant MeCP2 was separated by Superose 12 size exclusion 
chromatography. The molecular weight of standard proteins are indicated above and 
the radius of MeCP2 indicated below the Coomassie stained SDS PAGE. 
Native recombinant MeCP2 was separated through a 5-20% sucrose gradient by 
ultracentrifugation and fractions analysed by western blot analysis. The sedimentation 
co-efficient of standard proteins are indicated above, and the sedimentation co-
efficient of MeCP2 below. 
Hydrodynamic analysis of MeCP2 was carried out using the Siegel and Monty 
equation. Native MeCP2 has a derived mass corresponding to a monomeric MeCP2 
molecule, and frictional ratio calculations indicate that MeCP2 it is an elongated 
molecule. 
The frictional ratio of other globular (albumen and cytochrome C) and elongated 
(fibrinogen and myosin) molecules. 
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To facilitate Siegel and Monty analysis native MeCP2 produced in bacterial was 
separated on a size exclusion column and sedimented through a sucrose gradient. The 
Superose 12 size exclusion profile was the same as observed previously (Figure 
4.5B), and the radius of the molecule was extrapolated from the known radius of the 
calibrated molecular weight standards. The radius of native MeCP2 is 6.15 nM 
(Figure 4.7A). To determine the sedimentation coefficient, native MeCP2 and 
sedimentation markers were run through a 5-20% sucrose gradient by 
ultracentrifugation. The MeCP2 signal from the gradient fractions was analyzed by 
densitometry and the peak value used to extrapolate the sedimentation coefficient 
from the included sedimentation co-efficient standards. The sedimentation coefficient 
of native MeCP2 is 2.28 S (Figure 4.7B). To determine the molecular weight of 
MeCP2 the stokes radius and sedimentation co-efficient were plugged into the Siegel 
and Monty formula as follows, 
Mr= 62I12O w s20 RsN/(1- P20 v) 
Mr = 57.880 kDa 
where: 
Rs is the Stoke's radius (nm) (extrapolated from gel filtration profile of MeCP2) 
RS(MeCp2) 6.15 nm 
S20,w is the sedimentation velocity (S x 1013)  (extrapolated form the sucrose gradient) 
S20,w(MeCP2) 2.28 S 
20,w is the viscosity of water at 20 °C (0.01002 gUs' cm') 
N= Avogadro's number (6.022 x 1023 mol) 
P2o, is the density of water at 20 °C (0.9981 gcm3 ) 
is the partial specific volume (used 0.725 cm3lg). 
By combining the radius and sedimentation co-efficient the native mass of MeCP2 
was determined to be 57.880 kDa, which is very close to the predicted monomeric 
MeCP2 molecular weight of 53.437 kDa by amino acid sequence (Figure 4.7C). In 
agreement with the previous experiments in this chapter, MeCP2 does not self 
associate and the Siegel and Monty equation derives a mass corresponding to a single 
MeCP2 molecule. 
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4.2.5 Mammalian and Xenopus MeCP2 are both monomeric 
elongated molecules 
MeCP2 has a large radius and small sedimentation coefficient suggesting that is a 
non-globular molecule. The method of Siegel and Monty was used to determined the 
frictional ratio (fifo),  which is a measure of shape, 




Rs is the Stoke's radius (nm) (extrapolated from gel filtration profile of MeCP2) 
RS(MeCp2) 6.15 nm 
Mr = 57.880 kDa (calculated in Section 4.2.4) 
20w is the viscosity of water at20 °C (0.0 1002 gs cm). 
N= Avogadro's number (6.022 x 1023 mol) 
is the partial specific volume (used 0.725 cm3/9). 
MeCP2 has a frictional ratio of 2.41 (Figure 4.7C), and for the purposes of 
comparison the frictional ratio of several common proteins in shown in Figure 4.71). 
Globular molecules like albumen and cytochrome C have frictional ratios just above 
one, whereas elongated molecules like fibrinogen and myosin have frictional ratios 
above two. It has also been reported that a chicken protein, called ARBP, that shares 
homology with the MBD of MeCP2 has an elongated shape (von Kries et al., 1994). 
The significance of an elongated MeCP2 molecule remains to be evaluated. 
The size exclusion chromatography elution profile was determined for endogenous 
Xenopus laevis oocyte MeCP2 in Chapter 3. Like its mammalian counterpart, the 
Xenopus protein was found in a large molecular weight fraction devoid of Sin3a 
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Figure 4.8- Both human and Xenopus MeCP2 are elongated molecules. 
Diagram showing human MeCP2, Xenopus MeCP2, and MBD4 structures. These 
proteins were expressed in bacteria and purified. 
The three proteins purified in (A) were separated by size Superose 12 size 
exclusion chromatography and fractions analysed by Coomassie stained SDS PAGE. 
Both human and Xenopus MeCP2 have large radii as exemplified by large apparent 
molecular weight by size exclusion chromatography. MBD4, although larger by 
amino acid sequence, elutes with smaller relative molecular weight in comparison to 
MeCP2. 
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(Figure 3.2C). To address whether the high molecular weight elution profile of 
Xenopus MeCP2 was also the result of a highly elongated structure, xMeCP2 was 
produced as an untagged recombinant protein in bacteria (Figure 4.8A), and separated 
on a Superose 12 size exclusion column. Recombinant xMeCP2 had an elution 
profile similar to that of mammalian MeCP2 (Figure 4.813), suggesting that 
endogenous MeCP2 in Xenopus oocyte extracts is also an elongated monomeric 
molecule. Therefore both mammalian and amphibian MeCP2 appear to be highly 
elongated molecules. Interestingly when mammalian MBD4 was produced in 
bacteria and separated by size exclusion it had a much smaller radius despite 
containing an additional sixty eight amino acids (Figure 4.813). Therefore, elongated 
structure is not an intrinsic characteristic of MBD containing proteins. 
4.2.6 No individual domain of MeCP2 accounts for its elongated 
structure 
To try and address which domain(s) contribute to the large radius of MeCP2, a series 
of recombinant MeCP2 deletion mutants were generated (Figure 4.9A). MeCP2 
protein fragments were expressed and purified from bacteria under the same 
conditions as full length MeCP2. The purified proteins were then separated by size 
exclusion chromatography on a Superose 12 column. Figure 4.913 indicates how 
much larger the observed protein radius was than would be expected based on 
predicted amino acid sequence. The wild type protein has a radius about 9.5 times 
larger than would be predicted from amino acid sequence alone. The deletion 
proteins 1-373 and 1-318 both elute with radii more than 5 times greater that would be 
predicted. When smaller fragments encompassing individual domains of MeCP2 
were analyzed the values were only 2.5-3.1 times larger than predicted. The general 
trend observed from these experiments is that smaller MeCP2 fragments have a less 
pronounced disparity in predicted radius compared to observed radius. Therefore, the 
elongated structure of MeCP2 is not determined by a single domain, but rather by 
large portions of MeCP2 protein. Interestingly, MeCP2 is about 11% proline by 
amino acid composition which may contribute to the large radius. 
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Figure 4.9- No individual domain of MeCP2 contributes to its large radius. 
Diagram showing a series of deletion mutants which lack MeCP2 domains. 
These proteins were expressed in bacteria and purified. 
The proteins illustrated in (A) were separated by Superose 12 size exclusion 
chromatography and analysed by Coomassie stained SDS PAGE. Above each panel 
the relative molecular weight of each molecule is indicated and the predicted 
molecular weight by amino acid sequence is indicated far left. Immediately to the left 
of each panel is the fold difference in observed versus predicted radius of each 
molecule. An asterisk indicates the peak absorbance of each elution profile and to the 





4.3.1 Native MeCP2 is an elongated monomer 
Very little data is available about the biophysical properties of native MBD proteins. 
Purified native MeCP2 from rat brain was found in a large molecular weight fraction 
although it was not stably associated with other proteins. To address this discrepancy 
three possible explanations were tested; 1-MeCP2 associates with an RNA or DNA 
component, 2-MeCP2 stably self associates, 3-MeCP2 is a non globular molecule. By 
treating purified rat brain MeCP2 with nucleases no change in the size exclusion 
profile was observed, suggesting DNA or RNA are not involved. In order to study the 
second two possibilities, preparative amounts of recombinant MeCP2 were produced 
and shown to contain the same properties as the MeCP2 molecule purified from rat 
brain. No self association of MeCP2 was observed under several experimental 
conditions, and biophysical analysis using the Siegel and Monty analysis 
demonstrated that MeCP2 is an elongated monomer. 
4.3.2 Is there a structural reason that MeCP2 is an elongated 
molecule? 
Biophysical analysis demonstrates that mammalian and Xenopus MeCP2 are both 
highly elongated molecules. The biophysical properties of the other MBD proteins 
remain to be tested but preliminary evidence suggests that MBD4 does not have the 
same elongated structure as MeCP2. Efforts to map a domain required for the 
elongated shape of MeCP2 proved inconclusive, and the majority of the protein is 
required for the observed radius. A possible explanation for the large radius could be 
the relatively significant contribution of proline in MeCP2, which accounts for 11% 
of amino acids. Several other molecules including P-57 (Masure et al., 1986) and 
myosin light chain kinase (Crouch et al., 1981) have large radii and a disproportional 
contribution of the amino acid proline in their sequence. The peptide bond that forms 
in proline is inherently rigid and often causes in kinks in the protein backbone 
(Barlow and Thornton, 1988) and will act as a helix breaker. The frequent occurrence 
of the amino acid proline might be a structural factor that contributes to the large 
radius of native MeCP2 by perturbing normal globular protein folding. With the 
exception of the MBD, simple secondary structure prediction analysis of MeCP2 
reveals no obvious regions that might contribute to structure of the molecule and 
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domain mapping failed to reveal any highly elongated sub-domain (Figure 4.913). 
Protein crystallization and three dimensional structure analysis may be the only useful 
way to fully understand the amino acid determinants that result in an elongated 
MeCP2. Currently, crystallization trials are underway to try and elucidate the 
structural determinants that lead to elongation of MeCP2. 
4.3.3 Why might an elongated MeCP2 molecule be 
advantageous? 
The shape of a molecule usually serves a functional or structural requirement, for 
example, the rod like structure of myosin is functionally related to its structural role in 
muscle contraction (Holmes, 1997). While myosin has a distinct shape to suit its 
biomechanical functions, the yeast transcription factor TFIIIB is highly elongated and 
postulated to act as a bridge linking together proteins necessary for initiation of RNA 
p01 III transcription (Klekamp and Weil, 1987). Therefore, an elongated MeCP2 
molecule may serve some structural advantage related to function in vivo. One 
possibility is that elongated MeCP2 functions in a modular fashion with each of its 
domains functioning independently from each other (Figure 4.1 OA). For example, the 
MBD would be responsible for binding methylated DNA and other distinct protein 
domains, the TRD, N-terminus and the C-terminus, might carry out their function in a 
manner structurally independent of the MBD (Figure 4.9A). Therefore, MeCP2 might 
bind DNA with the N and C termini extended outward as a platform to mediate 
interactions with other proteins and/or potentially to exclude other factors from 
interacting with surrounding DNA sequence (Figure 4.1013). Recent evidence 
suggests that MeCP2 is involved in chromatin looping and uncharacterized domains 
of MeCP2 may be involved in this function (Horike et al., 2005). Since the MBD and 
TRD can both function independently when expressed as separate domains (Jones et 
al., 1998; Nan et al., 1997a; Yu et al., 2000), the suggestion that MeCP2 functions in a 
modular fashion might not be completely unfounded. Interestingly, Rett syndrome 
mutations exist along the length of the MeCP2 molecule, and regardless of whether 
these mutations affect mapped functional domains, they result in relatively similar 
disease phenotypes. Since many Rett mutations leave methyl-CpG binding and 
repression modules intact, these mutations could interfere with other structurally 
distinct functional domains in MeCP2 (Figure 4.1OC). With the recent discovery of 
MeCP2 regulated genes (Chen et al., 2003b; Horike et al., 2005; Martinowich et al., 
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2003) it will be of functional and structural importance to dissect what domains of 
MeCP2 are required for normal function, and analyze whether an elongated MeCP2 
molecule contributes to these functions. 
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Figure 4.10- Is MeCP2 elongated to act in a modular fashion? 
(A) MeCP2 is a highly elongated molecule suggesting that multiple modular domains 
may exist. Within the context of an elongated MeCP2 molecule each individual 
domain could function independently. 
(B and C) As explained in the text, an elongated modular MeCP2 molecule could act 
as a versatile landing pad for co-factor recruitment and/or to sterically hinder binding 
of other transcription factors to surrounding DNA (B). Because many patients with a 
classical Rett syndrome phenotype have mutations that occur outside of known 
functional domains, other modular domains could be important for normal MeCP2 
function (C). 
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5. Chapter five- 
MeCP2 DNA Binding Specificity 
5.1 How does MeCP2 recognize Methylated DNA? 
DNA methylation in vertebrates is recognized and interpreted by methyl-CpG binding 
proteins (MBP's) that repress transcription and translate epigenetic information found 
on DNA to surrounding chromatin. Little is known about how MBP's are targeted to 
specific methylated loci in vivo, but substantial in vitro evidence has defined the 
specificity of MeCP2 for methylated DNA (Free et al., 2001; Meehan et al., 1992; 
Nan et al., 1993; Yusufzai and Wolffe, 2000). The MBD domain structure of MeCP2 
and MBD1 in the absence of methylated DNA have been solved by NMR (Ohki et al., 
1999; Wakefield et al., 1999) More recently, the structure of the MBD1 MBD in 
complex with a methyl-CpG containing DNA fragment provided molecular insight 
into how methyl-CpG is recognized (Ohki et al., 2001). The core structure of the 
MBD is formed by an a/P sandwich, and distinct residues in the MBD contact both 
the major groove and each individual methyl-cytosine (Ohki et al., 2001). The NMR 
structure of a chicken protein, named ARBP 1, which has homology to the MBD 
domain of MeCP2 has been solved in the absence of DNA and shown to contain the 
same structural fold (Brunner et al., 2000; Heitmann et al., 2003). Initial reports 
characterized AREP 1 as a matrix attachment region (MAR) binding protein. ARBP 1 
binds the sequence GGTGT, but also has affinity for methyl-CpG (Buhrmester et al., 
1995; von Kries et al., 1991a; Weitzel et al., 1997a). The biologically relevant binding 
specificity of ARBP1 remains to be determined, but only methyl-CpG binding 
specificity has been thoroughly demonstrated for MeCP2. 	The biomedical 
importance of MBD function was realized with discovery that the human neurological 
disease Rett syndrome is caused by mutations in the MeCP2 gene (Amir et al., 1999). 
Mutational profiling of Rett syndrome patients has identified a significant portion of 
point mutations that inactivate the MBD of MeCP2, again pointing to the biological 
importance of active interpretation of the DNA methylation signal (Kriaucionis and 
Bird, 2003). 
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Recently, several studies have used chromatin immunoprecipitation (ChIP) to map 
MBP binding loci in vivo. Two studies have used cancer cell lines to identify genes 
that MeCP2 targets in malignant sources. In a study by Ballestar et al (2003) the 
binding profiles of MBP proteins were compared by hybridizing ChIP DNA to CpG 
island micro-arrays. This study showed that some methylated CpG islands were 
targeted by individual MBD proteins, but a large proportion were targeted by more 
than one MBP. A recent report using a chromatin immunoprecipitation-and-clone 
(ChIP-and-Clone) approach identified the DLX 5/6 locus in mouse brain as a target 
for MeCP2-mediated repression (Horike et al., 2005). This chapter investigates the 
binding properties of MeCP2 in vivo and in vitro, and identifies a new DNA binding 
requirement for high affinity recognition of methyl-CpG containing DNA by MeCP2. 
5.2 DNA binding properties of MeCP2 
5.2.1 MeCP2 binds unique loci in vivo 
Methyl-CpG is distributed ubiquitously throughout the mammalian genome (Bird, 
2002). MBD proteins can specifically recognize symmetrically methylated CpG, but 
how each individual MBD family member contributes to distinguishing this signal in 
a genomic context remains unclear. Our collaborator Dr. Irma Stancheva has used 
MeCP2 specific antibodies in ChIP-and-clone experiments to identify methylated loci 
that MeCP2 occupies in vivo in the human primary fibroblast line MRC5. In these 
studies MeCP2 bound to loci which were not extensively bound by other MBP 
molecules. MeCP2 binding in vivo was dependent on DNA methylation as pre-
treatment with 5-aza-cytidine caused loss of MeCP2 ChIP signal at normally bound 
loci. Because methyl-binding proteins recognize methylated CpG it was expected that 
overlap might exist between DNA's occupied by MBP's. In contrast to this 
expectation, it appears as if MeCP2 binds unique loci that generally do not contain the 
other MBD protein relatives. Given that all MBP's recognize methyl-CpG it was of 
interest to determine whether it was possible for other MBP family members to 
occupy MeCP2 binding sequences in the absence of MeCP2 protein. To investigate 
this possibility, Dr. Stancheva carried out depletion studies of MeCP2 and found that 
MBD2 could efficiently occupy unbound MeCP2 sites. Using similar experimental 
approach Dr. Stancheva isolated MBD2 binding loci in vivo and found that depletion 
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of MBD2 did not result in occupancy of MBD2 binding sites by MeCP2. These data 
suggest that MeCP2 may be targeted to specific methyl-CpG's in vivo. 
52.2 Enrichment of MeCP2 binding sites by Methyl-SELEX 
ChIP-and-clone experiments suggest that MBP's occupy distinct loci in vivo. MeCP2 
binds nearly exclusively to loci devoid of other MBP's and cannot take over sites 
vacated by MBD2 in depletion experiments. It is conceivable that the specific MeCP2 
occupancy observed in vivo may be due to a requirement for additional DNA binding 
determinants outside of methyl-CpG alone. To test this hypothesis an experiment was 
designed to isolate high affinity DNA binding sites for MeCP2, using a modified form 
of the in vitro selection technique SELEX (systematic evolution of ligands by 
exponential enrichment). Traditional SELEX has been used in many different 
systems to isolate aptaniers that are high affinity ligands for a given bait molecule 
(KIug and Famulok, 1994). A DNA aptamer has been successfully used to isolate 
DNA sequences that have a high affinity for DNA binding factors (He et al., 1996). 
Here a modification of traditional SELEX (Methyl-SELEX) was devised to determine 
whether MeCP2 has additional sequence binding specificity outside of its known 
binding requirement of methyl-CpG. 
Methyl-SELEX involved generating double stranded DNA fragments that have a 
fixed central CpG in the context of a HpaII methyltransferase/restriction endonuclease 
site, flanked by random DNA sequence (Figure 5.1A). The initial pool of DNA 
fragments was methylated using M.HpaII methyltransferase and tested for complete 
methylation by loss of sensitivity to cleavage by HpaII restriction endonuclease. The 
N-terminal half of human MeCP2 (amino acids 1 - 205) was used for Methy-SELEX, 
as it forms a discrete DNA-protein complex more reproducibly than the full-length 
protein (1 - 486). The protein was mixed with the starting DNA and the protein DNA 
complex was recovered following an electrophoretic mobility shift assay (EMSA). 
DNA from the complex was amplified, re-methylated and once more bound to 
MeCP2 (1-205). After 8 cycles, MeCP2 binding efficiency was increased 
approximately five fold, demonstrating the efficiency of this technique for isolating 
DNA fragments that have an enriched affinity for MeCP2 (Figure 5.1B). 
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Figure 5.1 -Methyl-SELEX efficiently selects for high affinity MeCP2 binding 
sequences. 
A four step Methyl-SELEX enrichment as detailed in the Results text involves 
evolution of high affinity MeCP2 binding sites by multiple EMSA enrichment steps. 
Unselected and selected DNA from Methyl-SELEX were end-labelled with 32P 
and used as probes in an EMSA. Methyl-SELEX selected material showed an 
increase in EMSA signal in comparison to that observed with unselected material. 
The methylation status of each probe is indicated above and MeCP2 protein 
concentration is shown below. (-) indicates free probe. The intensity of each signal 
was quantified and plotted as relative shift signal in the right hand panel. 
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5.2.3 DNA fragments enriched by MeCP2 using Methyl-SELEX 
have an A/T rich sequence adjacent to the methyl-CpG 
The sequence of 88 selected fragments and 86 unselected fragments was determined 
(5.3A)(Appendix 1). Analysis of these sequences revealed the frequent presence of an 
A/T run of 4 or more bases ([AlT]>4) close to the methyl-CpG site in the enriched 
sample. When sequences were aligned with the A/T run to the right of the methyl-
CpG (Figure 5.2A)(Appendix 1), an [AlT]>4 motif appeared to cluster in two vertical 
stripes located 1-3 base pairs or 6-9 base pairs from the methylated CCGG site. To 
determine whether the DNA fragments in the selected pool that contained [A/T]>4 had 
an increased affinity for MeCP2, these fragments were synthesized as individual 
double stranded DNA sequences. Five selected fragments Sl-S5 (Figure 5.213) were 
chosen for this analysis. Two fragments (Si and S2) that had an [A/TI>4 within three 
bases of the methyl-CpG, two fragments (S3 and S4) that had an [A/T]14 within eight 
bases of the methyl-CpG, and a single fragment (S5) that had no [AlT]>4 adjacent to 
the methyl-CpG. As a control two fragments from the unselected pool were chosen 
(Ui and U2). Fragments S1-5 and U1-2 were used in an EMSA with the central CpG 
methylated (M+) or unniethylated (M-). Fragments S1-S4 containing an [A/T]>4 
adjacent to the methyl-CpG demonstrated efficient methylation dependent binding 
(Figure 5.2C). Fragment S5 which was isolated from the selected pool of DNA's 
bound poorly to the methylated probe, suggesting that this is a low affinity binding 
site that has been retained though the enrichment. Fragments U6 and U7 were 
isolated from the unselected pool and showed little detectable binding even to the 
methylated fragment (Figure 5.2C). To determine if the presence of the A/T run 
causes directional binding of MeCP2 to a symmetrical methyl-CpG, the S 1 probe was 
bound to MeCP2 and subjected to DNAseI foot-printing analysis. The high affinity 
Si fragment resulted in a foot-print which covers the A/T run and causes an 
asymmetrical protection of the CpG in the direction of the A/T run containing 
sequence (Figure 5.2D). Therefore, DNaseI analysis suggests that the presence of an 
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Figure 5.2-High affinity MeCP2 binding sites isolated by Methyl-SELEX contain 
methyl-CpG with an adjacent run of [A/T],4  DNA. 
A representative sample of the random unselected and MeCP2 selected DNA 
sequences from the Methyl-SELEX experiment were cloned, sequenced, and aligned. 
The central fixed CCGG site is indicated by an open box and runs of four or more 
A/T's are highlighted with a shaded box. 
Five selected (S1-S5) and two unselected sequences (U6 and U7); see arrows in 
part A) were chosen for further analysis. 
EMSA analysis of MeCP2 selected probes S1-S4 show efficient binding, but 
selected probe S5 that lacks [A/T],4  binds poorly. No detectable binding was observed 
to unselected probes U6 and U7. M+ and M- indicate presence or absence of methyl-
CpG in the EMSA fragment. The concentration of MeCP2 is indicated below with (-) 
indicating free probe 
DNaseI foot-printing analysis on the 32P end labelled Si fragment demonstrates 
asymmetrical protection of the methyl-CpG towards the AlT run (large bracket with 
protected DNA sequence to the right). Location of the methyl-CpG in the foot-
printing probe is indicated by an arrow to the left. G+A indicates the Maxam/Gilbert 
sequencing reaction on the same DNA fragment as size marker. Samples were 
incubated with (+) or without (-) MeCP2 protein. 
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5.2.4 MeCP2 requires an A/T rich sequence adjacent to the 
Methyl-CpG for efficient DNA binding 
To test the requirement of [AlT]>4 for efficient MeCP2 binding, fragments Si and S3 
were mutated (Figure 5.3A) by the addition of cytosine or guanine at two positions 
within the A/T rich run. In both cases altering the base composition from an A/T run 
to non-A/T run containing probe drastically reduced binding efficiency (Figure 5.313). 
All probes used to this point in the study were methylated in the context of a fixed 
central HpaII methyltransferase site (CCGG). To ensure that the extra bases 
surrounding the central CpG did not contribute to the enhanced MeCP2 binding an 
artificial probe (Al) was generated in which the central CG of probe Si was placed 
in the context of GCGC and could be specifically methylated with HhaI 
methyltransferase (Figure 5.3A). Mutation of the HpaII site to a HhaI 
methyltransferase site did not affect the high affinity binding (Figure 5.313). If an 
[AlT]>4  adjacent to the methyl-CpG is a requirement for efficient MeCP2 binding it 
should be possible to engineer a high affinity MeCP2 binding site using these criteria. 
To test this hypothesis a probe was generated (A2) that contains a central CpG with 
an adjacent A/T run of four bases (Figure 5.3A) and is surrounded by random DNA 
sequence. In EMSA assays the engineered DNA sequence bound MeCP2 as 
efficiently as the Methyl-SELEX fragments containing an [AlT]>4 (Figure 5.313). To 
demonstrate that the [AlT]>4 contributes to enhanced binding, this element was 
mutated (A2M). The engineered probe with the mutated [A/T]>4 had a drastically 
reduced affinity for MeCP2. Together these observations demonstrate that the 
efficient DNA binding observed in the Methyl-SELEX fragments is due to the [A/T],4  
sequence that lies adjacent the methyl-CpG. 
5.2.5 The MeCP2 AT-Hook domain does not contribute to binding 
of an NT run containing site 
It was noted in early studies that MeCP2 contains a domain that is shared with 
proteins that bind the minor groove of A/T DNA (Lewis et al., 1992; Nan et al., 
1993). The effect of this domain on MeCP2 function remains unknown, but close 
sequence similarity with an AT-hook domain of HMGA 1 (formerly HMG IIY) and 
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Figure 5.3-Mutation of the [A/T]>4 in high affinity MeCP2 binding site reduces 
affinity. 
Selected fragments Si and S3 were mutated in the AlT run as indicated by the 
shading (Si M and S3M). In fragment Al, the HpaII has been altered to a HhaI site 
(GCGC), and Al M combines this with a mutated AlT run. Fragments A2 and A2M 
are artificially engineered MeCP2 binding sites consisting of random DNA sequence 
in which is embedded a methyl-CpG with an adjacent A/T run (A2) or mutated AlT 
run (A2M). 
EMSA analysis shows that mutation of the AlT run (S1M and S3M) reduces the 
affinity of MeCP2 for 51 and S3 as indicated by reduction of EMSA signal in the Si 
M and S3 M lanes. Al and A2 both bind tightly to MeCP2 and binding is dependent 
on an adjacent AlT run (AiM and A2M). 
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across MeCP2 orthologues is striking (Aravind and Landsman, 1998) (Figure 5.4A). 
Given the requirement for an [A/T],4  at high affinity MeCP2 binding sites, 
experiments were performed to analysed whether the AT-hook might be responsible 
for the binding specificity of MeCP2. To facilitate this analysis two conserved 
arginine amino acids within the MeCP2 AT-hook were mutated to glycine (Figure 
5.4A). Equivalent mutations within the AT-hook of HMGA1 significantly inhibited 
binding to heterochromatin in photobleaching experiments (Harrer et al., 2004). When 
wild type and mutant MeCP2 proteins were assayed by EMSA for binding to the Si 
and Si-mutated DNA fragments, loss of the AT-hook domain had no effect on the 
affinity or specificity of MeCP2 for probes that contained [A/T],4  (Figure 5.413). 
It seemed possible that the AT-hook affects MeCP2 binding in vivo, but escapes 
detection by in vitro EMSA. To examine the in vivo dynamics of the association 
between MeCP2 and mouse heterochromatin a collaborator, Dr. Lars Schmiedeberg, 
employed fluorescence recovery after photo-bleaching (FRAP). In mouse cells 
MeCP2 has a distinct sub-nuclear localization profile at pericentric heterochromatin, 
which contains the major satellite DNA (Figure 5.4C). Mouse satellite DNA accounts 
for about 7 - 10 % of the mouse genome and comprises an AlT-rich repeated 
sequence in which CpG dinucleotides are highly methylated (Hörz and Altenburger, 
1981; Manuelidis, 1981). Based on the observations reported above, the combination 
of concentrated methyl-CpGs adjacent to runs of A/T should provide an optimal 
binding location for MeCP2. For FRAP analysis, wild type and AT-hook mutant 
MeCP2 were fused to GFP and transfected into mouse cells. Both the wild type and 
the AT-hook mutant protein localized normally to DAPI bright spots, which 
correspond to heterochromatic foci (Figure 5.4C). To test the kinetics of MeCP2 and 
the MeCP2 AT-hook mutant in heterochromatic foci, NIH3T3 and p53 mouse 
fibroblasts were photobleached and the recovery time of GFP measured. Wild type 
MeCP2 had a recovery half time of about 25 s, with no significant difference 
(p>0.0001) between wild type and AT-hook mutant in both cell lines tested (Figure 
5.41)). This recovery time is comparable to linker histone Hi (Lever et al., 2000), but 
almost iO times slower than other structural non-histone chromatin proteins, for 
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Figure 5.4- The conserved MeCP2 AT-hook domain is not required for AlT run-
dependent binding of MeCP2 in vitro or in vivo. 
(Experiments in (C) and (D) were contributed by Dr. Lars Schmiedeberg) 
Alignment of the conserved AT-hook domains of MeCP2 with an AT-hook found 
in HMGA I. A mutant MeCP2 protein was generated by replacing two essential 
arginines in the MeCP2 AT-hook with glycine. 
Mutation of the AT-hook of MeCP2 does not affect methyl-CpG A/T run 
dependent binding to the Si probe as indicated by EMSA using 32P labelled probes. 
GFP-MeCP2 and GFP-MeCP2 (AT-hook mutant) both localized to DAPI stained 
foci in living cells. 
Fluorescence recovery after photobleaching at heterochromatic sites is 
indistinguishable between wild-type and mutant MeCP2 
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vitro EMSA and in vivo FRAP analysis the AT-hook is not essential for the 
recognition of high affinity MeCP2 binding sites in which methyl-CpG is followed by 
an AlT run. 
5.2.6 MeCP2 methyl-CpG AlT run dependent binding resides in a 
MeCP2 fragment containing the MBD and flanking 
sequences. 
The MeCP2 AT-Hook does not contribute to the observed requirement for an [A/T]14 
adjacent to methyl CpG for efficient MeCP2 binding. Therefore, to map the MeCP2 
domain responsible for high affinity binding, a series of deletion mutants were 
expressed as recombinant proteins (Figure 5.5A) and used in EMSA on probes Si and 
Si mutated. MeCP2 1-167, which completely lacks the AT-Hook, has the same 
selectivity for a methyl-CpG with an [AlT]>4 as fragment 1-205 that contains the 
intact AT-Hook domain (Figure 5.5A). This observation reaffirms the initial 
demonstration that the AT-Hook is not an obligate component of the observed 
specificity. Further deletion from both the N and C termini of MeCP2 toward the 
MBD (fragments 77-167 and 78-161) retained high affinity binding for the [AlT]>4 
containing probe (Figure 5.5A), excluding these regions as specificity determinants. 
A further N-terminal deletion of MeCP2, resulting in a fragment containing amino 
acids 90-161, completely abolishes DNA binding. Since a MeCP2 fragment 
containing amino acids 78-161 bound the Si probe, this suggests that high affinity 
MeCP2 binding requires amino acids between 78 and 90 in addition to the conserved 
MBD domain (Figure 5.5A). To verify that binding to methyl-CpU with an adjacent 
[AlT]>4 is a unique feature of the MeCP2 protein, a fragment of MBD2 covering the 
MBD, and having roughly the same amino acids as MeCP2 90-161 was used in an 
EMSA. Figure 5.513 demonstrates the MBD2 protein has no sequence specificity with 
respect to the presence of an [AlT]>4 adjacent to the methyl-CpU. Therefore MeCP2, 
but not MBD2, appears to require sequence determinants outside of methyl-CpG 
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Figure 5.5-A fragment of MeCP2 containing amino acids 78-161 confers methyl-CpG 
[AlT]>4 dependent binding. 
Deletion fragments of MeCP2 were used in EMSA with Si labelled probe. A 
fragment containing amino acids 78-161 has methyl-CpG [A/T],4 dependent binding 
but this activity is lost in a fragment containing only amino acids 90-161. 
MBD2a (145-218) was used in an EMSA on the same labelled Si probe and 
showed equivalent binding to both the Si and S 1 mutated probe, indicating MBD2 
does not require an [A/T]>4 for efficient binding. 
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5.2.7 Binding to the promoter sequence of the MeCP2 target gene 
Bdnf is mediated by an methyl-CpG AlT run containing 
sequence 
MeCP2 has been shown to bind an inducible promoter region of the rodent Bdnf gene 
and contribute to maintenance of the silenced state (Figure 5.6A)(Chen et al., 2003b; 
Martinowich et al., 2003). Bisulfite genomic sequencing and competitive EMSA 
analysis suggested that MeCP2 bound preferentially to a methyl-CpG at -148 base 
pairs from the transcription start site (Chen et al., 2003b; Martinowich et al., 2003). 
Analysis of the sequence surrounding -148 revealed an AlT run of four base pairs 
adjacent to the CpG (Figure 5.613). To test the efficiency of MeCP2 binding to this 
sequence, we generated a probe (-148) corresponding to the MeCP2 binding site and a 
control probe of the same length containing one CpG from a sequence within Bdnf 
exon 1 (Figure 5.613). The -148 sequence bound MeCP2 by EMSA, as predicted, and 
the control fragment showed no obvious binding (Figure 5.6C). Mutation of the 
[A/T],4  moiety of —148 significantly reduced the MeCP2 dependent EMSA. The 
persistence of residual MeCP2 binding is likely the result of an additional A/T rich 
segment further downstream of the CpG (Figure 5.6C). Interestingly, the sequence 
corresponding to the Bdnf site (5'CGGAATT3') occurred six times in the Methyl-
SELEX sample of 88 sequences (Figure 5.6A). To determine if MeCP2 utilizes the 
[AlT]>4 in the -148 Bdnf site for directional binding, DNaseI foot-printing analysis 
was performed. As was observed with artificially selected S  fragment (Figure 5.31)), 
MeCP2 binding was not centred on the methyl-CpG site, but extended asymmetrically 
to cover the AATT run (Figure 5.61)). These data suggest that MeCP2 binding at this 
regulatory region is orientated with respect to the methyl-CpG through interaction 
with the adjacent [A/T]>4. 
5.3 Discussion 
5.3.1 MeCP2 binds unique loci which are not redundantly 
occupied by other MBP's 
Studies analysing the specificity of MBD containing proteins for methylated DNA 
have mostly used artificial templates which contained a high density of CpG 
dinucleotides (Fraga et al., 2003; Meehan et al., 1992; Nan et al., 1993) and 
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Figure 5.6- A natural MeCP2 target gene has a high affinity MeCP2 binding site. 
Analysis of the mouse Bdnf promoter IV region showing the MeCP2 binding site 
at -148 bases from the transcription start. 
Probes are shown corresponding to the -148 sequence, -148 with a mutated A/T 
run, and a CpG-containing fragment from exon 1 of the Bdnf gene. 
EMSA shows that efficient MeCP2 binding to the —148 probe is reduced when the 
A/T run in mutated. The exon 1 control probe shows little detectable binding. (D) 
DNaseI foot-printing analysis on 32P labelled -148 Bdnf fragment in the presence (+) 
or absence (-) of MeCP2. The footprint due to the addition of MeCP2 is bracketed, 
with the protected DNA sequence to the right. G+A indicates the MaxamlGilbert 
sequencing reaction on the same DNA fragment as size marker. Methyl-CpG is 
indicated by an arrow (left). 
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fragments containing methylated promoters regions of tumour suppressor genes 
(Fraga et al., 2003). The EMSA probes used in these studies show the MBD 
specifically binds to methylated DNA. The relative contribution of MBD proteins to 
occupancy of methyl-CpG dinucleotides in vivo is unclear. Previous studies using 
chromatin immunoprecipitation to profile MBD bound loci were carried out in 
cancer cell lines and thus addressed the targeting of MBD proteins in malignant 
sources (Ballestar et al., 2003; Koch and Stratling, 2004; Sarraf and Stancheva, 2004). 
Recently, a ChIP and clone approach was used to isolate MeCP2 bound loci from 
mouse brain, which led to the isolation of DLX5/DLX6 genes as targets of MeCP2 
mediated repression (Horike et al., 2005). Since cancer tissue and transformed cell 
lines have perturbed methylation levels and patterns (Kiug and Famulok, 1994; Paz et 
al., 2003), our collaborator Dr. Stancheva used the primary human cell line MRC5 to 
analyse the binding characteristics of MeCP2. In Dr. Stancheva's study, MeCP2 
antibodies were used to chromatin immunoprecipitate and subsequently clone 
genomic fragments bound by MeCP2. Surprisingly, MeCP2 bound to unique loci that 
were mostly unoccupied by the other MBD proteins. Interestingly, MBD2- bound 
loci identified by ChIP-and-clone, also lacked MeCP2 occupancy. The fact that very 
little MBP co-occupancy occurs at the isolated MeCP2 and MBD2 loci suggests that 
MBD containing proteins recognize methyl-CpG containing loci in a non-redundant 
fashion. MBD2 was able to occupy MeCP2 binding sites when MeCP2 was depleted 
suggesting that normal binding of MeCP2 at its target loci excludes binding of other 
MBP's, in particular MBD2. 
5.3.2 Methyl-CpG with [AIT]?4  confers a high affinity directional 
binding site for MeCP2 
Binding of MeCP2 to unique loci in ChIP-and-clone experiments led to the hypothesis 
that MeCP2 might have additional binding specificity outside methyl-CpG. A 
modified form of SELEX (Klug and Famulok, 1994), Methyl-SELEX, isolated high 
affinity MeCP2 binding sites which contain methyl-CpG with an adjacent run of four 
or more nucleotides of AlT rich DNA. This extra DNA binding specificity suggests 
that MeCP2 may recognize a sub-set of genomic methyl-CpG containing sites. Under 
normal conditions in MRC5 cells, MeCP2 can out-compete MBD2 for binding to 
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specific methyl-CpG sites, suggesting that [A/T]>4 may confer sequence specific and 
high affinity binding for MeCP2 to these sites. High affinity MeCP2 binding sites are 
non symmetrical and DNaseI footprint analysis indicates that MeCP2 binding covers 
the [AlT]>4 and is asymmetrical with respect to the methyl-CpG. A MeCP2 binding 
site in the promoter region of the Bdnf gene (Chen et al., 2003b; Kiose and Bird, 
2003; Martinowich et al., 2003) also showed directional MeCP2 binding and A/T run 
protection in DNaseI assays. It is particularly attractive to hypothesize that the 
direction in which MeCP2 binds a regulatory region may have an influence on how 
other protein co-factors are oriented with respect to elements necessary for gene 
regulation. Interestingly, other transcription factors, including E2F4 (Zheng et al., 
1999) and SKN-1(Kophengnavong et al., 1999), bind a cognate sequence and rely on 
an adjacent run of A/T rich DNA for optimal DNA binding. This new insight into 
the binding specificity of MeCP2 will help to identify binding regions for MeCP2 in 
newly identified target genes, and it will be of interest to determine the consequence 
of directional MeCP2 binding. 
5.3.3 Does MeCP2 bind to non-methylated DNA sequences? 
Is MeCP2 primarily targeted to the sites identified here or is it potentially able to bind 
other sequences, including some that are non-methylated? The evidence that binding 
of MeCP2 is dependent on DNA methylation is based on multiple independent 
studies. In addition to many in vitro studies that define the preference for methylated 
CpG sites (Fraga et al., 2003; Meehan et al., 1992; Nan et al., 1993), ChIP analyses 
have consistently shown that MeCP2 associates with a specific DNA sequence in vivo 
when it is methylated, but not to the same sequence at the same genetic locus when it 
is hypo-methylated (El-Osta et al., 2002; Ghoshal et al., 2002; Gregory et al., 2001; 
Lorincz et al., 2001; Nan et al., 1996; Nguyen et al., 2001; Rietveld et al., 2002). In 
the present study, it was shown that 12 randomly selected MeCP2 binding sites all 
lose their association with MeCP2 when DNA methylation is reduced by 5-
azacytidine treatment. Taken together, these studies leave little doubt that MeCP2 
functions as a methyl-CpG binding protein in vivo. 
In vitro studies showed that MeCP2 can associate with non-methylated fragments of 
genomic DNA and mouse satellite DNA, although DNA methylation, when present, 
significantly altered the pattern and increased the affinity of these interactions (Lewis 
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et al., 1992; Weitzel et al., 1997b). Analysis of binding sites for chicken MeCP2 
(originally designated ARBP1; (von Kries et al., 1991b) identified a common GGTGT 
motif, mutation of which reduced the affinity for MeCP2. In vitro binding site 
selection with mammalian MeCP2 did not lead to enrichment of the GGTGT motif in 
the tight binding population of DNA fragments. Interestingly, earlier studies proposed 
that ARBP1 binding to GGTGT is enhanced by a flanking A/T run, as two molecules 
that intercalate with A/T DNA interfered with binding to MeCP2 (Buhrmester et al., 
1995). These findings might be explained if GGTGT represents a weak mimic of 
methyl-CpG whose affinity for MeCP2 can be strengthened by a flanking run of A/T 
DNA. Whether this DNA methylation-independent binding has biological relevance 
remains to be seen. 
Most surprising in this context is a report (Georgel et al., 2003) that MeCP2 can 
complex with non-methylated DNA assembled in vitro into nucleosomal arrays, 
leading to compaction of the arrays as assayed by electron microscopy. In contrast a 
prior study indicated that MeCP2 exclusively targets nucleosomal arrays that contain 
methylated DNA, but ignores non-methylated arrays in the same chromatin solution 
(Nan et al., 1997b). Given this discrepancy and the reported inability of others to find 
MeCP2 bound to non-methylated loci in vivo (see above), it will be essential to show 
that the association of MeCP2 with nucleosomes that carry non-methylated DNA is 
biologically relevant. 
5.3.4 Do other MBP's have sequence specific DNA binding 
determinants? 
MBD proteins were initially identified based on their ability to recognize methyl-CpG 
containing sequences, and little effort has been spent investigating whether sequence 
determinants in addition to a methyl-CpG contribute to their DNA binding properties. 
Evidence is provided in this chapter that demonstrates MeCP2 binds with a high 
affinity to sequences with a methyl-CpG and an adjacent run of [AlT]>4 DNA. These 
observations raise the important question of whether other MBP's utilize sequences in 
addition to methyl-CpG for high affinity binding. Currently, studies are underway to 
address this possibility utilizing the methyl-SELEX procedure, but some evidence is 
already emerging that suggests that MBD1 and Kaiso have additional targeting 
determinants. MBD1 can utilize a zinc co-coordinating CxxC domain to bind to 
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nonmethylated CpG dinucleotides (Jorgensen et al., 2004). Whether the MBD and the 
CxxC domain of MBD1 collaborate to recognize methyl-CpG in a specific context 
remains to be determined, but this suggests that there may be some interplay between 
methyl-CpG and nonmethyl-CpG DNA recognition by MBD1. Kiaso, a zinc finger 
DNA binding transcription factor binds specifically to methyl-CpG containing 
sequences. For Kaiso, DNA binding specificity has been partially determined, and it 
was shown to prefer methyl-CpG in the context of CGCG. It will be interesting to 
determine whether the additional DNA binding properties of MBD1 and Kaiso 
contribute to their binding specificities in vivo. 
To date, MBD2 has not revealed any sequence specificity outside methyl-CpG. 
Bioinformatic analysis suggests that MBD2 is the ancestral methyl binding domain 
protein because it is the only MBD protein found in lower eukaryotes (Hendrich and 
Tweedie, 2003). No alternative DNA binding domains have been identified in MBD2, 
nor has sequence preference outside a single symmetrically methylated CpG 
dinucleotide been observed. It is possible that MBD2 first evolved the capacity to 
bind methyl-CpG dinucleotides in a context independent manner, and perhaps it has 
maintained this function where other MBD containing proteins have evolved and 
diverged in their DNA binding preferences. The data in this chapter supports this idea, 
as un-occupied MeCP2 loci were a good substrate for MBD2 but not MBD1. The 
sequence independent binding properties of MBD2 raise an interesting possibility 
with regard to the evolution of the MBD domain. If the ancestral MBD (MBD2) 
protein arose to recognize methyl CpG, in any context, it is possible to envisage that 
expansion of the MBD protein family in vertebrates created specialised MBD proteins 
that acquired additional DNA sequence specificity as seen for MeCP2. 	With 
identification of more MBP binding loci, and genes that these proteins regulate, it will 
begin to become more clear as to how the DNA methylation signal is interpreted by 
proteins that recognize methyl-CpG. 
5.3.5 Mouse genetics suggest MBP's are not redundant 
Null mice have been generated for all identified mammalian MBP's that are involved 
in transcriptional repression; MeCP2 (Chen et al., 2001; Guy et al., 2001), MBD1 
(Zhao et al., 2003), MBD2 (Hendrich et al., 2001), MBD3 (Hendrich et al., 2001), and 
Kiaso (Selfridge et al unpublished). The phenotypes of these null mice are mild, with 
142 
the exception of MeCP2 which is a model for the debilitating human disease Rett 
syndrome. Interestingly, when MeCP2 and MBD2 null mice were crossed the 
phenotype of the resulting double null progeny was not more severe than the MeCP2 
single null mice (Guy et al., 2001), perhaps indicating that MeCP2 is responsible for 
regulating a non-overlapping set of genes. This contention is further supported by the 
fact that a MeCP2, MBD2 and Kaiso triple null animals do not display synergy in 
phenotype, but again have the same symptoms as the MeCP2 null mouse (Selfridge et 
al unpublished). If MeCP2 affects a specific sub-set of methylated target genes, which 
can not be regulated by other MBP's, this could explain why its deficiency causes 
such a severe and non-overlapping phenotype when compared to other MBP null 
mice. 
It is tempting to hypothesize from these genetic observations that MBP's are 
functioning in non-redundant pathways through intrinsic DNA recognition 
determinants. One could envisage that MeCP2, MBD 1, and Kaiso are targeted to 
specific loci by intrinsic recognition of methyl-CpG in the context of a defined DNA 
sequence. In contrast, MBD2 might have a wider and more probabilistic affect on 
methyl-CpG dependent silencing due to a less discriminatory role in recognizing 
methylated loci (Hutchins et al., 2002). 
5.3.6 Two modes of methyl-CpG recognition? 
If DNA binding specificity has a role in division of work between MBP's one can 
envisage two modes of methyl-CpG dependent repression. The first mode would be 
global, in which a protein would have the capacity, like MBD2, to recognize methyl-
CpG and repress transcription without context dependent requirements. Therefore, 
MBD2 with its tightly associated chromatin remodeling complex NURD may act as 
the global minder of methylation dependent silencing (Figure 5.7). The second mode 
would be a more defined and targeted means of methyl-CpG repression in which 
sequence specific determinants outside methyl-CpG alone are required to target the 
MBP's to genes they regulate. MeCP2, MBD1 and Kaiso might fit this role, as each 
has DNA binding preference, or activity, in addition to a single methylated CpG. As 
introduced in Chapter 1, site specific recruitment of MBP's may also explain their 
differential usage of co-repressor molecules. For instance, MeCP2 may require the 
services of Sin3a to repress a subset of methylated genes to which it is specifically 
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targeted by DNA specificity (Figure 5.7). Likewise, MBD1 and Kaiso would utilize 
their distinct co-repressor molecules to repress an independent subset of target genes. 
Therefore, within this division of labor, each MBP would be tailored to efficiently 
repress their respective target genes, and MBD2 would have a role in maintaining the 
global fidelity of methylation-mediated repression. With more defined understanding 
of DNA recognition by MBP's and their functions in vivo it will become more clear 
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Figure 5.7- Two modes of methyl-CpG recognition? 
MBD2 appears to recognize methyl-CpG independent of DNA context, and therefore 
may fit the role of global repressor of methylated loci (Left). On the other hand, 
factors like MeCP2 that have sequence specificity in addition to methyl-CpG may be 
targeted to specific methyl-CpG containing sequences (Right) and use specially 
tailored repression mechanisms to modulate the expression of a sub-set of specific 
target genes. 
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6. Chapter Six- 
Phosphorylation of MeCP2 
6.1 MeCP2 is a phosphoprotein 
MeCP2 is involved in silencing the Bdnf gene in rodent neurons (Chen et al., 2003b; 
Martinowich et al., 2003). Bdnf silencing is in part maintained through binding of 
MeCP2 to methylated DNA upstream of the promoter, and recruitment of the Sin3a 
chromatin remodelling complex. One study suggested that MeCP2 was lost from the 
Bdnf promoter during gene activation due to a reduction of DNA methylation in the 
promoter region, but the changes in methylation were subtle (Martinowich et al., 
2003). The second also study showed that Bdnf expression induced by calcium 
signalling pathway resulted in MeCP2 loss from the promoter concomitant with 
transcriptional activation (Chen et al., 2003b). Interestingly, in this study very little 
change in the DNA methylation pattern was observed at the Bdnf promoter region, 
before or after gene induction, indicating mechanisms other than loss of methylation 
profile are causative in removal of MeCP2 from the promoter (Chen et al., 2003b). 
The authors also showed that a more slowly migrating form of MeCP2 was observed 
by western blot analysis when calcium signalling pathways were activated. The 
slower migrating form of MeCP2 was eliminated by treating the protein extracts with 
recombinant phosphatase, demonstrating that the change in mobility was due to 
phosphorylation. This suggests that phosphorylation may have a role in liberating 
MeCP2 from the Bdnf gene during gene activation. 	In agreement with 
phosphorylation affecting MeCP2 occupancy of the Bdnf promoter during gene 
activation, south-western blot analysis showed that phosphorylated MeCP2 had 
reduced methyl-CpG binding capacity (Chen et al., 2003b). The identification if Bdnf 
as a MeCP2 target gene has led to the discovery that MeCP2 can act as dynamic 
interpreter of DNA methylation through modulation of its DNA binding capacity. 
Recently MeCP2 was identified in a proteomic screen for phosphoproteins in HeLa 
cell nuclear extract (Beausoleil et al., 2004), but little is know about the exact 
phosphorylation sites or kinases that mediate modification of MeCP2. 
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In this Chapter the DNA binding capacity of phosphorylated MeCP2 produced in 
baculovirus was analysed and a kinase activity that modifies MeCP2 was partially 
purified from HeLa cell nuclear extract. 
6.2 Phosphorylation and MeCP2 
6.2.1 Phosphorylation of baculovirus produced MeCP2 does not 
affect DNA binding 
Recombinant MeCP2 produced in baculovirus is a phosphoprotein (Section 4.2.2). In 
light of the recent observation that phosphorylation of MeCP2 affects DNA binding 
(Chen et al., 2003b; Martinowich et al., 2003), the capacity of Baculovirus produced 
MeCP2 to bind methylated DNA was analyzed. Full length MeCP2 protein does not 
perform well in EMSA, therefore a protein encompassing amino acids 1-205 of 
MeCP2, that works well in EMSA, was produced in baculovirus. MeCP2 1-205 viral 
stock was amplified and used for large scale infection of SF9 cells ( 109 cells)(Figure 
6.1A). The clarified extract was applied to Ni-Nta resin and eluted in 250 mM 
imidazole. A strong Coomassie stained band at approximately 32.5 kDa on SDS 
PAGE, corresponding to MeCP2 1-205, was observed in the first two elutions from 
the Ni-Nta column (Figure 6. 1A). MeCP2 containing fractions were pooled, applied 
to a Mono-S cation exchange column, and eluted with a linear gradient of increasing 
NaCl concentration from 0.2 M to 1 M. The majority of MeCP2 eluted over three 
fractions (Figure 6. 1 A), which were dialyzed into storage buffer and the concentration 
determined by a combination of Bradford assay and visual quantification by 
Coomassie stained SDS-PAGE (Figure 6.1A). 
To verify that MeCP2 1-205 was also modified by phosphorylation in SF9 cells, 
purified MeCP2 1-205 was treated with lambda phosphatase, in the presence or 
absence of phosphatase inhibitors, and then analyzed for a change in electrophoretic 
mobility. As was observed with full length MeCP2, treatment with phosphatase 
caused an increase in the mobility of MeCP2 1-205 and this was ablated by 
phosphatase inhibitors (Figure 6. 1B). Although the change in mobility is very modest 
upon phosphatase treatment the increase in mobility is convincingly demonstrated on 
a high resolution gel in Figure 6.2A. In contrast to full length MeCP2 (Section 4.2.2), 
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Figure 6.1- Production of baculovirus MeCP2 1-205. 
Amplified viral stock was used to infect iü SF9 cells and 20 ml of clarified 
whole cell extract was applied to a Ni-Nta column. MeCP2 eluted from the Ni-Nta 
column with 250 mM imidazole. Elutions (El-5) were analysed by Coomassie stained 
SDS PAGE. MeCP2 containing fractions El and E2 were applied to a Mono-S cation 
exchange column and eluted with a linear gradient of NaCl from 0.2 M to 1M. 
MeCP2 eluted between 450-550 mM NaCl as determined by Coomassie stained SDS 
PAGE. MeCP2 containing fractions were dialysed into storage buffer and the protein 
concentration determined by Bradford and Coomassie stained SDS PAGE. 
Baculovirus produced MeCP2 1-205 is a phosphoprotein. Purified MeCP2 1-205 
was treated with lambda phosphatase and this resulted in an increase in 
electrophoretic mobility which was alleviated by phosphatase inhibitors. 
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MeCP2 1-205 exhibited a less pronounced shift in mobility indicating that perhaps 
fewer residues are modified in this truncated molecule. 
To accurately determine whether the DNA binding capacity of the phosphorylated 
Baculovirus MeCP2 1-205 protein was different from the unmodified protein it was 
first necessary to remove phosphorylation from an aliquot of protein sample. To this 
end, phosphorylated MeCP2 1-205 was incubated with lambda phosphatase or mock 
treated with lambda phosphatase, and then purified away from the phosphatase 
protein by cation exchange chromatography (Figure 6.2A). Purified phosphorylated 
and dephosphorylated proteins were quantified by Bradford analysis and visualization 
by Coomassie stained SDS PAGE. Efficient dephosphorylation was evident from the 
increased mobility of the lambda phosphatase treated material (Figure 6.2A). The 
DNA binding efficiently of the modified MeCP2 1-205 protein was compared to the 
unmodified protein in EMSA using probe Si (Section 5.2.3). MeCP2 1-205 bound 
specifically to methylated DNA irrespective of its phosphorylation state, and had 
similar DNA binding properties to the corresponding protein produced in bacteria 
(Figure 6.213). These data suggest that phosphorylation of MeCP2 in SF9 cells is not 
sufficient to inhibit DNA binding, and therefore the modifications in Baculovirus 
produced MeCP2 may not correspond to the phosphorylation modifications that 
inhibit DNA binding in mammalian cells. 
6.2.2 An activity that can phosphorylate MeCP2 is present in 
HeLa nuclear extracts 
A recent report identified MeCP2 as a phosphoprotein in HeLa cell nuclear extract 
(Beausoleil et al., 2004). It would be of interest to identify kinases that affect MeCP2 
in mammalian cells and use this information to understand what affect 
phosphorylation has on normal MeCP2 function. To identify nuclear MeCP2 kinase 
activity an in vitro assay was devised to monitor incorporation of phosphate groups 
into MeCP2. The basis of the assay is very simple and involves producing full length 
recombinant MeCP2 in bacteria and then mixing it with nuclear extract. By adding a 
32  labeled phosphate donor (32P gamma-ATP), potential kinase activity can be 
monitored by incorporation of isotopic phosphate into MeCP2. Since MeCP2 is 
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Figure 6.2- Phosphorylation of baculovirus-produced MeCP2 1-205 does not inhibit 
DNA binding 
Preparative amounts of phosphorylated and dephosphorylated MeCP2 were made 
by treating purified baculovirus MeCP2 1-205 with lambda phosphatase 
(dephosphorylated) or a mock treatment (phosphorylated). The MeCP2 molecules 
were re-purified by Sp-Sepharose cation exchange chromatography and visualized by 
Coomassie stained SDS PAGE. The phosphorylated form of MeCP2 has a slower 
mobility compared to the dephosphorylated protein. 
The phosphorylated and dephosphorylated MeCP2 1-205 samples were used in an 
EMSA experiment. The phosphorylation status of the MeCP2 molecule did not affect 
DNA binding and both fragments bound specifically to methylated DNA with a 
similar affinity to MeCP2 1-205 produced in bacteria 
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phosphorylated in HeLa cells, HeLa nuclear extract was used as a source potential 
kinase activity, and an in vitro kinase assay was carried out. The reaction was carried 
out using various concentrations of HeLa nuclear extract in the presence of 
phosphatase inhibitors so that newly incorporated phosphate groups would not be 
removed. The in vitro kinase reaction products were then separated by SDS-PAGE 
and visualized by phosphor-imaging. Labeled phosphate was efficiently incorporated 
into recombinant MeCP2 indicating there is a kinase activity in HeLa nuclei that can 
phosphorylate MeCP2 (Figure 6.3). To verify that the 32P labeled band in the in vitro 
kinase assay was MeCP2, a parallel experiment was carried out in which the MeCP2 
protein was immunoprecipitated before SDS PAGE analysis. The resulting signal on 
the phosphor-imager corresponded to the immunoprecipitated MeCP2 protein, 
verifying that MeCP2 is the target of phosphorylation in these assays (Figure 6.3). 
6.2.3 There are two major activities in HeLa nuclei that 
phosphorylate MeCP2 
To gain a better understanding of the biochemical nature of the MeCP2 kinase 
activity, HeLa nuclear extract was subjected to biochemical fractionation (Figure 
6.4A). The majority of the kinase activity extracted from HeLa nuclei remained 
soluble after dialysis into low salt anion exchange buffer and the soluble extract was 
applied to a 1 ml fractogel-TMAE anion exchange column. The bound protein was 
eluted with increasing salt concentration, and the majority of the MeCP2 kinase 
activity eluted from the column between 250 and 400 mM NaC1 as indicated by an in 
vitro kinase assay (Figure 6.413). The active fractions were pooled and applied to a 
Superose 12 size exclusion column. In vitro kinase reactions were carried out on the 
Superose 12 fractions and two peaks of activity were resolved, one corresponding to 
300 kDa and the second corresponding to 45 kDa (Figure 6.4C). Therefore, HeLa 
nuclei have two major MeCP2 kinases that bind an anion exchange column have 
different apparent molecular weights by size exclusion chromatography. 
To verify that the MeCP2 kinase activities that elute in the same fractions on the 
anion exchange column are biochemically distinct, HeLa nuclear extract was applied 
to a 1 ml Sp-Sepharose cation exchange column and eluted with increasing salt 
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Figure 6.3- HeLa cells have MeCP2 kinase activity 
An in vitro kinase assay was designed to monitor kinase activity directed towards 
MeCP2. Varying amounts of HeLa nuclear extracts (20, 10, and 5 ug) were mixed 
with recombinant MeCP2, and 32P labelled ATP to monitor MeCP2 phosphorylation 
(Lanes 1, 2, and 3). The top gel is a Coomassie stained gel of the proteins in the 
reaction, and the bottom gel is a phosphor-imager screen analysing incorporated 
isotope. MeCP2 was heavily labelled by addition of HeLa nuclear extract in the in 
vitro kinase assay. To verify that the phosphorylated 80 kDa band was MeCP2 the 
same reaction was carried out, but before analysis by SDS PAGE the recombinant 
MeCP2 protein was immunoprecipitated by virtue of an N-terminal flag-tag. The 80 
kDa protein with incorporated 32P immunoprecipitated with flag antibody (Lanes 4, 5, 
and 6) verifying that it is recombinant MeCP2. 
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Figure 6.4- HeLa cell nuclear extract contains two MeCP2 kinase activities 
To biochemically characterize the MeCP2 kinase activity 10 mg of HeLa nuclear 
extract was applied to a 1 ml Fractogel-TMAE anion exchange column and eluted 
with increasing NaCl concentration. 
The fractions collected from the anion exchange column were used in an in vitro 
kinase reaction. The majority of the MeCP2 kinase activity eluted between 250 and 
400 mM NaCl. 
The fractions containing MeCP2 specific kinase activity from the anion exchange 
column were applied to a Superose 12 size exclusion chromatography column. The 
size excluded fractions were used in an in vitro kinase assay, which resolved two 
MeCP2 kinase activities, the first with a relative molecular weight of— 300 kDa and 
the second with a relative molecular weight of 60 kDa. 
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Figure 6.5- The two nuclear HeLa MeCP2 kinase activities are biochemically distinct 
HeLa cell nuclear extract was applied to a Sp-Sepharose cation exchange column 
and eluted with increasing NaCl concentration. 
The fractions collected from the cation exchange column were used in an in vitro 
kinase reaction. MeCP2 kinase activity was observed in both the flow through / wash 
phase of the elution and the 280 and 370 mM NaCl elution. 
Both the flow through / wash elution and the 280 - 370 mM NaCl elutions were 
applied independently to a Superose 12 size exclusion column. The flow through / 
wash phase corresponded to the — 60 kDa MeCP2 kinase activity (activity 2), and the 
280 - 370 mM elution corresponded to the 300 kDa activity (activity 1). 
To determine if kinase activity one or two were Casein Kinase II (CKII), the peak 
fractions from the Superose 12 size exclusion step were used for in vitro kinase assays 
in the presence or absence of heparin, which inhibits CKII activity. MeCP2 kinase 
activity 1 is not affected by heparin, but activity 2 was completely abolished by the 
addition of heparin to the reactions. Therefore activity 2 likely corresponds to CMI. 
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concentration in an attempt to separate the two activities (Figure 6.5A). Again, the 
majority of the kinase activity remained soluble when dialysed into low salt cation 
exchange buffer, but in contrast to the anion exchange column, some of the activity 
eluted in the flow through / wash stage and the remainder between 280 and 370 mM 
NaCl (Figure 6.5B). To determine if these two elution profiles corresponded to a 
separation of the MeCP2 kinase activities, each was applied to a Superose 12 column 
independently. The flow through / wash activity eluted from the size exclusion 
column at - 45 kDa and the 280 - 370 mM elution corresponded to the 300 kDa 
activity (Figure 6.5C). Therefore, cation exchange chromatography is efficient in 
separating the two MeCP2 kinase activities. 
One of the most abundant nuclear kinases in the HeLa cells is Casein kinase II (CKII). 
CKII has relatively loose substrate specificity and often phosphorylates a multitude of 
substrates in vitro that it may not significantly modify in vivo (Meggio and Pinna, 
2003). Fortunately, CKII activity is readily inhibited by heparin, so its presence can 
be easily identified in crude extracts by testing the sensitivity of the kinase activity to 
heparin (O'Farrell et al., 1999). To determine if either of the two MeCP2 kinase 
activities was due to CKII, an in vitro kinase assay was carried out in the presence of 
a CKII inhibiting concentration of heparin. The 300 kDa (activity 1) or the 45 kDa 
(activity 2) activity was used as an enzyme source. Activity 1 is unaffected by 
heparin, but activity 2 was completely abolished by addition of heparin, suggesting 
activity 2 contains CKII (Figure 6.5D). 
6.2.4 Partial purification of MeCP2 kinase activity I 
The speed and sensitivity of the in vitro kinase assay makes it ideal for following 
kinase activity during biochemical purifications. 	Several other studies have 
successfully used this approach to purify and identify kinases that modify a specific 
target molecule (Friedl et al., 2003; Hong et al., 2004). MeCP2 kinase activity 2 
likely corresponds to nuclear CKII and was not nearly as robust as activity 1. 
Therefore activity 1 was chosen for further purification and analysis. Large amounts 
('-j 1.3 grams) of HeLa nuclear extract were prepared using a 350 mM NaCl extraction 
followed by dialysis into AE100. The dialysed extract was applied to a 180 ml 
Fractogel- 
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Figure 6.6- Partial purification of MeCP2 kinase activity 1. 
A schematic illustrating the purification steps and elution conditions used to 
purify MeCP2 kinase activity 1. At each step of the purification the activity was 
followed by in vitro kinase activity against recombinant MeCP2. 
The fractions collected from the final Superose 12 purification step were used in 
an in vitro kinase assay. MeCP2 kinase activity 1 was purified intact and retained its 
- 300 kDa relative molecular weight (Compare with Figure 6.5). 
An aliquot of the fractions used in (B) were separated on a 10 % SDS PAGE gel 
and analysed by silver stain. The peak fraction containing MeCP2 kinase activity 
consists of ten major polypeptides, four of which (6,7,8, and 9) co-migrate with the 
MeCP2 kinase activity. 
155 
TMAE column and batch eluted in steps of 100 mM NaCl from AE100 to AE600. 
Both activities eluted in the AE300 elution (Figure 6.6A). The AE300 elution was 
dialysed into CE150 and applied to an 8 ml Sp-Sepharose column. Activity 1 was 
recovered by a linear gradient elution from CE 150 to CE600 in fractions between 200 
and 280 mM NaCl. These fractions were then dialysed into PE600 and applied to a 2 
ml Phenyl-Sepharose hydrophobic interaction column and eluted with a downward 
gradient of ammonium sulfate from 600 mM to 0 mM. The majority of activity eluted 
between 276 mM and 0 mM ammonium sulfate. The active fractions were pooled 
and dialysed into CEI50 and applied to 1 ml heparin sulfate affinity column. The 
majority of the MeCP2 kinase activity was found in the flow through from the 
Heparin column. The flow through was dialysed into AE150 and applied to a 1 ml 
Fractogel-TMAE column and eluted with a linear salt gradient from 150 mM to 600 
mM. The MeCP2 kinase activity eluted between 200 and 325 mM NaCl. The active 
fractions from the Fractogel-TMAE column were pooled and directly applied to a 
Superose 12 size exclusion column. The fractions from the size exclusion column 
were used in a kinase assay (Figure 6.6B), and the resulting activity had a apparent 
molecular weight of 	300 kDa indicating that activity 1 has been specifically 
enriched. Aliquots from the Superose 12 fraction were separated by SDS-PAGE and 
analyzed by silver staining. Four major polypeptides appear to co-fractionate with the 
observed MeCP2 kinase activity (Figure 6.6C). 
6.2.5 CDKI corresponds to the peak of MeCP2 kinase activity 
The peak fraction from the Superose 12 size exclusion step was electrophoresed on a 
10 % SIDS PAGE gel and visualized with Sypro-Ruby stain (Figure 6.7). Ten major 
polypeptides were observed in the active fraction, of which four proteins co-elute with 
the MeCP2 kinase activity on the Superose 12 column (Figure 6.6C). The isolated 
proteins were subjected to identification by mass spectrometry. The only kinase 
identified in the in the ten bands analyzed was human CDK1, which was identified as 
of two individual proteins (Figure 6.7). Because the relative molecular weight of the 
MeCP2 kinase activity is - 300 kDa by size exclusion chromatography it is possible 
that the activity is contained in a protein complex containing CDK1. In this 
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Figure 6.7- MeCP2 kinase activity 1 contains CDK1/CyclinB 1 
The proteins from the peak MeCP2 kinase activity fraction in the Superose 12 size 
column step were separated on a 10 % SDS PAGE gel and analysed by Sypro-Ruby 
staining. Bands were identified by mass spectrometry (right) and the percentage (%) 
peptide coverage of the protein indicated in brackets 
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chromatography is CyclinBi. Previous studies have shown that CyclinBi is stably 
associated with CDK1 at most stages of the cell cycle. The fact that CDK1/CyclinB1 
purify together as an MeCP2 kinase activity suggests that MeCP2 is modified by the 
HeLa cell equivalent of the maturation promoting factor (MPF) protein complex 
which consists of CDK1 and CyclinBi (Doree and Hunt, 2002). An additional 
protein that co-elutes with CDK1, Guanine nucleotide binding protein G, is not likely 
to be a component of the MPF complex, as it did not co-migrate with 
CDK1/CyclinBlin a previous purification step (data not shown). Further purification 
of the MeCP2 kinase activity to homogeneity will clarify if there are other 
constituents of the MeCP2 kinase complex in addition to CDK1/CyclinBl. 
6.3 Discussion 
6.3.1 Phosphorylation of MeCP2 in baculovirus does not inhibit 
DNA binding. 
In rodent neurons, activation of calcium signalling pathways causes phosphorylation 
of MeCP2 which appears to inhibit its DNA binding capacity (Chen et al., 2003b). In 
this Chapter, a phosphorylated fragment of MeCP2 consisting of amino acids 1-205 
was expressed in S179 cells. Phosphorylation did not inhibit binding to methylated 
DNA as tested by EMSA analysis. Since there is no insect homologue of MeCP2, 
phosphorylation of exogenous MeCP2 in this protein expression system is likely the 
result of an insect kinase with broad substrate specificity. These data indicate that 
residues modified by phosphorylation in MeCP2 1-205 do not interfere with DNA 
binding, but this does not rule out the possibility that phosphorylation of MeCP2 in C-
terminus (amino acids 205-486) may contribute to inhibition of DNA binding. 
Assuming that phosphorylation of MeCP2 over the MBD domain will be involved in 
regulating DNA binding, the inhibition of DNA binding which is observed in rodent 
neurons is likely to be the result of a kinase with different modification target sites to 
those modified the baculovirus MeCP2 protein. It may be of interest to identify 
modified sites in baculovirus-expressed MeCP2 to eliminate these residues as 
potential modification sites involved in inhibition of DNA binding in rodent neurons. 
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6.3.2 CDKI phosphorylates Mecp2 
CDKI is the mammalian homologue of the fission yeast cdc2 (bakers yeast cdc28) 
protein kinase. The major cellular function of CDKI is to promote progression 
through the G2/M phases of the cell cycle (Murray, 2004). Activation of the 
CDK1/Cyclin BI containing maturation promoting factor (MPF) complex allows 
phosphorylation of a variety of nuclear and cytoplasmic substrate molecules (Murray, 
2004). The exact role of CDKI in modifying proteins required for cell cycle 
progression remains incompletely defined. CDKI is mostly cytoplasmic prior to 
catalytic activation at which point it is translocated to the nucleus (Kao et al., 1999; 
Riabowol et al., 1989). At the G2/M transition there is an influx of active CDKI into 
the nucleus, and this correlates with phosphorylation of nuclear substrates. An active 
CDKI complex is found in nuclear extracts of rapidly dividing cells (Kao et al., 
1999), and one of the first homogenous purifications of CDKI from mammalian cells 
was obtained by salt extraction of rat tissue culture cell nuclei (Chambers and Langan, 
1990). Rapidly dividing HeLa cells also contain abundant nuclear MPF as other 
groups have observed a five fold increase in enzyme recovery by addition of a nuclear 
extraction step to the typical cytoplasmic preparation (Bischoff et al., 1990). In this 
chapter CDKI was purified from a nuclear preparation of asynchronously growing 
HeLa cells, using MeCP2 as a substrate. Given that CDKI was purified from the 
nucleus in a catalytically active state this likely corresponds to the active sub-
population of CDK1/CyclinBlfound in the nucleus prior to the breakdown of the 
nuclear envelope at the G2/M transition. Interestingly, the linker histone Hi is also a 
substrate for MPF, suggesting that phosphorylation of chromatin associated proteins 
may be an important function of CDK1/CyclinBl in cycle progression. It will be 
important to further purify the MeCP2 kinase activity to determine whether other 
factors in addition to CDK1/CyclinBl are components of the MeCP2 kinase complex. 
6.3.3 The MeCP2 kinase complex, a work in progress... 
How relevant phosphorylation of MeCP2 by CDK1/CyclinB1 is in vivo remains 
unknown, but the nature of this kinase suggests that MeCP2 may be modified during 
the cell cycle. It would be premature to speculate on the biological relevance of the 
CDKI phosphorylation of MeCP2 without verifying that CDKI does indeed modify 
MeCP2 in vitro and in vivo. To try and determine whether CDKI is a bona fide 
MeCP2 kinase this initial partial purification will be followed up by two avenues of in 
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vitro and in vivo analysis. To test the functional importance of MeCP2 
phosphorylation by CDK1, active recombinant CDK1/CyclinBl, which is 
commercially available, will be used to modify MeCP2 substrates. Large amounts of 
phosphorylated MeCP2 will be used to identify modified sites through mass 
spectrometry. In addition, the purified CDK1 enzyme will be used to verify 
modification sites using commercially available MeCP2 peptide arrays. 	The 
consequences of MeCP2 phosphorylation on DNA binding will be analyzed using 
purified in vitro phosphorylated MeCP2 and EMSA analysis. If an affect of 
phosphorylation on DNA binding is observed, mutagenesis will be utilized to 
determine which residues are important for phosphorylation-mediated inhibition of 
DNA binding. To address whether CDK1 is responsible for phosphorylation of 
MeCP2 in vivo, the modification state of MeCP2 will initially be analyzed during the 
cell cycle using synchronized HeLa cells. The aim of this experiment will be to 
determine whether phosphorylation of MeCP2 occurs at the same time as temporal 
peaks of CDK1 activity observed throughout the cell cycle. Through combined in 
vitro and in vivo analysis the relevance of CDK1 kinase activity in the modification of 
MeCP2 will be determined. 
6.3.4 Are there other important MeCP2 kinases? 
MeCP2 is phosphorylated by CDK1 in vitro, but this is unlikely to account for the 
modification of MeCP2 observed in terminally differentiated non-dividing neurons 
(Chen et al., 2003b; Martinowich et al., 2003). It is highly possible that MeCP2 is 
modified by several kinases, and that different activities target MeCP2 in different 
tissues and cell types. Recent studies have identified mutations in the STK9/CDKL5 
gene in patients with a phenotypic variant of Rett syndrome (Scala et al., 2005; Tao et 
al., 2004; Weaving et al., 2004). Individuals with mutations in STK9/CDKL5 have 
similar phenotypic characteristics to patients with mutations in MECP2 except that 
they also suffer from infantile spasms (Scala et al., 2005; Tao et al., 2004; Weaving et 
al., 2004). Interestingly, the predicted STK9/CDK5L protein has homology to known 
serine-threonine kinases (Montini et al., 1998). It is possible that STK9ICDKL5 
could phosphorylate MeCP2 and regulate some aspect of normal MeCP2 function. 
This possibility is attractive given the overlap in symptoms between patients with 
mutations in MECP2 and STK9/CDKL5, and the recent observation that MeCP2 is 
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phosphorylated in neurons. In future studies it will be important to determine if 
STK9/CDKL5 is catalytically active and whether MeCP2 is a substrate. 
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7. Chapter Seven- 
Conclusions I Future Directions 
7.1 Learning more about MeCP2 using biochemistry 
In aim of this study was to use a biochemical approach to better understand MeCP2 
function. There were three basic questions that were posed to initiate these studies; 
(1) What are the native biochemical properties of MeCP2? (2) What specific DNA 
sequences does MeCP2 bind? and (3) What are the affects of post-translational 
modification on MeCP2? 
To investigate the native biochemical properties of MeCP2, rat brain MeCP2 was 
purified to near homogeneity (Section 3.3). This purification showed that mammalian 
MeCP2 is not a stable component of the Sin3a chromatin remodelling complex. 
Subsequent biochemical studies using Xenopus laevis oocyte extract also 
demonstrated that MeCP2 is not a component of the Xenopus Sin3a complex. 
Biophysical analysis of purified recombinant MeCP2 showed that MeCP2 is a highly 
elongated molecule. Determining why MeCP2 is elongated remains a topic for future 
investigation, but this feature may aid in protein-protein interaction or be required for 
chromatin associated functions. 
In collaboration with Dr Irma Stancheva and Dr. Lars Schmiedeberg the DNA 
sequence binding specificity of MeCP2 was analysed both in vitro and in vivo. 
Differential occupancy of methyl-CpG containing DNA binding sites in vivo 
complemented in vitro studies that uncovered a new DNA binding requirement for 
efficient recognition of methyl-CpG by MeCP2 (Section 5.2.4). Using a newly 
developed SELEX technique, called methyl-SELEX, it was shown that MeCP2 
requires an [A/T],4  adjacent to methyl-CpG for high affinity DNA binding. The 
importance of this DNA binding requirement was highlighted by the observation that 
an MeCP2 binding site in the Bdnf promoter requires an [AlT]14 for efficient binding 
to the methyl-CpU. Interestingly, binding sites with an [AlT]>4 result in asymmetrical 
association of MeCP2 with CpU dinucleotide, suggesting that high affinity binding 
sites may result in directional orientation of MeCP2 with respect to surrounding DNA 
elements. 	This observation suggests that directional association of MeCP2 with 
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DNA may impact how recruited co-factors are oriented with respect to target genes. 
The relevance of directional DNA binding by MeCP2 to transcriptional repression 
remains an interesting topic for further investigation. 
The observation that MeCP2 is phosphorylated during gene activation events at the 
Bdnf promoter (Chen et al., 2003b) has sparked a floury of interest within the field 
regarding the affects of phosphorylation on MeCP2 repression. In order to study the 
affects of phosphorylation on MeCP2 it will be important to identify modified 
residues and potential kinases. A preliminary study in this thesis indicates that the 
phosphorylation that inhibits DNA binding of MeCP2 in rodent cells is likely due to 
modification of specific target residues, and not simply a protein charge affect, as 
phosphorylated MeCP2 obtained from insect cells bound methylated DNA efficiently. 
Using MeCP2 as a bait molecule for nuclear kinases, CDK1 was identified as a 
potential MeCP2 kinase. Future studies on this enzyme will help to map sites in 
MeCP2 that are modified by phosphoryation, and provide a basis for examining the 
affects of these modifications on DNA binding and MeCP2 function in vivo. 
7.2 Determining co-factors required for MeCP2 function 
Given that other MBD molecules are part of multi-protein complexes, it was 
unexpected to discover that MeCP2 was not stably associated with other co-
repressors. Other MBD proteins appear to rely on stably associated co-factors to 
repress transcription and remodel chromatin (Ng et al., 1999; Sarraf and Stancheva, 
2004; Zhang et al., 1999). This raises questions regarding which cellular co-repressors 
are important for transcriptional repression by MeCP2, and a future challenge will be 
to delineate which transiently interacting molecules are used by MeCP2 to carry out 
its normal functions within the cell. The observation that MeCP2 is a monomeric 
molecule does suggest that MeCP2 may use a varying repertoire of co-factors in 
regulating context dependent transcription. As more MeCP2 target genes are 
identified a unique opportunity will arise to interrogate which MeCP2 binding co-
factors are used at specific promoters to repress transcription. It will be of particular 
interest to understand the contribution of MeCP2 to re-establishing silencing of 
inducible genes like Bdnf. For example, when the expression of an inducible gene is 
no longer required, is there a hierarchal recruitment of silencing factors to the 
promoter that culminates with the arrival of MeCP2 to lock the gene into a silenced 
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state, or is MeCP2 associated with the initiation of silencing through recruitment of 
co-factors like HDAC's and HMT's? The ease with which endogenous protein levels 
can be manipulated using techniques like RNA interference, it will be possible to use 
model gene systems to determining how DNA methylation, and specifically MeCP2, 
is associated with gene silencing. 
7.3 The epigenome and MeCP2 targeting 
One exciting aspect of this study was uncovering a new DNA binding requirement for 
MeCP2. The observation that MeCP2 requires [AlT]>4 in addition to methyl-CpG for 
efficient DNA binding will likely impact how the repressive capabilities of MeCP2 
are targeted to sites of DNA methylation within the cell. Teasing out the biological 
affect of this binding preference is challenging as there appears to be an inherent 
flexibility in the distance that an [AlT]>4 run can be situated from the methyl-CpG, 
and therefore the occurrence of these sequences within the genome is high. To 
efficiently use this knowledge to predict MeCP2 target genes is even more 
challenging given the lack of information regarding the precise DNA methylation 
patterns near promoters and regulatory elements. The advancement of epigenorne 
sequencing projects will provide valuable information regarding DNA methylation 
patterns in cells (Gius et al., 2004; Rakyan et al., 2004). Epigenome information will 
allow categorization of potential MeCP2 binding loci based on knowledge of both 
methylation status and the presence or absence of an [AlT]>4. A more defined set of 
potential promoter associated MeCP2 binding sites will facilitate targeted 
investigation of candidate genes to determine whether methylation and MeCP2 is 
important for their regulation. The advantage of this approach is the potential to 
exclude CpG dinucleotides that are not methylated, and concentrate on gene 
associated methyl-CpG sites that are good substrates for MeCP2. 
7.4 Modulating epigenetic readout by post translational modification 
Many transcription factors are post-translationally modified (Khidekel and Hsieh-
Wilson, 2004). Common post-translational modifications include: glycosylation, 
methylation, phosphorylation, acetylation, ubiquitination, and sumoylation. For many 
nuclear factors, like P53, the nature and extent of these modifications can have 
profound affects on their function (Bode and Dong, 2004). Preliminary evidence 
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suggests that MeCP2 is phosphorylated and this affects its DNA binding capacity. 
Currently, efforts are being invested in identifying kinases that modify MeCP2 and 
determining the affect that phosphorylation has on MeCP2 function. These data will 
begin to elucidate the molecular switch that controls MeCP2/DNA association. The 
observation that MeCP2 is phosphorylated is interesting but also raises questions 
regarding other modifications which may exist on MeCP2, and what functional affects 
might these modifications have? The streamlining of mass spectrometry technology 
over the last decade has made identifying posttranslational modification more routine, 
and determining the complement of modifications on endogenous MeCP2 will be of 
great interest. 
7.5 A search for the cause of Rett syndrome 
The majority of the work in this thesis dealt with very basic aspects of MeCP2 
function, and did not directly address any of the functions of MeCP2 as they relate to 
the Rett syndrome phenotype. By studying the basic functions of MeCP2 the goal is 
to understand how the molecule functions normally and use this information to 
determine how its malfunction leads to disease. Using the newly identified MeCP2 
DNA binding requirements it will be exciting to try and identify potential MeCP2 
target genes with the aid of bioinformatics and epigenetic genome information. It will 
be particularly interesting to examine whether Rett syndrome mutations outside of 
known functional domains affect the biophysical properties of MeCP2, and what the 
relationship is between specific MeCP2 co-factors and the Rett phenotype. By 
extending our basic knowledge about MeCP2 through general scientific investigation, 
leads will inevitably arise to expedite the possibility of developing therapies to treat 
this debilitating disease. 
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34 CCCAGGGCTGTGATGCCCGGAATTAkGCCGACGTTCTG * 
49 	CCAAOGCACGGGGGGTCCCGGAAATAAGGGGGCTGTCCG 


























* BDNF -148 site CGGAATT 
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chemical synthesis (3). This technology 
was recently commercialized by Thomas 
Swan & Co., Ltd., in a chemical plant de-
signed for multipurpose synthesis. Together 
with ionic liquids (4-6), these alternative 
solvent strategies (sometimes referred to as 
alternative reaction media or green sol-
vents) provide a range of options to indus-
trialists looking to minimize the environ-
mental impact of their chemical processes. 
What are the advantages of using a 
room-temperature ionic liquid in an indus-
trially relevant catalytic process? As noted 
above, ionic liquids have no detectable va-
por pressure, and therefore contribute no 
VOCs to the atmosphere. But this is not the 
only reason for using ionic liquids. Another 
is that at least a million binary ionic liquids, 
and 1018  ternary ionic liquids, are potential-
ly possible (7). (For comparison, about 600 
molecular solvents are in use today.) 
This diversity enables the solvent to be 
designed and tuned (2) to optimize yield, se-
lectivity, substrate solubility, product separa-
tion, and even enantioselectivity. Ionic liq-
uids can be highly conducting (8), dissolve 
enzymes (9), form versatile biphasic systems 
for separations (10), can form both polymers 
and gels for device applications (8), are me-
dia for a wide range of organic and inorgan-
ic reactions (4-6), and are the basis for at 
least one industrial process, called the 
BASIL process (see the figure) (11). 
The BASIL process was developed and 
is operated by BASE At the meeting, 
Matthias Maase (BASF) revealed that use 
of the BASIL process increases the produc-
tivity of their alkoxyphenyiphosphine for-
mation process by a factor of 80,000 com-
pared with the conventional process. Other 
companies are also pursuing the use of ion-
ic liquids. Bernd Weyershausen (Degussa) 
presented an ionic liquid—based process for 
the synthesis of organosilicon compounds. 
Use of an ionic liquid solvent enabled the 
catalyst to be easily recycled and reused 
without further treatment after separation 
from the product at the end of the reaction. 
Christian Melmert (ExxonMobil) described 
biphasic hydroformylation with rhodium 
catalysts in ionic liquids. 
Because research into ionic liquids is at 
an early stage, many of their properties re-
main to be elucidated. Nonetheless, ionic 
liquids have already provided access to 
new chemical processes. Recent papers de-
scribe their potential application as em-
balming fluids (12), in ion drives for space 
travel (13), for desulfurization of fuels 
(14), and as lubricants (15). 
Ionic liquids have already found many 
laboratory applications in synthesis, catal-
ysis, batteries, and fuel cells (4-6, 8, 16), 
and numerous new combinations of ionic 
liquid solvent properties are available or  
predicted. The next decade should see ion-
ic liquids being used in many applications 
where conventional organic solvents are 
used today. Furthermore, ionic liquids will 
enable new applications that are not possi-
ble with conventional solvents. In the fu-
ture, solvents will be designed to control 
chemistry, rather than the chemistry being 
dictated by the more limited range of mo-
lecular solvents currently used. 
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microarray analyses designed to search for 
target genes that are derepressed in the 
brains of MeCP2-deficient mice, and thus 
might be causally implicated in Rett syn-
drome, have not yielded any clear candi-
dates (2). The existence of a genuine target 
gene is now highlighted on pages 885 (3) 
and 889 (4) of this issue. Chen etal. (3) and 
Martinowich et al. (4) describe their dis-
covery that normal MeCP2 regulates ex-
pression of the gene encoding brain-de-
rived neurotrophic factor (BDNF), a secret-
ed protein that is essential for neural plas-
ticity, learning, and memory. Their new 
findings, together with recent work in the 
amphibian Xenopus !aevis (5), confirm that 
MeCP2 is a methyl-CpG—dependent tran-
scriptional repressor and reveal its unex-
pected role in the induction of gene expres-
sion in the nervous system. 
Belonging to a set of proteins synthe-
sized in response to neuronal activity, BDNF 
is thought to be essential for converting tran-
sient stimuli into long-term changes in brain 
activity (6). Understanding how BDNF is 
regulated in neurons is important if we are to 
comprehend brain development, learning, 
and memory. There are four BDNF promot-
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How MeCP2 lets go. Despite the existence of methylated CpGs throughout the vertebrate genome, loss 
of MeCP2 ( a methyl-CpG binding domain protein) does not cause global deregulation of gene expres-
sion. MeCP2 binds to and represses the promoters of two specific genes: promoter Ill of the rat BDNF 
gene (A) and the Hairy2a gene promoter of Xenopus (B). In both cases, MeCP2 binds to the upstream 
fully methylated (black dot) or partially methylated (black and white dot) CpGs, but not to the down-
stream methylation-free (white dot) promoter region. MeCP2 recruits corepressor complexes, maintain-
ing and solidifying a state of gene repression (red cross). Induction of gene expression leads to complete 
loss of MeCP2 from the upstream promoter region (dashed arrow), enabling transcription to proceed. 
PERSPECTIVES 
to artificial stimulation of cultured rodent 
primary cortical neurons treated with 
potassium chloride (KCI). By immuno-
precipitating chromatin fragments con-
taining MeCP2, Chen et al. and Martino-
wich et al. discovered that MeCP2 is 
bound to methylated CpG sites near pro-
moter III of BDNF in resting neurons. But 
when the neurons were exposed to KCI—
which causes membrane depolarization, 
calcium influx, and BDNF activation—
MeCP2 dissociated from the BDNF gene 
promoter. Martinowich et al. further 
demonstrated that Sin3a—a transcription-
al corepressor that forms complexes with 
histone deacetylases and associates with 
MeCP2 (7)—is also displaced after KCI 
treatment. Accordingly, loss of MeCP2 is 
accompanied by changes in histone modi-
fication (8), resulting in a transcriptional-
ly repressive chromatin state being re-
placed by a permissive one. 
How is MeCP2 displaced from promoter 
III when the BDNF gene is activated? One 
possibility is that the CpG methylation hold-
ing MeCP2 at the promoter is abruptly lost. 
In line with this hypothesis, Martinowich et 
al. found somewhat reduced CpG methyla-
tion in the relevant region of the activated 
promoter. An alternative mechanism for 
MeCP2 loss could involve modification of 
MeCP2 during the induction of gene expres-
sion such that it loses its affinity for the  
methylated promoter site. In support of this 
possibility, Chen et al. observed a time-
dependent increase in phosphorylation of 
MeCP2 when neurons were stimulated with 
KCI. Moreover, Southwestern blot analysis 
indicated that the phosphorylated form of 
MeCP2 had a lower affinity for methylated 
DNA, although its presence at an unrelated 
methylated promoter—that of the imprinted 
H19 gene—was not diminished by KCI treat-
ment. Conceivably, displacement of MeCP2 
is caused by a combination of cytosine 
demethylation and MeCP2 phosphorylation. 
If MeCP2 is required for repression of 
promoter III before and after induction of 
BDNF gene expression, its absence should 
disrupt this process. Chen et al. tested this in 
vivo by examining inducible BDNF gene ex-
pression in cultured neurons from MeCP2-
deficient mice. They found that BDNF tran-
scription doubled in resting cells, whereas un-
der stimulatory conditions there was no dif-
ference in BDNF transcription between wild-
type and MeCP2-deficient neurons. While 
supporting the idea that MeCP2 helps to re-
press basal levels of BDNF expression, the 
effects of deleting the Mecp2 gene appear to 
be subtle; uninduced BDNF gene expression 
increased from —1% to -2% of the induced 
level. It is perhaps not surprising that mi-
croarrays failed to detect such an effect. 
BDNF is an important player in neuronal 
development, raising the possibility that mis- 
regulation of its gene because of the absence 
of MeCP2 may contribute to the symptoms 
of Rett syndrome. Other inducible promoters 
in neurons may also rely on repression by 
MeCP2. Recently, another bona fide MeCP2 
target gene was discovered, this time in 
Xenopus. Stancheva and colleagues (5) found 
that reducing production of MeCP2 during 
early Xenopus embryogenesis by injecting 
antisense oligonucleotides caused gross de-
fects in frog neurogenesis. By screening can-
didate genes known to be involved in Notch-
Delta signaling cascades, they found that a 
transcriptional repressor protein, Hairy2a, is 
abnormally up-regulated in the absence of 
MeCP2. Hairy2a represses expression of 
proneuronal genes in non-neuronal cells sur-
rounding developing neurons. Neurogenesis 
defects and gene expression changes caused 
by depletion of MeCP2 could be completely 
rescued by reexpressing wild-type human 
MeCP2, but not mutant forms of MeCP2 
from Rett syndrome patients. The behavior of 
MeCP2 at the Hairy2a promoter has striking 
parallels with the BDNF story. Once again, 
MeCP2 is localized to the methylated up-
stream flank of the promoter (see the figure) 
and vacates the promoter upon activation of 
the gene (although CpG methylation in this 
case apparently remains unchanged). A defi-
ciency of Xenopus MeCP2 leads to inappro-
priate activation of the Ha!,' y2a gene, with se-
vere consequences for the embryonic nerv-
ous system. 
DNA methylation is often thought of as a 
"global" parameter in gene regulation. It is 
pervasive, being distributed throughout the 
genome. It is also an essential process—
mice lacking the DNA methyltransferase 
enzyme, DNMT1, die during embryogene-
sis (9). Furthermore, mouse cells lacking 
DNMTI display genomic instability (10), 
implying that methylation has wide-ranging 
effects on global genome function and in-
tegrity. Whether individual MBD proteins 
qualify as global gene regulators through 
their interpretation of methylation marks is 
less certain (11). Mice lacking MBD2, for 
example, are viable and fertile, but show 
deregulated expression of the interleukin-4 
gene in T helper cells, indicating a gene-spe-
cific requirement for MBD2 (12). The pa-
pers discussed here establish for the first 
time that MeCP2 itself has specific gene tar-
gets and that it may work in concert with 
other factors as part of a multiprotein pro-
moter complex. More unexpected still is its 
dynamic association with DNA, perhaps 
regulated by phosphorylation. This scenario 
contrasts with the conventional view that 
DNA methylation and MBD proteins create 0 
an almost immovable repressive environ-
ment. The new findings reveal unexpected 
plasticity in the biological interpretation of 
methylated DNA. 
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Questions inevitably remain. Is the dy-
namic behavior of MeCP2 associated with 
the BDNF or Hairy2a gene promoters the 
exception or the rule? What other genes are 
induced when MeCP2 becomes phospho-
rylated? Which are the genes whose mis-
regulation causes Rett syndrome? The ex-
plosion of knowledge about DNA methyla- 
PHYSICS 
O
f the four known fundamental 
forces—gravity, electromagnetism, 
and the weak and strong forces—
gravity is by far the weakest. The reasons 
for this weakness have long remained enig-
matic. Recent proposals suggest, however, 
that the weakness of gravity may be evi-
dence for extra spatial dimensions. 
Experiments ranging from tabletop tests of 
Newtonian gravity to searches for micro-
scopic black holes in kilometer-scale detec-
tors are now putting these ideas to the test. 
The importance of gravity in everyday 
life results not from its strength but from 
its universality: Objects cannot be gravita-
tionally neutral, and all bodies with mass 
attract. Yet as an interaction between ele-
mentary particles, gravity is extremely 
weak. For example, the gravitational at-
traction between two protons is 35 orders 
of magnitude weaker than their electro-
magnetic repulsion. This holds for protons 
separated by any distance r, because both 
gravitational and electromagnetic forces 
are proportional to I 1r2. 
The observed weakness of gravity may, 
however, not be an intrinsic property of 
gravity, but may instead be an effect of extra 
spatial dimensions. This possibility is based 
on a simple consideration. Suppose that our 
three-dimensional (3D) world is merely a 
subspace of a higher-dimensional space, 
and that gravity propagates freely in all di-
mensions, but that all other forces are con-
fined to our three dimensions. In contrast to 
the familiar three dimensions, the extra di-
mensions are curled up in small circles of 
circumference L. Hence, moving a distance 
L in the direction of any of the extra dimen-
sions brings one back to one's starting place. 
Now suppose that at some separation 
distance r < L, gravity is strong, that is, 
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tion and the brain is at last making these 
questions experimentally accessible. 
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Gravity in extra dimensions. The strength of 
gravity for various numbers of large extra dimen-
sions n is compared to the strength of electro-
magnetism (dotted). Without extra dimensions, 
gravity is weak relative to the electromagnetic 
force for all separation distances. With extra di-
mensions, the gravitational force rises steeply for 
small separations and may become comparable 
to electromagnetism at short distances. 
comparable to electromagnetism. As r in-
creases, the electromagnetic force drops as 
11-2. However, the gravitational field 
spreads out in all available spatial dimen-
sions, and the gravitational force therefore 
decreases much more rapidly as lIr', 
where n is the number of extra dimensions. 
This rapid drop continues until r > L, at 
which point the extra dimensions become 
less and less important and gravity recov-
ers its hr2 behavior (see the figure). 
If this picture is correct, then gravity is 
not intrinsically weak: It is as strong as 
electromagnetism at small length scales. It 
appears weak at the relatively large dis-
tances of common experience only because 
its effects are diluted by propagation in ex-
tra dimensions. The distance at which the 
gravitational and electromagnetic forces 
might have equal strength is unknown, but 
a particularly interesting possibility is that 
it is l0-' m, the distance at which the elec-
tromagnetic and weak forces are known to 
unify to form the electroweak force (1). 
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A priori, the size of the extra dimensions 
L and their number n are independent param-
eters. However, to achieve equality of gravi-
tation and electromagnetic forces at 10.19  m, 
they become constrained by the relation 
L 	10(32/) 19 in 	(I) 
For large n, the strength of gravity grows very 
rapidly at microscopic length scales. Gravity 
may then deviate from its 11,2  behavior only 
at very small distances and still be compara-
ble to electromagnetism at 10_19  in. 
This scenario, called "large extra dimen-
sions" because the length L of Eq. 1 is large 
relative to typical length scales in pai'ticle 
physics, raises many more questions than it 
answers. When first proposed, perhaps its 
most surprising aspect was that such a bold 
modification of Newtonian gravity was not 
immediately excluded by data. Now, howev-
er, a wide variety of experiments are reaching 
the sensitivity required to test these specula-
tive ideas. In combination, they probe all pos-
sible values for the number of extra dimen-
sions, placing the entire scenario on the 
threshold of detailed investigation. 
The possibility of one large extra di-
mension is untenable. It requires the extra 
dimension to be of size L 10 13 m, a length 
scale where the hr2 gravitational force law 
is clearly still valid. For two extra dimen-
sions, each extra dimension would have L 
1 mm. Sensitive tests of gravity are noto-
riously difficult at such length scales. 
Nonetheless, recent tabletop experiments 
with torsion pendulums have excluded sig-
nificant deviations from the 1 1r2 force law 
at length scales as small as 0,1 mm (2). 
Astrophysical observations provide less 
direct but more stringent constraints on low 
numbers of extra dimensions (3, 4). For two 
extra dimensions, for example, the gravita-
tional force would be enhanced at large 
enough length scales that supernovae should 
release much of their energy as gravitational 
energy—in conflict with observations. These 
constraints, which were noted immediately 
after the proposal of large extra dimensions, 
exclude scenarios with few extra dimensions. 
The challenge, then, has been to explore 
large numbers of extra dimensions, such as 
the six or seven favored by string theory. In 
such cases, tabletop and astrophysical con-
straints are ineffective, because the predict-
ed deviations from Newtonian gravity oc- 
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MeCP2 is a transcription factor that recognizes and 
binds symmetrically methylated CpG dinucleotides to 
repress transcription. MeCP2 can associate with the 
Sin3alhistone deacetylase corepressor complex and me-
diate repression in a histone deacetylase-dependent 
manner. In extracts from rodent tissues, cultured cells, 
and Xenopus laevis oocytes, we find that only a small 
amount of mammalian MeCP2 interacts with Sin3a and 
that this interaction is not stable. Purification of rat 
brain MeCP2 (53 kDa) indicates no associated proteins 
despite an apparent molecular mass by size exclusion 
chromatography of 400-500 kDa. Biophysical analysis 
demonstrated that the large apparent size was not be-
cause of homo-multimerization, as MeCP2 consistently 
behaves as a monomeric protein that has an elongated 
shape. Our findings indicate the MeCP2 is not an obli- 
gate component of the Sin3a corepressor complex and 
may therefore engage a more diverse range of cofactors 
for repressive function. 
Cytosine methylation is an important epigenetic mark on 
vertebrate genomes (1). In mammals, methylation occurs 
mostly in the context of the CpG dinucleotide and can account 
for about 70-80% of genomic CpGs (2). CpG methylation acts 
as an additional means of controlling genome function, beyond 
DNA base pair sequence. Because DNA methylation is copied 
faithfully to the newly replicating DNA strands during cell 
division, these marks can be maintained across development 
and act as a form of epigenetic memory. There are two general 
mechanisms by which CpG methylation is believed to function. 
First, modification of cytosines in the recognition sequence of 
DNA-binding proteins can inhibit their binding to cognate se-
quences and thus deny access to regulatory regions. Second, 
proteins have been identified that specifically bind the methyl-
CpG dinucleotide via a methyl-CpG binding domain (MBD)' (3) 
or, in the case of Kaiso (4), by a zinc finger domain. These 
proteins can interact with methylated CpGs and affect nearby 
genes by repressing transcription and modulating chromatin 
structure (5). 
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There are five mammalian members of the MBD family: 
MeCP2 and MBD1-4. With the exception of MBD3, all MBD 
family members bind methylated CpG dinucleotide specifically. 
MBD1 (6-8), MBD2 (9-12), MBD3, and MeCP2 (13) are all 
transcriptional repressors. Elucidation of the relationship be-
tween MBD proteins and their partner corepressors is a pre-
requisite for understanding how DNA methylation represses 
transcription and modulates chromatin structure. Several 
methyl-CpG-binding proteins have been shown to associate 
with histone deacetylases (HDACs) (10, 14, 15) or histone 
methyltransferases (16, 17). MBD2 and MBD3 are stable com-
ponents of the NuRD chromatin remodeling complex (10, 12), 
and Kaiso can be purified in a complex containing NCoR (18). 
In this study, we have asked whether MeCP2 is also part of a 
stable repression complex. 
MeCP2 dysfunction is the sole identified determinant of Rett 
syndrome, the most common inherited form of mental retarda-
tion in females (19). The majority of Rett syndrome point muta-
tions in the MECP2 gene cluster in the MBD and the transcrip-
tional repression domain (20), suggesting that methyl-CpG 
binding and transcriptional repression are important func-
tional determinants of MeCP2 in vivo. MeCP2 has been shown 
to interact with the Sin3a-HDAC chromatin remodeling com-
plex (14). In Xenopus laeuis it was reported that MeCP2 par-
tially cofractionated with the Sin3a complex and proposed that 
xMeCP2 occurs in a stable complex with xSin3a (21, 22). The 
link between MeCP2 and Sin3a has been strengthened recently 
with the identification of MeCP2 target genes. Both MeCP2 
and Sin3a bind the promoter region of the brain-derived neu-
rotrophic factor (Bdnf) gene (23-25) and modulate its expres-
sion. A similar situation occurs at the X. laevcs xHairy2a gene, 
where MeCP2 and Sin3a bind upstream of the promoter region 
and repress transcription (26).2 
In addition to Sin3a, several other factors have been reported 
to bind mammalian MeCP2, including DNMT1, CoREST, 
Suv39H1, and c-SKI (14, 27-29), although the contribution of 
these factors to MeCP2-mediated repression is not known. Na-
tive MeCP2 has not been purified previously from mammalian 
sources, leaving open the possibility that it may exist in a novel 
multiprotein complex. Here we investigate the association of 
MeCP2 with the Sin3a complex from both mammalian sources 
and X. laeuis, and we purify native MeCP2 from rat brain. We 
conclude that MeCP2 does not stably associate with the Sin3a 
complex. Moreover, we find no evidence that MeCP2 forms a 
stable association either with itself or with other proteins in 
nuclear extracts. Hydrodynamic analysis of MeCP2 shows that 
it behaves as an elongated monomeric molecule. These findings 
raise the possibility that DNA-bound MeCP2 interacts differ-
ently with partner proteins compared with its unbound form. 
In addition, the results suggest that MeCP2 might interact 
with a range of cofactors in addition to Sin3a. 
21  Stancheva, personal communication. 
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Cell Culture—NG-108 cells were a gift of Rod Bremner (University of 
Toronto) and were maintained in Dulbecco's modified Eagle's medium 
(Invitrogen) supplemented with 10% bovine calf serum, nonessential 
amino acids, sodium pyruvate, and antibiotics (Invitrogen). 
Chromatography Solutions—Chromatography buffers were filtered 
through a 0,2-.Lm filter before application to fast protein liquid chro-
matography or disposable columns. Anion exchange buffer 20 mm Tris-
HCI (pH 7.9), 0.2 mil EDTA, 1 mm DPI', 10% glycerol, supplemented 
with 100 mm NaCl (AE100), or 1000 mM NaCl (AE1000). Cation ex-
change buffer was 20 mm Hopes (pH 7.6), 0.2 mm EDTA, 1 mm DPI', 
10% glycerol, supplemented with 100 mm NaCl (CE100), or 150 mm 
NaCl (CE150), or 200 mm NaCl (CE200), or 1000 mm NaCl (CR1000). 
Ni-Nta affinity buffers (N) were 50 mm NaH2PO4, 300 miii NaCl , 10% 
glycerol (pH 8.0), supplemented with 20 mm imidazole (N20), 100 mm 
imidazole (N100), or 250 mm imidazole (N250). Gel filtration buffers 
were made in 20 mm Hepes-KOH (pH 7.9), 3 MM  MgC121  10% glycerol, 
supplemented with 150 mm KC1 (GF150) or 500 mm KCI (GF500). 
Isolation of Rat Brain Nuclei and Nuclear Protein Extraction—Rat 
brains (-450 brains obtained from Pei-Freez Biologicals) were ground 
to a fine powder in liquid nitrogen with a mortar and pestle. The brain 
powder was diluted 5 volumes to 1 in ice-cold buffer A containing 10 miii 
Hepes (pH 7.5), 25 miii KCI, 0.15 mm spermine, 0.5 mm spermidine, 1 
mm EDTA, 2 M sucrose, 10% glycerol, and complete protease inhibitors 
(Roche Applied Science) followed by homogenization in a 60-ml Dounce 
(Braun) on a Potter S (Braun) motorized homogenizer (five strokes at 
1100 rpm). The homogenate was layered onto a 10-ml cushion of buffer 
A and centrifuged in pro-chilled SW28 rotor at 24,000 rpm in an Beck-
man XL100 ultracentrifuge for 40 min at 3 °C. Recovered nuclei were 
resuspended in 5 volumes of buffer B containing 10 miii Hepes (pH 7.9), 
1.5 mm MgCl2, 10 miii KCI, 0.5 miii DTT, complete protease inhibitors 
(Roche Applied Science) and incubated on ice 10 mm. The nuclei were 
pelleted at 250 x g and resuspended in 1 volume of buffer C containing 
5 mm Hepes (pH 7.9), 26% glycerol, 1.5 miii MgC121  0.2 mm EDTA, and 
complete protease inhibitors (Roche Applied Science) supplemented 400 
mm NaCl. The extraction was allowed to proceed for 1 hon ice, and then 
the nuclei were pelleted at 13,000 rpm for 20 min at 4 °C. The super-
natant was taken as the nuclear extract and dialyzed to the indicated 
salt concentration. 
Imznunoprecipitation—MeCP2 or Ga14 antibodies were incubated 
with 500 pg of rat brain nuclear extract at 4 °C for 4 h. Protein 
A-Sepharose beads (Amersham Biosciences) were added to the reaction 
and incubated for 1  at 4 T. Beads were washed four times with 20 miii 
Hopes (pH 7.9), 0.1 M NaCl, 10% glycerol, 0.2 mm EDTA, 0.01% Triton 
X-100. Bound proteins were eluted in Laemmli buffer and run on an 8% 
SDS-polyacrylamide gel. MeCP2 (14), Sin3a (Santa Cruz Biotechnology 
SC994 1(20), and topoisomerase I (SC 10783 H300) were identified by 
Western blotting. 
Large Scale Purification of Native MeCP2—All chromatography and 
dialyses were performed at 4 iC,  and MeCP2 (14), Sin3a (Santa Cruz 
Biotechnology SC994 K20), and H1)AC 1/2 (Santa Cruz Biotechnology 
SC7879 H51/SC7899 H54) containing fractions were identified by West-
ern blotting. Rat brain nuclear extract (26 ml of 400 mlvi NaC1 extrac-
tion) was dialyzed against CE150, and the insoluble material was 
pelleted at 13,000X g for 20 min at 4 T. Soluble material (140 mg) was 
loaded onto an 8-ml SP-Sepharose (Amersham Biosciences) column and 
eluted with a 160-ml linear gradient ofCElOO to CE1000 collecting 4-ml 
fractions. MeCP2-containing fractions were combined (8.8 mg) and di-
alyzed against AE100. Dialyzed protein was loaded onto a 1-ml MonoQ 
(Amersham Biosciences) column and eluted with a 40-ml linear gradi-
ent of AE100 to AE1000. MeCP2-containing fractions from the flow-
through and wash were combined (4 mg) and dialyzed against CE100. 
The protein was loaded onto a 1-ml heparin (Amersham Biosciences) 
affinity column and eluted with a 40-ml linear gradient of CR100 to 
CE1000. MeCP2-containing fractions (0.408 mg) were combined and 
dialyzed into N20. Ni-NTA resin (0.65 ml; Qiagon) pre-equilibrated 
with N20 was added to the dialyzed protein and mixed at 4 °C for 1 h. 
The Ni-NTA was applied to a 10-ml disposable column (Bio-Rad). The 
column was washed thoroughly with N20 and then eluted in batch with 
N100 and N250. MeCP2 eluted at the N100 step, and these fractions 
were pooled (0.148 mg). An aliquot of the N100 elution was applied to a 
Superose 12 (Amersham Biosciences) column and eluted from the col-
umn in GF500 collecting 0.5-ml fractions. Proteins from the gel filtra-
tion column were Western-blotted to identify MeCP2-containing frac-
tions, and subsequently trichloroacetic acid-precipitated, subjected to 
SDS-PAGE, and stained with Sypro-Ruby stain (Bio-Rad). Bands were 
excised and analyzed by mass spectrometry. 
Mass Spectrometry—To identify purified proteins, excised bands 
were in-gel trypsinized, and peptides were eluted from the gel slice. 
Mass spectrometry analysis was carried out on an Applied Biosystems 
Voyager DE-STR matrix-assisted laser desorption ionization time-of-
flight instrument using cs-cyano-4-hydroxycinnamic acid matrix, Spec-
tra were analyzed in MS-Fit and then submitted to Protein Prospector 
(prospector.ucsf.edu]) for peptide matching. 
Xenopus Oocyte Extract and xMeCP2 Chromatography—Oocyte ex-
tract was prepared from one female as described previously (21). The 
extract (90 mg) was then loaded onto a 10-ml Bio-Rex 70 column exactly 
as described previously (21) in Bio-Rex 70 exchange buffer (BE100) 
containing 100 mm NaCl, 20 mr,i Hopes (pH 7.5), 10 mr,i f3-glycerophos-
phate, 1.5 miii MgCI21  1 mm EGTA, 0.5 mm DPT, 10% glycerol, complete 
protease inhibitors (Roche Applied Science) and washed with three 
column volumes of BE100. The column was batch-eluted with Bio-Rex 
70 exchange buffer containing 500 miii NaCl (BE500), and fractions 
were analyzed by Western blotting with three independent xMeCP2 
antibodies and an xSin3a antibody (a gift of P. L. Jones). The BE500 
elution (250 .cl) was separated on a Superose 6 (Amersham Biosciences) 
gel filtration column in GF150 collecting 0.5-ml fractions. Proteins were 
trichioroacetic acid-precipitated and run on an 8% SDS-polyacrylamide 
gel and Western blotted for xMeCP2 and xSin3a. 
MeCP2 Expression Plasmid—A human MeCP2 cDNA was used to 
PCR-amplify MeCP2 with primer pairs containing a 5' NdeI site corre-
sponding to the initiating ATG and 3' EcoRl site downstream of the 
endogenous MeCP2 stop codon. The PCR fragment was inserted into 
the NdeIJEcoRI sites of the bacterial expression plasmid pET30b (No-
vagen) to create an untagged bacterial MeCP2 expression vector 
pET30bhMeCP2. 
Expression and Purification of Full-length Untagged MeCP2 in Bac-
teria—pET30bhMeCP2 was transformed into BL21 codon plus bacteria 
(a gift from Robin Alishire). Bacterial cultures (usually 0.5 or 1 liter) 
were grown in LB at 37 °C until the culture reached an A600 of 0.5 
absorbance units. Cultures were induced with 1 miii isopropyl 1-thio-f3-
o-galactopyranoside for 3 h at 30 iC.  Cells were pelleted and lysed in 20 
mm Tris-HCI (pH 8.0), 500 mm NaCl, 0.1% Nonidet P-40, complete 
protease inhibitors (Roche Applied Science) by sonicating on output 
setting 4-5 at 30% for 3 min with a Branson 250 sonifler. Extracts were 
centrifuged at 4 °C for 20 min at 20,000 x g, and Ni-NTA beads 
(Qiagen) pro-equilibrated with lysis buffer were added to the superna-
tant. Recombinant MeCP2 was allowed to bind the beads mixing for 1 h 
at 4 C and then applied to a 10-ml disposable column. The column was 
washed with 20 column volumes of N20 and batch-eluted with N250. 
MeCP2-containing fractions were identified by Coomassie Blue staining 
and dialyzed into CE200. The protein from the Ni-NTA elutions was 
loaded onto an Sp-Sepharose column and eluted with a linear gradient 
of CE200 to CE1000, and the MeCP2-containing fractions were com-
bined and directly loaded onto a Sephacryl S-300 26/60 (Amersham 
Biosciences) column and eluted with GF500. MeCP2-containing frac-
tions were combined and dialyzed against CE200 and then loaded onto 
a 1-ml MonoS column. Proteins were eluted with a linear gradient of 
CE200 to CE1000, and MeCP2-containing factions were combined and 
dialyzed into CE200 and stored at —20 T. 
Bandshift Analysis—Increasing concentrations of rMeCP2 (50, 100, 
250, 500, and 750 ng) were bound to the CG11 probe (30) either meth-
ylated or unmethylated. The CG11 probe containing 27 CpGs was 
generated by digesting out an EcoRl/Hindlil (New England Biolabs) 
fragment from the piasmid pCG11 (30). The 135-bp CG11 fragment was 
purified by gel electrophoresis and agarose gel extraction. The CpGs in 
the resulting fragments were methylated with SssI methyitransferase 
(New England Biolabs), and the methylated or unmethylated CG11 
probe was end-labeled with I32PIdCTP using Klenow (Roche Applied 
Science). The binding reactions were assembled in buffer containing 6 
mm MgCl,, 3% glycerol, 1 miii DPI', 150 miii KCI, 100 ng/ci poly(dA-dT) 
(Sigma) for 10 min at room temperature in the absence of probe, and 
then the probe was added and incubated a further 25 mm. The reactions 
were run on a 1.5% agarose gel and dried onto DE-81 anion exchange 
paper (Whatman). The bandshifts were exposed on a phosphor screen 
and analyzed on a Storm 840 Phosphorlmager (Amersham Bio-
sciences). Competition with cold methylated and unmethylated probe at 
—100-fold excess was used to demonstrate the specificity of the 
bandshift. 
EGS Cross-linking—An EGS (Pierce) stock solution was made fresh 
to 25 mm in Mo2SO. 5 jig of rMeCP2 was incubated in CE200 (without 
DPI' or EDTA) with increasing concentrations of EGS (0.25, 0.5, 1.0, 
2.5, 5.0 mm) in a 50-.cl reaction volume. BSA (5 sg, monomer) and ADH 
(5 pg tetramer) were included as internal controls for cross-linking 
efficiency. Cross-linking reactions were carried out at room tempera- 
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FIG. 1. a, Sin3a is coimmunoprecipitated from rat brain nuclear extracts by anti-MeCP2 antibodies but not an irrelevant antibody (anti-Gal4). 
b, Superose 6 size exclusion chromatography of nuclear extracts (N.E.) from rat brain or NG108 cells. Fractions were analyzed by Western blotting 
with antibodies raised against Sin3a, MeCP2, and HDAC 1/2 as indicated. The elution profile of molecular weight standards and the void volume 
(V5) is indicated above each Western blot. IF, immunoprecipitation. 
ture for 30 mm. Tris-HCl (pH 8.8) (5 pl of 1.5 M) was added to quench 
the reaction for 15 min at room temperature. SDS-PAGE loading buffer 
(4X) was added, and the proteins separated on an 8% SDS-polyacryl-
amide gel followed by Coomassie Blue staining to visualize the proteins. 
Gel Filtration and Sucrose Gradient Analysis of rMeCP2—A Super-
ose 12 HR 10/30 gel filtration column was pre-equilibrated with gel 
filtration standards thyroglobin (669 kDa, R. = 8.5), apoferritin (443 
kDa, R8 = 6.1), B-amylase (200 kDa, R9 = 5.4), ADH (150 kDa), BSA 
(66 kDa, R. = 3.55), and carbonic anhydrase (29 kDa, R. = 2). Recom-
binant MeCP2 (125 pg) was loaded onto the column pre-equilibrated 
with buffer GF500. Fractions (0.5 ml) were collected, and 50 pi of each 
fraction was separated on an 8% SDS-polyacrylamide gel and Coomas-
sie Blue-stained to verify the identity of protein observed from the A255 
trace. Relative absorbance at 280 nm was plotted as the protein eluted 
from the Superose 12 column, and the radius was calculated by using an 
equation derived from the plotted standards. For sucrose gradient sed-
imentation —15 pg of rMeCP2, 50 pg of apoferritin (17.7 S), 30 pg of 
B-amylase (8.9 S) 50 pg ofADH (7.4 S), and 50 pg of BSA (4.3 S) were 
loaded onto a 13-ml linear 5-20% sucrose gradient made in 0.3 M KCI, 
20 mm Hepes (pH 7.9), 2 mm EDTA, 10% glycerol, 10 mm -mercapto-
ethanol. The gradient was centrifuged for 19 h at 40,000 rpm in a 
Beckman SW40 rotor at 4 °C. Fractions (0.5 ml) were taken from the top 
of the gradient, trichloroacetic acid-precipitated, run on an 8% SDS-
polyacrylamide gel, Western-blotted using an anti-MeCP2 antibody or 
on a 10% SDS-polyacrylamide gel, and Coomassie Blue-stained for the 
indicated standards. Densitometric analysis utilized Gene Tools Anal-
ysis Software package (SynGene), and values were adjusted for back-
ground. Intensity was plotted by fraction to determine the relative 
sedimentation coefficient of rMeCP2. 
Molecular Weight and Frictional Coefficient Calculations—Calcula-
tions to determine molecular weight and frictional coefficient ( f/f0) were 
applied as described (31, 32) using Equations 1 and 2, 
M, = 67rit20,,,,s20,,RsN/(1 - p 0,5) 	 (Eq. 1) 
fiTs = 6rq20,,RsI6ir7 2o,(3vM,/4irN)1° 	(Eq. 2) 
where R. is the Stoke's radius (cm), S20,. is the sedimentation velocity 
(S x 10_03), t20 is the viscosity of water at 20 °C (0.01002 gs' cm), 
N = Avogadro's number (6.022 x 1023 mol'), '= is the density of 
water at 20 °C (0.9981 gcm°), e is the partial specific volume (used 
0.725 cm'/g). 
RESULTS 
Biochemical Analysis of MeCP2 in Nuclear Extracts—Previ-
ous studies have demonstrated that Xenopus (21) and mamma-
lian MeCP2 can associate with the Sin3a complex (14), but the  
properties of the mammalian Sin3a/MeCP2 interaction remain 
to be investigated. We confirmed that in rat brain nuclear 
extracts Sin3a is coimmunoprecipitated by antibodies against 
MeCP2 (Fig. la), but the amounts are small relative to input. 
In order to evaluate the relative amount of MeCP2 residing in 
a stable Sin3a complex, nuclear extracts from either rat brain 
or NG108 (mouse-rat neural-glial fusion) tissue culture cells 
were separated by size exclusion chromatography, and the 
resulting fractions were analyzed by Western blot with anti-
bodies against MeCP2, Sin3a, and HDACs 1 and 2, which are 
components of the Sin3a complex. To our surprise most of 
Sin3a-containing fractions were devoid of detectable MeCP2. 
The majority of Sin3a eluted over the apparent molecular mass 
range of 500 kDa to 2 mDa, showing significant overlap with 
HDAC 1/2-containing fractions (Fig. lb). In contrast, MeCP2 
eluted with an apparent molecular mass of 400-500 kDa 
(Fig. lb). 
Biochemical Purification of MeCP2 from Rat Brain—The 
predicted molecular mass of MeCP2 based on its amino acid 
sequence is between 52.4 and 53 kDa, depending on species. 
This is much smaller than the apparent molecular weight 
observed by size exclusion chromatography, indicating that 
MeCP2 may exist in a multiprotein complex. To test this pos-
sibility, a large scale biochemical purification of rat brain 
MeCP2 was devised (Fig. 2a). During the purification, MeCP2, 
Sin3a, and HDAC 1/2 were tracked by Western blotting. Sp-
Sepharose and MonoQ columns efficiently separated MeCP2 
from the majority of the Sin3a and HDAC 1/2-containing frac-
tions, confirming that the majority of MeCP2 from nuclear 
extract is absent from the Sin3a complex. After four purifica-
tion steps, three polypeptides were detected by SDS-PAGE, of 
which the middle band was identified as MeCP2 by Western 
blot (Fig. 20. A final size exclusion chromatography step was 
applied to fractions eluted from the Ni-NTA column. SDS-
PAGE of the resulting fractions (Fig. 2d) demonstrated that the 
apparent molecular weight of MeCP2 (400-500 kDa) remained 
constant over the purification. The SDS-PAGE analysis also 
showed a 90-kDa band whose elution profile overlapped with 
MeCP2. This protein was identified by mass spectrometry 
(data not shown) as topoisomerase I. We were able to rule out 
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numbers are shown below each blot. c, protein quantities (left) and Sypro-Ruby stained SDS-polyacrylamide gel (right) of proteins from each 
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Ni-NTA-purified protein in c visualized by Sypro-Ruby stain. The solid arrowhead indicates the position of MeCP2, and the open arrowhead 
indicates topoisomerase 1, as identified by mass spectrometry. Below the Sypro-Ruby stained gel are the same fractions analyzed by Western 
blotting with anti-MeCP2 antibodies. Elution profile of molecular weight standards (kDa) and void volume (V5 ) is indicated at the tap and the 
fraction number at the bottom. e, anti-MeCP2 antibodies or an irrelevant antibody (anti-Gal4) does not coimmunoprecipitate JP) topoisomerase 
I from rat brain nuclear extract. 
the possibility that MeCP2 associated with topoisomerase I as 
MeCP2 antibodies were unable to immunoprecipitate topoi-
somerase I from rat brain nuclear extract (Fig. 2e). Further-
more, an independent purification starting with 10 mg of rat 
brain extract yielded MeCP2 with the same Superose 12 size 
exclusion profile but in the absence of detectable topoisomerase 
I (data not shown). We conclude that MeCP2 in rat brain 
extracts, despite its large apparent molecular weight, does not 
exist in a complex with other proteins. 
Biochemical Analysis of MeCP2 from X. laevis Oocytes—A 
previous report (2 1) suggested that X. laevis MeCP2 cofraction-
ated with X. laevis Sin3a (xSin3a). To re-visit this observation, 
we made extract from X. laevis oocytes and separated it by 
Bio-Rex 70 ion exchange chromatography (Fig. 3, a and b), 
using the procedures described previously (21). Western blots 
using antibodies directed against xMeCP2 and xSin3a were 
used to monitor the elution of these proteins (Fig. 3b). Proteins  
from the Bio-Rex 70 step were separated by size exclusion 
chromatography, and fractions were analyzed by Western blot 
(Fig. 3c). The xSin3a protein elutes in a complex with an 
apparent mass of 500 kDa to 2 mDa, whereas xMeCP2, like 
mammalian MeCP2, elutes with an apparent molecular mass 
of 400-500 kDa. In agreement with our observations in mam-
malian extracts (Fig. 1 and Fig. 2) and with an independent 
study of Xenopus oocyte extracts (33), X. laevis MeCP2 does not 
coelute with fractions containing the majority of the xSin3a 
corepressor complex. 
Purification of Recombinant Untagged Human MeCP2—To 
examine further the discrepancy between the observed molec-
ular weight (400-500 kDa) and the monomeric molecular 
weight (53 kDa) of MeCP2, we developed a four-step scheme to 
obtain pure recombinant MeCP2, free of protein tags, from 
bacterial lysates (rMeCP2) (Fig. 4, a and b). To ensure that this 
protein was active and suitable for further biophysical analy- 
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FIG. 4. a, a four-step chromatographic purification procedure (Ni-
NTA, Sp-Sepharose, Sephacryl-S300, and Mono S) was used to purify 
untagged recombinant MeCP2 (rMeCP2) from bacterial extracts. b, 
Coomassie Blue stained gel showing a typical purification of rMeCP2 
with protein molecular weight marker (left) and rMeCP2 (right). c, 
rMeCP2 has the capacity to specifically recognize methylated (Meth) 
DNA. Increasing amounts of rMeCP2 (50, 100, 250, 500, and 750 ng) 
were incubated with methylated (left) or unmethylated (right) CG1 1 
probe. Cold competitor DNA, either methylated (Camp M+) or un-
methylated (Camp M—) were added to show specificity of bandshift. 
sis, we confirmed that untagged rMeCP2 specifically interacted 
with a methylated probe (Fig. 4c). This bandshift was success- 
fully competed by cold methylated competitor but not by un-
methylated competitor (Fig. 40. Most importantly, rMeCP2 
maintained an apparent molecular mass of 400-500 kDa by 
size exclusion chromatography (Fig. 5b), identical to that seen 
for native MeCP2. 
Hydrodynamic Analysis of rMeCP2—Since MeCP2 does not 
associate stably with other proteins, we entertained the follow- 
ing three possible explanations for the discrepancy in observed 
versus predicted molecular weight: 1) MeCP2 self-associates to 
create a homomultimeric complex; 2) MeCP2 interacts with a 
DNA or RNA component that alters its molecular size; and 
3) MeCP2 is a monomeric molecule with an abnormal shape 
(radius). To address whether MeCP2 might self-associate, 
chemical cross-linking experiments using glutaraldehyde (data 
not shown) or EGS were carried out. Although the control 
protein ADH was cross-linked as expected to give multimers, 
MeCP2 showed no evidence of multimerization (Fig. 5a). A 
slight reduction in the size of treated MeCP2 was observed, 
presumably due to compaction of the protein as a result of 
intramolecular cross-links. To determine whether MeCP2 is 
associated with a DNA or RNA component, purified rat MeCP2 
was treated with Benzonase, which contains both DNase and 
RNase activity. Nuclease treatment had no effect on the appar-
ent molecular weight as determined by size exclusion chroma-
tography (data not shown). 
To explore more thoroughly the biophysical properties and 
molecular shape of MeCP2, we carried out hydrodynamic anal-
ysis. Seigel and Monty (31) demonstrated that the mass of a 
protein (or protein complex) can be determined accurately by 
combining size exclusion chromatography and sucrose gradient 
sedimentation. rMeCP2 was fractionated by size exclusion 
chromatography, and the peak elution of protein was deter-
mined by the absorbance at 280 nm. This value was used to 
calculate the apparent radius of MeCP2 to —6.15 nm (Fig 5b). 
To determine the sedimentation coefficient, rMeCP2 was sep-
arated on a 5-20% sucrose gradient and an approximate sedi-
mentation coefficient of ---2.28 S (Fig. 5c) was observed. By 
combining the values from our hydrodynamic analysis, we cal-
culated the derived mass of MeCP2 in solution (Table I). The 
derived mass (57.8 kDa) falls within --10% of the predicted 
monomeric molecular weight of MeCP2 (52.4 kDa). Further-
more, the calculated frictional ratio of --2.41 indicates that 
rMeCP2 is a highly elongated molecule (34). 
DISCUSSION 
Mammalian MeCP2 can interact with Sin3a as a recombi-
nant protein in vitro or by coimmunoprecipitation from nuclear 
extracts (14). Also, it is reported that Xenopus MeCP2 partially 
cofractionates with xSin3a, suggesting that the proteins may 
exist in a stable complex (21). In this study, we have investi-
gated the mammalian MeCP2/Sin3a interaction biochemically, 
and we found that MeCP2 does not exist in a stable Sin3a 
complex. Reinvestigation of the biochemical properties of Xe-
nopus oocyte MeCP2 led us to conclude that xMeCP2 does not 
coelute with the majority of xSin3a either. Therefore, neither 
amphibian nor mammalian MeCP2 appears to form a stable 
complex with Sin3a in cellular extracts. 
Biochemical purification of MeCP2 from rat brain demon- 
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FIG. 5. a, BSA (monomer), rMeCP2, and ADH (tetramer) were cross-linked with increasing concentrations of EGS (0.25, 0.5, 1.0, 2.5, 5.0 mm). 
rMeCP2 did not cross-link, whereas the ADH monomer when cross-linked formed several multimeric species (arrowheads right). b, rMeCP2 was 
separated by Superose 12 size exclusion chromatography, and fractions were separated by SDS-PAGE and stained with Coomassie Blue. Elution 
profile of molecular weight standards (kDa) and of the void volume (V0 ) is indicated above, and calculated radius in nm below. c, rMeCP2 was 
separated by 5-20% sucrose gradient sedimentation, and the fractions were separated by SDS-PAGE and Western-blotted by using anti-MeCP2 
antibodies. The sedimentation profile of protein standards are indicated above, and the calculated sedimentation value in Svedberg units (S) is 
shown below. 
TABLE I 
Hydrodynamic Properties of rMeCP2 
Theoretical 	Sedimentation 	Stokes 	Frictional 	Derived 
mass coefficient radius ratio mass 
Do 	 °2O,, 	 nm 	[ifs 	Do 
52,437 —2.28 —6.15 2.41 57,880 
strated that MeCP2 does not stably associate with other pro-
teins. Nevertheless, purified rat brain MeCP2 had an apparent 
molecular mass by size exclusion chromatography of 400-500 
kDa, which is nearly 10 times its true molecular mass (52 kDa). 
By generating recombinant untagged MeCP2, we were able to 
study in more detail the biophysical properties of MeCP2. 
rMeCP2 maintained the same large apparent molecular weight 
as the native rat and X. laevis proteins. This large apparent 
molecular weight was not because of an RNA or DNA compo-
nent or self-association. Based on the experimentally deter-
mined radius and sedimentation coefficient, we were able to 
deduce the native molecular weight of rMeCP2 and determine 
the frictional ratio, which indicates molecular shape (31, 32). 
The derived molecular weight fits closely to the theoretical 
molecular weight of MeCP2, indicating that, despite its aber-
rant gel filtration properties, MeCP2 exists as a monomeric 
protein in solution. The frictional ratio of —2.41 is consistent 
with an elongated molecule. Globular proteins invariably show 
frictional ratios of <1.5, whereas elongated proteins have fric-
tional ratios in excess of 2.0 (34). As size exclusion chromatog-
raphy separates proteins largely based on radius (i.e. shape), 
this finding can account for the large apparent molecular 
weight of native MeCP2. MeCP2 has 11.5% proline by amino 
acid composition, and the inherent rigidity of this amino acid 
(35) may in part give rise to the nonglobular nature of MeCP2. 
The biological significance of the elongated MeCP2 molecular 
shape is currently unclear. 
Two bona fide target genes whose transcriptional activity 
responds to MeCP2 have been identified: xHairy2a (26) and 
Bdnf(23, 24). Sin3a is also localized to each of these promoter 
regions by chromatin immunoprecipitation analysis  (23, 24, 
26). These findings provide support for the idea that MeCP2 
and Sin3a interact on DNA templates. It is also noteworthy 
that loss of MeCP2 from the Bdnf promoter results in a loss of 
local histone methylation (23, 24), in agreement with previous 
evidence that MeCP2 can interact with the histone methyl-
transferase activity (17). To reconcile these results with the 
present findings, we propose that MeCP2 enters into a stable 
association with cofactors that modulate gene expression only 
when bound to DNA. Given recent evidence for a gene-specific 
role of MeCP2, it is possible that sustained interactions be-
tween MeCP2 and its protein partners rely on the specific DNA 
sequence architecture of its cognate target promoters. Thus 
monomeric MeCP2 may act as a multifunctional repressor that 
recruits Sin3a and perhaps other corepressors in a template-
dependent manner. The biochemical properties of MeCP2 sup-
port this view. Efficient extraction of MeCP2 from nuclei re-
quires more stringent conditions than does extraction of its 
methyl-CpG-binding counterparts MBD2 and Kaiso, which are 
components of large molecular weight chromatin remodeling 
complexes (30, 36). This biochemical distinction is compatible 
with the view that methyl-CpG-binding proteins belonging to 
free multiprotein complexes interact with DNA in a transient 
manner, whereas MeCP2 remains tightly associated with chro-
matin and recruits corepressors in its DNA-bound context. 
Our findings may have relevance to Rett syndrome, which is 
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caused by mutations in the MEGP2 gene (19). The absence of 
an exclusive MeCP2-Sin3a repression complex leaves open the 
possibility that other protein partners, including those re-
ported previously (14, 17, 27-29) and others as yet unidenti-
fied, play an important role in mediating the effects of MeCP2 
on gene expression. Given the broad distribution of Rett muta-
tions within the MECP2 coding sequence, it seems likely that 
the surface of MeCP2 is capable of multiple intermolecular 
interactions that are of relevance to neuronal function. Under-
standing these interactions at clinically relevant MeCP2 target 
genes is a challenge for the future. 
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Note Added in Proof—Since publication of this paper, we have be-
come aware of an earlier study (von Kries et al., 1994) reporting that the 
chicken protein ARBP has an elongated shape based on its Stokes 
radius. ARBP was subsequently found to be chicken MeCP2 (Weitzel 
et al., 1997). The conclusion of von Kries and colleagues is confirmed by 
this aspect of our study and should have been cited (von Kries, J. P., 
Rosorius, 0., Buhrmester, H., and Stratling, W. H. (1994) FEBS Lett. 
342, 185-188 and Weitzel, J. M., Buhrmester, H., and Stratling, W. H. 
(1997) Mol. Cell. Biol. 17, 5656-5666). 
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